

Description

The present invention relates to certain novel substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit mammalian steroid 5- α -reductase.

The class of steroidal hormones known as androgens is responsible for the physical characteristics that differentiate males from females. Of the several organs that produce androgens, the testes produce these hormones in the greatest amounts. Centers in the brain exert primary control over the level of androgen production. Numerous physical manifestations and disease states result when ineffective production control results in excessive androgen hormone production. For example, acne vulgaris, seborrhea, female hirsutism, and benign prostatic hypertrophy are correlated with elevated androgen levels. Additionally, the incidence of male pattern baldness has been associated with high androgen levels.


Testosterone is the principal androgen secreted by the testes and is the primary androgenic steroid in the plasma of males. It now is known that 5- α -reduced androgens are the active hormones in some tissues such as the prostate and sebaceous gland. Circulating testosterone thus serves as a prohormone for dihydrotestosterone (DHT), its 5- α -reduced analogue in these tissues but not in others such as muscle and testis. Steroid 5- α -reductase is a NADPH-dependent enzyme that converts testosterone to DHT. The importance of this enzyme in male development was dramatically underscored by discovery of a genetic steroid 5- α -reductase deficiency in male pseudohermaphrodites. Imperato-McGinley, J., et al., (1979), *J. Steroid Biochem.* 11 : 637-648.

Recognition of the importance of elevated DHT levels in many disease states has stimulated many efforts to synthesize inhibitors of this enzyme. The structures of several known steroid 5- α -reductase inhibitors are shown in Table 1.

Table 1

5- α -Reductase Inhibitors





(1)



$K_1=1.1 \times 10^{-6}M$
(Reversible)

Hsia and Voight
1973

Table 1 (Continued)

5	(2)		$1 \times 10^{-6} \text{M}$ (Irreversible)	Robaire, <u>et al.</u> , 1977
10				
15	(3)		3.5×10^{-8} (Irreversible)	Blohm, <u>et al.</u> , 1980
20				
25	(4)		$5 \times 10^{-9} \text{M}$ (Reversible)	Liang, <u>et al.</u> , 1983
30				
35				
40	(5)		$1.25 \times 10^{-6} \text{M}$ (Irreversible)	Petrow, <u>et al.</u> , 1981
45				

The first inhibitor described was the 17- β -carboxylic acid (1) by Hsia and Voight in 1973. *J. Invest. Dermat.* 82 : 224-227. The secosteroid (2) was the next inhibitor to be described and also has found utility as an affinity label for 5- α -reductase. Robaire, B., et al., (1977), *J. Steroid Biochem.* 8 : 307-310. The diazoketone (3) has been reported as a potent, time-dependent inhibitor of steroid 5- α -reductase. Blohm, T.R., et al. (1980), *Biochem. Biophys. Res. Comm.* 95 : 273-280 ; United States Patent 4,317,817, March 2, 1982. Compound (4) is exemplary of a group of 4-aza steroid inhibitors of steroid 5- α -reductase described in United States Patent 4,377,584 which issued March 22, 1983, and in Liang, T., et al. (1983), *J. Steroid Biochem.* 19, 385-390. The 6-methylene steroid (5) also has been shown to be a time-dependent inactivator of steroid 5- α -reductase. Petrow, V., et al., (1981), *Steroids* 38 : 121-140.

Other steroid 5- α -reductase inhibitors also have been described. United States Patent 4,381,578 which issued June 2, 1986, describes a class of homosteroid enzyme inhibitors. United States Patent 4,191,759 discloses amides of 17 β -carboxy-4-androsten-3-one that are active as steroid 5- α -reductase inhibitors. Japanese Patents J60148855-A and J60116857-A disclose various aniline derivatives having numerous activities including 5- α -reductase inhibiting activity. Japanese Patent I60142941-A discloses phenyl-substituted ketones having 5- α -reductase inhibiting activity and European Patent EP173516-A discloses various phenyl-substituted amides having similar activity. Shisaido referenced terpene derivatives that are active inhibitors of steroid 5- α -reductase. Japanese Patent No. J58053417-A.

Palladium-catalyzed carbonylation of substituted androstene derivatives has been described. Cacchi, S., et al., (1985), Tet. Letters 26 : 1109-1112. No biological activity for the synthesized compounds, however, is disclosed.

Preparation of steroidal 3-chloro-3,5-dienes has been described by Deghenghi, R. and R. Gaudry, Canadian J. Chem. (1982) 40 : 818-820.

Use of phosphorous trihalides to convert steroidal Δ^4 -3-ketones to corresponding 3-halo-3,5-dienes has been reported. Ross, J.A. and M.D. Martz, J. Org. Chem. (1964) 29 : 2784-2785.

The present invention resides in the discovery that steroid 5- α -reductase is inhibited by certain substituted acrylate analogues of steroidal synthetic compounds. The compounds are potent enzyme inhibitors.


Presently preferred compounds of the invention and compounds used in the invented pharmaceutical compositions and the invented methods include :

20- α -(hydroxymethyl)-5- α -pregn-3-ene-3-carboxylic acid,
 N,N-diisopropyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid,
 N,N-diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid,
 17 β -(N,N-diisopropylcarboxamide)-4-fluoro-5- α -androst-3-ene-3-carboxylic acid,
 20- α -(hydroxymethyl)-4-fluoro-5- α -pregn-3-ene-3-carboxylic acid,
 20- α -(hydroxymethyl)-4-nor-5- α -pregn-1-ene-2-carboxylic acid,
 17 β -N,N-diisopropylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid,
 N-t-Butyl Androst-3,5-diene-17 β -carboxamide-3-carboxylic acid,
 N,N-Diisopropyl 5- α -Androst-2-ene-17 β -carboxamide-3-carboxylic acid,
 N,N-Diisopropyl Androst-2,4,-diene-17 β -carboxamide-3-carboxylic acid,
 N,N-Diisopropyl 5- α -Androstane-17 β -carboxamide-3 β -carboxylic acid,
 N,N-Diisopropyl Estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic acid,
 N,N-Diisopropyl Estr-3,5-diene-17 β -carboxamide-3-carboxylic acid,
 17 β -(N,N-Diisopropylcarboxamide)-androst-3,5,11-triene-3-carboxylic acid,
 17 β -(N,N-Diisopropylcarboxamide)-androst-3,5-diene-3-thiocarboxylic acid,
 17 β -(N-t-Butylcarboxamide)-androst-3,5,11-triene-3-carboxylic acid, and
 17 β -(N-t-Butylcarboxamide)-androst-3,5-diene-3-thiocarboxylic acid.

In a further aspect of the invention there are provided novel processes useful in preparing the presently invented 5- α -reductase inhibiting compounds.

The invention also is the use of said compounds for inhibiting 5- α -reductase activity in mammals, including humans, and pharmaceutical compositions comprising them.

The presently invented compounds that inhibit 5- α -reductase have the following Formula (I) :



in which :

The A ring has up to 2 double bonds ;

The B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C₇-C₁₄ double bond when the B ring has a C₇-C₈ double bond ;

M is O or S ;

Z is $(CH_2)_n$ and n is 0-2 ;

X is H, Cl, F, Br, I, CF_3 , or C_{1-3} alkyl ;

Y is H, CF_3 , F, or Cl, CH_3 , provided that Y is H when there is no C_5-C_6 double bond ;

R^1 is H or C_{1-3} alkyl ;

R^2 is absent or present as H or CH_3 , provided R^2 is absent when the carbon to which it is attached is double bonded ;

R^{10} is absent when there is a C_4-C_5 , C_7-C_8 , or C_9-C_{10} double bond ;

or present as an alpha hydrogen, and

R^3 is

- (1) α -hydrogen, α -hydroxyl, or α -acetoxy and/or
(a)



where W is a bond or C_{1-12} alkylene and R^4 is

(i) hydrogen,

(ii) hydroxyl,

(iii) C_{1-3} alkyl,

(iv) hydroxy C_{1-3} alkyl,

(v) C_{1-3} alkoxy,

(vi) $\beta-NR^5R^6$, where R^5 and R^6 are each independently selected from hydrogen, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl ; or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen, or

(vii) QR^7 , where R^7 is hydrogen, alkali metal, C_{1-12} alkyl, benzyl, or

(b) $\beta-Alk-OR^8$, where Alk is C_{1-12} alkylene, and R^8 is

(i) phenyl C_{1-3} alkylcarbonyl,

(ii) C_{5-10} cycloalkylcarbonyl,

(iii) benzoyl,

(iv) C_{1-3} alkoxy carbonyl,

(v) amino-, or C_{1-3} alkyl substituted aminocarbonyl,

(vi) hydrogen, or

(vii) C_{1-3} alkyl,

(2) $=CH-W-CO-R^4$ or $=CH-W-OR^8$, where W is a bond or C_{1-12} alkylene, and R^4 and R^8 have the same meaning as above and R^8 also is hydrogen or C_{1-20} alkylcarbonyl ;

(3)



where the dashed bond replaces the 17- α -hydrogen,

(4) α -hydrogen and $\beta-NHCOR^9$ where R^9 is C_{1-12} alkyl or $\beta-NR^5R^6$ where R^5 and R^6 have the same meaning as above,

(5) α -hydrogen and β -cyano,

(6) α -hydrogen and β -tetrazolyl, or

(7) keto ;

or a pharmaceutically acceptable salt thereof ; except compounds in which :

The A ring has a C_3-C_4 double bond and the B ring has a C_5-C_6 double bond, R^1 is CH_3 , and R^3 is keto ;

The A ring has a C_3-C_4 double bond and the B ring has a C_5-C_6 double bond and

The D ring has a $C_{16}-C_{17}$ double bond, R^1 is CH_3 , and R^3 is $COOCH_3$; and


The B ring has a C_5-C_6 double bond, R^1 is CH_3 , and R^3 is $COCH_3$.

As used herein, unless otherwise specified, $C_{1-n'}$ alkyl and $C_{1-n''}$ alk means a straight or branched hydrocar-

bon chain having 1 to n' carbons and Alk means a straight or branched hydrocarbon chain having 1 to 12 carbons.

Preferred among Formula (I) compounds are those in which Z is $-\text{CH}_2-$.

Also, preferred among the presently invented compounds are those having Formula (II):



(II)

In which:

The A ring has up to 2 double bonds;

The B and C rings have optional double bonds where indicated by the broken lines;

M is O or S;

X is H, or halo, and

R^1 is H or C_{1-8} alkyl; R^2 is H or C_{1-8} alkyl;


R^{10} is absent when there is a C_4-C_5 , C_5-C_6 , or C_8-C_9 double bond, or present as an alpha hydrogen, and R^{13} is

(a) $\text{HC}(\text{CH}_3)\text{CH}_2\text{OR}^{20}$ wherein R^{20} is H or C_{1-8} alkyl, or

(b) $\text{CONR}^{21}\text{R}^{22}$ wherein R^{21} and R^{22} independently are H or C_{1-8} alkyl.

Particularly preferred are Formula (II) compounds in which the A ring has a C_3-C_4 double bond.


Also preferred among the presently invented compounds are those having Formula (III):



(III)

In which R^1 , R^2 , R^{13} , and the B ring broken lines are as in Formula (II) and M is O or S.


Additionally, preferred among the presently invented compounds are those having Formula (IV):



(IV)

In which R^1 , R^2 , and R^{13} are as in Formula (II) and M is as in Formula (I).

Compounds of Formula (Ia) are included in the pharmaceutical compositions of the invention and used in the methods of the invention.



(Ia)

in which :

The A ring has up to 2 double bonds ;

The B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C₇-C₁₄ double bond when the B ring has a C₇-C₈ double bond ;

M is O or S ;

Z is (CH₂)_n and n is 0-2 ;

X is H, Cl, F, Br, I, CF₃, or C₁₋₃ alkyl ;

Y is H, CF₃, F, or Cl, CH₃, provided that Y is H when there is no C₅-C₆ double bond ;

R¹ is H or C₁₋₃ alkyl ;

R² is absent or present as H or CH₃, provided R² is absent when the carbon to which it is attached is double bonded ; and

R¹⁰ is absent when there is a C₄-C₅, C₅-C₆, or C₅-C₁₀ double bond, or present as an alpha hydrogen, and R³ is

- (1) α-hydrogen, α-hydroxyl, or α-acetoxy and/or
(a)



where W is a bond or C₁₋₁₂ alkylene and R⁴ is

(i) hydrogen,

(ii) hydroxyl,

(iii) C₁₋₃ alkyl,

(iv) hydroxy C₁₋₃ alkyl,

(v) C₁₋₃ alkoxy,

(vi) NR⁵R⁶, where R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₃ alkyl, C₃₋₆ cycloalkyl, phenyl ; or R⁵ and R⁶ taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen, or

(vii) OR⁷, where R⁷ is hydrogen, alkali metal, C₁₋₁₂ alkyl, benzyl, or

(b) β-Alk-OR⁸, where Alk is C₁₋₁₂ alkylene, and R⁸ is

(i) phenyl C₁₋₃ alkylcarbonyl,

(ii) C₆₋₁₀ cycloalkylcarbonyl,

(iii) benzoyl,

(iv) C₁₋₃ alkoxy carbonyl,

(v) amino-, or C₁₋₃ alkyl substituted aminocarbonyl,

(vi) hydrogen, or

(vii) C₁₋₃ alkyl,

(2) =CH-W-CO-R⁴ or =CH-W-OR⁸, where W is a bond or C₁₋₁₂ alkylene, and R⁴ and R⁸ have the same meaning as above and R⁸ also is hydrogen or C₁₋₂₀ alkylcarbonyl ;

(3)



where the dashed bond replaces the 17- α -hydrogen,

(4) α -hydrogen and β -NHCOR⁹ where R⁹ is C₁₋₁₂ alkyl or β -NR⁵R⁶ where R⁵ and R⁶ have the same meaning as above,


(5) α -hydrogen and β -cyano,

(6) α -hydrogen and β -tetrazolyl, or

(7) keto ;


or a pharmaceutically acceptable salt thereof.

As used above and throughout the remainder of the specification and claims the carbons of the steroid nucleus are numbered and the rings and lettered as follows :




Formula (Ia) compounds are prepared as shown in Schemes I through X wherein R² and X are as defined in Formula (Ia). R¹⁴ is R³ or moieties which can be chemically converted to those of R³ by known chemical reactions such as described in 2 J. Fried and J. Edwards, Organic Reactions in Steroid Chemistry, Pub : Van Nostrand Reinhold Company (1972) provided that R¹⁴ does not include any such moieties that render inoperative the Schemes I to X processes. As demonstrated in the following Examples, reactions to convert R¹⁴ to R³ are performed on products of the synthetic pathways of Schemes I through IX or, where appropriate or preferable, on certain intermediates in these synthetic pathways.

SCHEME I




1) Li/NH_3
 2) n -phenyltrifluoromethylsulfonimide


SCHEME I (Continued)



(b)



(c)



(d)

Scheme I depicts formation of Formula (Ia) compounds having a double bond at C₃-C₄, X is H, and n is 1. The starting 4-ene-3-one compounds are known and readily available and are synthesized from available precursors using known procedures. According to Scheme I, a solution of a 4-ene-3-one compound (a) and a suitable organic proton donor such as t-butanol, or, preferably aniline in an appropriate organic solvent, preferably tetrahydrofuran (THF) are added to a reducing metal amine, preferably a lithium/ammonia (Li/NH₃) solution, to form a reaction mixture. This reaction mixture is stirred at -100°C to -30°C, preferably -78°C, quenched with

a lithium scavenger such as dibromoethane, bromobenzene, or, preferably isoprene, and evaporated to form a residue. Formula (b) compounds then are prepared by reacting the residue dissolved in a suitable organic solvent, preferably THF, with an N-aryltrihaloalkylsulfonimide, preferably N-phenyltrifluoromethylsulfonimide at a temperature of -20°C to 20°C .

5 Formula (c) compounds are prepared by adding to a formula (b) compound dissolved in a suitable organic solvent such as dimethylformamide (DMF) an organic base such as trimethylamine, or, preferably, triethylamine, a phosphine such as bis (diphenylphosphino) propane, or, preferably triphenylphosphine, a palladium (II) compound such as palladium (II) chloride, or, preferably, palladium (II) acetate, and a C_{1-6} alkyl alcohol (C_{1-6} alkOH), followed by addition of carbon monoxide (CO). Addition of a strong base such as sodium hydroxide, potassium
10 hydroxide, or, preferably, lithium hydroxide to a formula (c) compound dissolved in a suitable organic solvent such as THF and methanol followed by addition of strong acid, preferably, hydrochloric acid yields formula (d) compounds.

15

20

25

30

35


40

45

50


55

SCHEME II





(a)

- 1) 2,6-di-*t*-butyl-4-methylpyridine
- 2) trifluoromethanesulfonic anhydride



(b)


triethylamine, bis(triphenyl)-
phosphine palladium(II)
acetate
C₁-galactose, CO

SCHEME II (Continued)



Scheme II outlines synthesis of Formula (Ia) compounds wherein there is a C_5-C_6 double bond and n is 1. The starting materials are the formula (a) 4-ene-3-one compounds from Scheme I. According to Scheme II, to a formula (a) compound dissolved in an appropriate organic solvent, preferably methylene chloride, is added 2,6-di-*t*-butyl-4-methylpyridine. A trihaloalkyl sulfonic anhydride, preferably trifluoromethane sulfonic anhydride then is added to yield formula (f) compounds. To formula (f) compounds dissolved in a suitable organic solvent such as DMF an organic base such as trimethylamine, or, preferably, triethylamine, a palladium (II) compound such as bis (diphenylphosphino) propane, palladium (II) acetate, or, preferably bis (triphenylphosphine) palladium (II) acetate, and a C_{1-8} alkOH followed by addition of CO to give formula (g) compounds. Salts of formula (h) compounds then are prepared by hydrolyzing with a strong base such as sodium hydroxide, lithium hydroxide, potassium hydroxide, or, preferably, potassium carbonate the formula (g) ester compounds. Formula (h) free acids are prepared by treating the salts with a strong acid such as hydrochloric, sulfuric, or hydrobromic

acids.


SCHEME III




(a)




(j)



(k)




SCHEME III (Continued)




(I)

pyridinium poly(hydrogen fluoride) →






(II)

1) lithium bis(trimethylsilyl)amide
2) phenyltrifluoromethylsulfonimide →



(III)

triethylamine, triphenylphosphine
palladium(II) acetate
C₁₋₆alkOH, CO →

SCHEME III (Continued)

(s)

40

45

50

55

Scheme III illustrates synthesis of Formula (Ia) compounds in which X is fluoro. The starting compounds are the 4-ene-3-one compounds (a) used in Schemes I and II. According to Scheme III, formula (a) compounds dissolved in a suitable organic solvent such as THF and t-butyl alcohol are added to a metal amine solution, preferably a Li/NH₃ solution, to form a reaction mixture which is cooled to -100°C to -30°C, preferably -78°C,


and quenched with a lithium scavenger agent such as dibromoethane, bromobenzene, or, preferably, isoprene to form an enolate. This enolate then is treated with a salt of a strong acid and base, preferably ammonium chloride (NH_4Cl), to yield a formula (j) compound. Addition of phenylselenenyl chloride to a formula (j) compound dissolved in a suitable organic solvent, preferably ethyl acetate, followed by addition of an oxidizing agent, preferably hydrogen peroxide (H_2O_2), yields a formula (k) compound. The formula (1) epoxide compounds next are prepared by addition of an oxidizing agent, preferably H_2O_2 , to a formula (k) compound dissolved in a suitable organic solvent, preferably methanol, cooled to 5°C to 25°C , preferably 15°C , followed by addition of a strong base such as NaOH .


Formula (1) compounds then are dissolved in a suitable organic solvent, preferably THF, and cooled to -20°C to 0°C , and a fluorinating agent such as hydrogen fluoride, or, preferably, pyridinium poly (hydrogen fluoride) is added to yield formula (m) compounds in which X is fluoro. Formula (m) compounds are dissolved in a suitable organic solvent such as THF followed by addition to a solution of a metalloamide base such as lithium diisopropylamide or, preferably lithium bis (trimethylsilyl) amide in a suitable organic solvent such as THF. To this reaction mixture then is added a triflating agent such as trifluoromethanesulfonic anhydride, or, preferably, N-phenyltrifluoromethanesulfonimide to yield formula (o) compounds.

Formula (p) compounds then are synthesized by adding to a formula (o) compound dissolved in a suitable organic solvent such as DMF an organic base such as trimethylamine, or, preferably, triethylamine, a phosphine such as bis (diphenylphosphino) propane, or, preferably triphenylphosphine, and a palladium (II) compound such as palladium (II) chloride, or, preferably, palladium (II) acetate followed by addition of CO. Hydrogenation of formula (p) compounds dissolved in a suitable organic solvent such as ethyl acetate and hexane using an appropriate hydrogenation agent such as platinum dioxide, Raney nickel, or, preferably palladium on carbon (Pd/carbon) yields formula (q) compounds. Hydrolysis of the ester with a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, or, preferably potassium carbonate dissolved in an aqueous C_{1-6} alkyl alcohol solution, preferably methanol yields a salt of a formula (s) compound. Treatment of the salt with strong acid yields a formula (s) compound.


Formula (a) compounds in which X is other than hydrogen or fluoro are prepared using processes such as exemplified in Examples 23, 24, and 25.

SCHEME IV



SCHEME IV (Continued)

(v)




(w)

Scheme IV depicts formation of Formula (la) compounds in which n is O. The starting materials for this formation are formula (j) compounds prepared as described in Scheme III. According to Scheme IV, formula (j) compounds are dispersed in a strong acid, preferably glacial acetic acid, and treated with thallic acetate sesquihydrate to prepare formula (t) compounds. Formula (u) compounds next are prepared by treating formula (t) compounds dispersed in a suitable organic solvent, preferably diethylether, with an alkylating agent such as an alkyl halide and base, for example methyl iodide and sodium carbonate, ethyl iodide and 1,8-diazabicyclo-[5.4.0]undec-7-ene, or diazomethane.

Formula (u) compounds then are dissolved in a suitable organic solvent, preferably THF, cooled to -100°C to -30°C , preferably -78°C , and a metalloamide base, preferably lithium isopropyl cyclohexyl amide, is added. Thereafter phenylselenenylbromide is added followed by an oxidizing agent, preferably hydrogen peroxide, to yield formula (v) compounds. Formula (w) compounds then are prepared by processes employed in synthesis-


zing formula (d) compounds in Scheme I.

SCHEME V




(k)

- 1) 2,6-di-*t*-butyl-4-methylpyridine
- 2) trifluoromethanesulfonic anhydride




(2a)

- triethylamine, triphenylphosphine-
palladium(II) acetate
C₁₋₆alcoh., CO

SCHEME V (Continued)


(bb)



(cc)


Scheme V outlines formation of Formula (la) compounds in which Δ^1 is —CH=CH— . The starting materials in Scheme V are formula (k) compounds prepared as described in Scheme III. According to Scheme V, formula (aa) compounds are prepared using the processes used in making formula (f) compounds of Scheme II. Next formula (bb) compounds are prepared by the reactions employed to form formula (c) compounds in Scheme I. Thereafter, treatment of formula (bb) compounds as described in forming formula (s) compounds of Scheme III yields formula (cc) compounds.

SCHEME VI




(dd)

- 1) Dibromentin →
- 2) LiBr
- 3) Triethylamine/benzenethiol
- 4) m-chloroperoxybenzoic acid
- 5) Triethylamine
- 6) K_2CO_3




(ee)

- 1) butanone →
- 2) $Al(iPrO)_3$



(ff)

- 1) Li/NH_3 →
- 2) NH_4Cl

SCHEME VI (Continued)

Scheme VI shows synthesis of Formula (Ia) compounds in which there is a C_8-C_{14} double bond. The formula

(dd) starting materials are known and available and can be synthesized from available materials using known methods. Formula (ee) compounds are prepared by first treating formula (dd) compounds in a suitable organic solvent such as hexane with a brominating agent such as N-bromosuccinimide, or, preferably dibromantin and a mild base, preferably sodium bicarbonate, and heated, preferably at reflux. Thereafter, the mixture is treated with lithium bromide (LiBr), cooled to -20°C to 20°C , preferably 0°C , and treated with triethylamine and benzothiol. Treatment with an oxidizing agent such as sodium periodate, hydrogen peroxide, or preferably m-chloroperoxybenzoic acid follows and is followed by heating to 40°C to 100°C , preferably 70°C , and treatment with an organic base such as trimethylamine, or preferably triethylamine. Treatment with a strong base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, or, preferably, potassium carbonate yields formula (ee) compounds.

Formula (ee) compounds then are dissolved in a suitable organic solvent, preferably toluene, and treated with an alkyl ketone agent such as cyclohexanone, or, preferably butanone followed by treatment with aluminum isopropoxide and heating, preferably at reflux, to prepare formula (ff) compounds. Reaction of formula (ff) compounds as described in forming Scheme III, formula (j) compounds yields formula (gg) compounds. Hydrogenation of formula (gg) compounds using suitable catalysts such as platinum dioxide, Raney nickel, or, preferably Pd/carbon, yields formula (gg') compounds. Formula (hh) compounds there are prepared by adding phenylselenenyl chloride to a formula (gg') compound dissolved in a suitable organic solvent, preferably ethyl acetate, followed by addition of an oxidizing agent, preferably H_2O_2 . Substitution of formula (hh) compounds for formula (m) compounds in Scheme III yields formula (kk) compounds.


SCHEME VII

5

10

15

20


Chloranil →

(a)

25

30

35




(II)

40

45

50




(III)


55

Scheme VII outlines formation of Formula (Ia) compounds in which Δ^6 and Δ^7 are $-\text{CH}=\text{CH}-$ from Scheme I, formula (a) compounds. Treatment of formula (a) compounds in a suitable solvent such as t-butanol with


chloranil, with heating, preferably at reflux, yields formula (11) compounds. Thereafter, substituting formula (11) compounds for formula (a) compounds in the Scheme II process yields formula (mm) compounds.

SCHEME VIII

(a)



(mm)



(oo)

Scheme VIII shows formation of Formula (1a) compounds in which n is 2 from Scheme I, formula (a) compounds. Formula (nn) compounds are prepared by treatment of formula (a) compounds in a suitable organic solvent such as diethyl ether and methanol cooled to -20°C to 20°C, preferably 0°C, with a strong base such as sodium hydroxide, lithium hydroxide, potassium carbonate, or, preferably potassium hydroxide (KOH), followed by treatment with a diazomethane precursor such as N-methyl-N'-nitro-N-nitrosoguanidine, or, preferably N-methylnitrosourea. Substituting formula (nn) compounds for formula (a) compounds in the process of Scheme II yields formula (oo) compounds.

10

15

20

25

30

35


40

45

50

55


SCHEME IX



(a)


Ethylene glycol

p-toluene sulfonic acid



(b)

m-chloroperbenzoic acid




3.

(c)


1) $Hy^1(gas), CHCl_3$
 2) H^+

SCHEME IX (Continued)




(rr)

- 1) 2,6-di-*t*-butyl-4-methylpyridine
- 2) trifluoromethanesulfonic anhydride



(ss)

- Triethylamine
 bis(triphenylphosphine)palladium(II)
 acetate
 C₁₋₆alkOH
 O



(tt)

Scheme IX outlines formation of Formula (la) compounds in which Y is chloro or fluoro (Y¹) from Scheme I, formula (a) compounds. Formula (pp) compounds are prepared by reacting formula (a) compounds with a suitable keto group protecting agent such as ethylene glycol in the presence of an acid catalyst such as p-to-

luene sulfonic acid. Treatment of formula (pp) compounds with a suitable oxidizing agent, preferably m-chloroparbenzoic acid in a suitable organic solvent such as dichloromethane yields formula (qq) epoxide compounds.

Formula (rr) compounds then are prepared by adding gaseous hydrogen fluoride or hydrogen chloride to a formula (qq) compound in a suitable organic solvent such as chloroform, or (where $Y^1 = F$) by adding boron-trifluoride-etherate to a formula (qq) compound in a suitable organic solvent, preferably benzene : ether followed by treatment with strong acid, preferably hydrogen chloride in glacial acetic acid. Next, 2,6-di-t-butyl-4-methylpyridine followed by trifluoromethanesulfonic anhydride are added to a formula (rr) compound to yield a formula (ss) compound. Reaction of a formula (ss) compound in a suitable organic solvent, preferably dimethylformamide, with triethylamine, a C_{1-8} alkOH, bis (triphenylphosphine) palladium (II) acetate, and carbon monoxide yields formula (tt) compounds. The free acids of formula (tt) optionally are prepared by processes shown in the preceding schemes. Compounds of Formula (t) in which Y is trifluoromethyl are prepared by processes such as exemplified in Example 26.

Compounds having a double bond at C_{11} are prepared by modifications of the Schemes I through X by procedures which would be apparent to those skilled in the art and are exemplified in Example 34, below.

Compounds of Formula (la) wherein M is sulfur are prepared from Formula (la) compounds wherein M is oxygen using known procedures such as shown in Example 36, below.

SCHEME X

5

10

15

20

25

30


35

40

45


50

55



(i)

- (a) phosphorous tribromide or
oxalyl bromide
(b) optional step(s) for R^{14}
interconversions




(ii)

- 1) Butyllithium
- 2) Carbon dioxide
- 3) Acid

or

Triethylamine, triphenylphosphine-
palladium (II) acetate, C_{1-6} alkOH,



(iii)

Scheme X shows a preferred synthetic method for preparing Formula (Ia) compounds having double bonds at C_3-C_4 and C_5-C_6 . The starting materials are the formula (a) 4-ene-3-one compounds from Scheme I. X^1 is bromo, chloro, fluoro, or iodo. According to Scheme X, formula (i) compounds are treated with a carboxylic acid halide such as acetyl chloride, acetyl bromide, oxalyl chloride, or preferably, oxalyl bromide to yield formula (ii) compounds. Alternately, formula (ii) compounds are prepared by treating formula (i) compounds with a phos-

phorus trihalide, or phosphorous pentahalide, such as phosphoryl chloride, phosphorous pentachloride or preferably phosphorous tribromide, in acid, preferably acetic acid. Included in this process may be desired inter-conversions among the various groups comprising R^{14} using standard procedures known to organic chemists, especially conversion of esters to carboxylic acids, then to acid halides and then to carboxamides.


Formula (III) compounds, Formula (Ia) compounds unsaturated at C_3-C_4 and C_6-C_7 , then are prepared by adding an alkyl lithium reagent such as *n*-butyllithium, *s*-butyllithium or *t*-butyllithium to a compound (II) followed by treatment with a carboxylating agent such as diethyl carbonate, ethyl chloroformate, or, preferably, carbon dioxide. Alternatively, such formula (III) compounds are prepared by adding a palladium catalyst, preferably triphenylphosphine palladium (II) acetate in the presence of a base, preferably triethylamine and a C_{1-6} alcohol, preferably methanol, under an atmosphere of carbon monoxide.

Scheme X shows preparation of Formula (Ia) compounds in which X and Y are hydrogen. Scheme X is used to prepare Formula (Ia) compounds in which X or Y is other than hydrogen by replacing the formula (I) starting materials with appropriately substituted alternates. Compounds are selected so that they can be converted by known procedures to the R^2 and R^3 groups of the target Formula (Ia) compounds by additional steps in the synthetic process, as stated above, for example.

In the above Schemes, the starting materials are selected so that the R^2 and R^{14} groups in the formula (a) compound are the same as the R^2 and R^3 groups in the Formula (Ia) compound being synthesized. Alternatively, the R^2 and group of the formula (a) compound are selected so that they can be converted by known procedures to the R^2 and R^3 groups of the target Formula (Ia) compounds by additional steps in the synthetic process. For example, Formula (Ia) compounds wherein R^3 is carboxylic acid are converted to the corresponding amides by reaction with amines or substituted amines via the corresponding acid chlorides. Similarly, Formula (Ia) compounds wherein R^3 is $CH_2CHCOOH$ are prepared by oxidation of the corresponding alcohol.

Pharmaceutically acceptable acid addition salts of the compounds of the invention containing a basic group are formed where appropriate with strong or moderately strong organic or inorganic acids in the presence of a basic amine by methods known to the art. For example, the base is reacted with an inorganic or organic acid in an aqueous miscible solvent such as ethanol with isolation of the salt by removing the solvent or in an aqueous immiscible solvent when the acid is soluble therein, such as ethyl ether or chloroform, with the desired salt separating directly or isolated by removing the solvent. Exemplary of the acid addition salts which are included in this invention are maleate, fumarate, lactate, oxalate, methanesulfonate, ethanesulfonate, benzenesulfonate, tartrate, citrate, hydrochloride, hydrobromide, sulfate, phosphate and nitrate salts. Pharmaceutically acceptable base addition salts of compounds of the invention containing an acidic group are prepared by known methods from organic and inorganic bases include nontoxic alkali metal and alkaline earth bases, for example, calcium, sodium, and potassium hydroxide; ammonium hydroxide, and nontoxic organic bases such as triethylamine, butylamine, piperazine, and (trihydroxymethyl) methylamine.


In preparing the presently invented compounds of Formula (Ia), novel intermediates of the following Formula (V) are synthesized;



in which:

The A, B, C, and D ring double bonds, X, Y, Z, R^2 and R^{10} are as defined in Formula (Ia) R^3 as defined in formula (Ia) or moieties convertible into a group R^3 .

Also prepared in synthesizing the presently invented formula (Ia) compounds were n the formula (VI):



in which X¹ is halogen, the A, B, C and D ring double bonds, X, Y, Z, R² and R¹⁰ are as defined in formula (Ia) and R¹⁴ is the same as R³ as defined for formula (Ia) or moieties which can be chemically converted into R³.

Because Formula (Ia) compounds inhibit steroid 5- α -reductase activity, they have therapeutic utility in treating diseases and conditions wherein decreases in DHT activity produce the desired therapeutic effect. Such diseases and conditions include acne vulgaris, seborrhea, female hirsutism, prostate diseases such as benign prostatic hypertrophy, and male pattern baldness. The potency of several compounds of the invention was tested for potency in inhibiting human steroid 5- α -reductase using tissue from hyperplastic human prostates. In determining potency in inhibiting the human enzyme, the following procedure was employed:

Frozen human prostates were thawed and minced into small pieces (5 mm³). The tissue was homogenized in 3 to 5 volumes of 20 mM potassium phosphate, pH 6.5, buffer containing 0.33 M sucrose, 1 mM dithiothreitol, and 50 μ M NADPH with a Brinkmann Polytron (Sybron Corporation, Westbury, New York). The solution was subjected to sonication for 3 to 5 minutes with a Sonifier (Branson Sonic Power Co.) followed by hand homogenization in a glass-to-glass Dounce homogenizer (Kontes Glass Company, Vineland, New Jersey).

Prostatic particles were obtained by differential centrifugation at 600 or 1000 $\times$ g for 20 minutes and 140,000 $\times$ g for 60 minutes at 4°C. The pellet obtained from the 140,000 $\times$ g centrifugation was washed with 5 to 10 tissue volumes of the buffer described above and recentrifuged at 140,000 $\times$ g. The resulting pellet was suspended in 20 mM potassium phosphate buffer, pH 6.5, containing 20% glycerol, 1 mM dithiothreitol, and 50 μ M NADPH. The suspended particulate solution was stored at -80°C.

A constant amount of [¹⁴C]-testosterone (52 to 55 mCi/mmol, New England Nuclear, Boston, MA) in ethanol and varying amounts of the potential inhibitor in ethanol were deposited in test tubes and concentrated to dryness in a SAVANT Speed Vac. To each tube was added buffer, 20 μ l of 10 mM NADPH and an aliquot of prostatic particulate solution to a final volume of 1.0 ml of 50 mM sodium citrate, pH 5.0. After incubating the solution at 37°C for 20 to 30 minutes the reaction was quenched by the addition of 4 ml ethyl acetate and 0.25 μ mol each of testosterone, dihydrotestosterone, androstenediol, and androstenedione as carriers. The organic layer was removed to a second test tube and evaporated to dryness in a Speed Vac. The residue was dissolved in 20 to 30 μ l chloroform, spotted on an individual lane of a 20 $\times$ 20 cm prechannelled silica gel TLC plate (SI 250F-PA, Baker Chemical) and developed twice with acetone : chloroform (1 : 9). The radiochemical content in the bands of the substrate and the products was determined with a BIOSCAN Imaging Scanner (Bioscan, Inc., Washington, D.C.). The percent of recovered radiolabel converted to product was calculated, from which enzyme activity was determined. All incubations were conducted such that no more than 12% of the substrate (testosterone) was consumed.

The experimentally obtained data was computer fitted to a linear function by plotting the reciprocal of the enzyme activity (1/velocity) against the variable inhibitor concentration (Dixon, M. (1953), *Biochem. J.*, 55, 170). Assuming that the steroidal inhibitor is a competitive inhibitor against testosterone, a value for the inhibition constant (K_i) can be calculated from equation 1:

$$K_i = (B/A)/(S/K_m + 1) \text{ Equation 1}$$

where B is the intercept on the 1/velocity axis, A is the slope of the line, S is the concentration of substrate (testosterone) used in the experiment, and K_m is the Michaelis-Menton constant of the substrate (testosterone) determined in a separate experiment to be 4.5 μ M.

Table II displays the results of the above testing and shows that the tested compounds of the invention are potent inhibitors of human steroid 5- α -reductase.

Table II
Inhibition Constants of Human Prostatic Steroid
5- α -Reductase






<u>Compound</u>	<u>K_i (nM)</u>
	5000
	2000
	30
	7
	4000
	52

Table II (Continued)







<u>Compound</u>	<u>K_i (nM)</u>
	26
	85
	2200
	30
	50
	32
	50
	62

Table II (Continued)

5	<u>Compound</u>	<u>K_i (nM)</u>
10		110
15		900
20		35
25		790
30		170
35		110

Certain compounds of the invention also were tested for their *in vivo* potency in inhibiting steroid 5- α -reductase activity. Male Charles River CD rats, 48 days old, weighing approximately 200 gm were administered 10 mg/kg of N,N-diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid dissolved in propylene glycol and diluted in normal saline. Following compound administration the animals were sacrificed, the ventral prostates were excised, and DHT levels were measured by the following procedure.

Prostate tissue was excised, trimmed, weighed, minced and washed with phosphate buffer. The tissue then was homogenized in phosphate buffer and extracted by addition of ethyl acetate and mixing on an orbital mixer for forty-five minutes. The ethyl acetate was evaporated, the residue was reconstituted in ethanol, and was centrifuge filtered using 0.45 μ m filter paper. The components then were separated using reverse-phase HPLC collecting the DHT fraction. The fraction was reduced to dryness and reconstituted in standard DHT assay buffer available from Amersham. DHT levels then were measured using standard techniques such as radioimmunoassay.

In the compound-treated rats, prostatic DHT levels were decreased forty percent relative to vehicle-treated controls four hours after compound administration. The decreased DHT levels were maintained for greater than eight hours after administration, and had returned to control levels twenty-four hours after treatment. A single 10 mg/kg dose of the methyl ester of the above compound decreased prostatic DHT levels forty-eight percent relative to vehicle-treated controls after six hours. Thus, even though this compound does not inhibit steroid 5- α -reductase *in vitro*, *in vivo* administration of this compound produces significant enzyme inhibition.

N,N-diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid also was tested for its effects on prostatic growth. Twice daily oral administration for fourteen days of 0.5 to 50 mg/kg of this compound to immature rats produced a dose-dependent decrease in prostatic growth. Prostate weights from animals in the

maximum dose group were forty to fifty percent less than controls.

Using procedures similar to those described above the *in vivo* effects of B 17B-N-t-butylcarboxamideandrost-3,5-diene-3-carboxylic acid also were studied. Rats received a single oral dose of vehicle or 5, 10, 20 or 50 mg/kg of this compound. At all doses, prostate dihydrotestosterone levels were significantly reduced to approximately fifty percent of controls while testosterone levels remained unaffected.

Rats also were given 10 mg/kg of this compound and prostate testosterone and dihydrotestosterone levels at several points over twenty-four hours.

Dihydrotestosterone levels were significantly depressed to approximately sixty percent of controls at all time points from two to eighteen hours after treatment, at returned to control values by twenty-four hours post treatment. Prostate testosterone levels were viable without consistent trends.

Additionally, rats were given this compound at 1, 5, 10, 25, or 50 mg/kg twice daily for two weeks to determine if repeated treatment caused a reduction in ventral prostate weight. Ventral prostate weight was ninety percent of control at 5 mg/kg dose level and sixty-five percent of control at the 10 and 50 mg/kg dose level. Seminal vesicle weights were significantly reduced at all treatment levels.

The compounds of Formula (Ia) are incorporated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers are employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.

The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.

Doses of the present compounds of Formula (Ia) in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity selected from the range of 0.1-1000 mg/kg of active compound, preferably 1-100 mg/kg. The selected dose is administered to a human patient in need of steroid 5- α -reductase inhibition from 1-6 times daily, topically, orally, rectally, by injection, or continuously by infusion. Oral dosage units for human administration preferably contain from 1 to 500 mg of active compound. Parenteral administration, which uses lower dosages is preferred. Oral administration, at higher dosages, however, also can be used when safe and convenient for the patient.

The method of this invention of inhibiting steroid 5- α -reductase activity in mammals, including humans, comprises administering to a subject in need of such inhibition an effective steroid 5- α -reductase inhibiting amount of a compound of Formula (Ia).

Contemplated equivalents of Formula I compounds are compounds otherwise corresponding thereto wherein substituents have been added to any of the unsubstituted positions of the Formula (Ia) compounds or the methyl group at C-13 is absent or replaced by C₁₋₄ alkyl provided such compounds have the pharmaceutical utility of Formula (Ia) compounds.

The following examples illustrate preparation of Formula (Ia) compounds and pharmaceutical compositions containing these compounds. The examples are not intended to limit the scope of the invention as defined hereinabove and as claimed below.

EXAMPLE 1

20- α -(Hydroxymethyl)-5- α -pregn-3-ene-3-carboxylic acid

(i) 20- α -(Hydroxymethyl)-pregn-4-ene-3-one

Pregn-4-ene-3-one-20- α -carboxaldehyde (16.4 g, 50 mmol) in ethanol (250 ml) and THF (50 ml) was cooled to 0°C and a solution of sodium borohydride (NaBH₄) in 125 ml ethanol was added dropwise. The reaction mixture was stirred overnight at 25°C. Acetic acid was added to the reaction mixture until neutral pH and then the solution was evaporated to remove excess ethanol. The residue was dissolved in trichloromethane and washed with saturated sodium bicarbonate solution, water and brine. The organic layer was then dried over sodium sulfate and evaporated to dryness to yield 13.9 g (82%) of 20- α -(hydroxymethyl)-pregn-4-ene-3-one.

(ii) 20- α -(t-Butyldimethylsiloxyethyl)-pregn-4-ene-3-one

A solution of 20- α -(hydroxymethyl)-pregn-4-ene-3-one (1.2 g, 3.5 mmol), t-butyldimethylsilyl chloride (627 mg, 4.15 mmol) and imidazole (287 mg, 4.22 mmol) in DMF (40 ml) was stirred overnight at 40°C. The reaction mixture was then poured into ice water and the emulsion was washed three times with ethyl acetate. The organic layers were combined, washed with cold dilute hydrochloric acid, water and brine; dried over sodium sulfate and evaporated to dryness. Recrystallization from methanol afforded 1.1 g (70%) of 20- α -(t-butyldimethylsiloxyethyl) pregn-4-ene-3-one.

(iii) 20- α -(t-Butyldimethylsiloxyethyl)-3-trifluoromethylsulfonate)-5- α -pregn-3-ene

Ammonia (200 ml) was double distilled into a 3-neck roundbottom flask equipped with a dry ice condenser and argon bubbler. Lithium (Li) wire (120 mg, 17.4 mmol) was dissolved in ammonia (NH₃). A solution of 20- α -(t-butyldimethylsiloxyethyl)-pregn-4-ene-3-one (3 g, 6.76 mmol) and aniline (49.5 l, 5.4 mmol) in THF (50 ml) was added dropwise to the Li/NH₃ solution. The reaction mixture was stirred at -78°C for 15 minutes and then quenched with isopropane until the blue color disappeared. The volatiles were slowly evaporated (to avoid excess foaming) by slow warming, and eventually at 0.5 mmHg for 1 and 1/2 hours. The residue was redissolved in THF (50 ml) and cooled to 0°C. A solution of N-phenyltrifluoromethylsulfonimide (7 g, 20 mmol) in THF (10 ml) was added to the reaction mixture, and stirring was continued overnight at 4°C. The solvent was then evaporated and the residue was chromatographed on silica gel eluting with 3% ethyl acetate in hexane to yield 2.24 g (57%) of the 20- α -(t-butyldimethylsiloxyethyl)-3-(trifluoromethylsulfonate)-5- α -pregn-3-ene.

(iv) 20- α -(t-Butyldimethylsiloxyethyl)-3-carbomethoxy-5- α -pregn-3-ene

20- α -(t-Butyldimethylsiloxyethyl)-3-(trifluoromethylsulfonate)-5- α -pregn-3-ene (100 mg, 0.173 mmol) was dissolved in methanol (0.5 ml) and DMF (1 ml). Triethylamine (55 μ l, 0.386 mmol), triphenylphosphine (9 mg, 0.034 mmol) and palladium (II) acetate (3.8 g, 0.017 mmol) were then added to the solution and CO was bubbled through the solution for 5 minutes. The reaction mixture was then stirred overnight at 45°C under 1 atmosphere of CO, diluted with ethyl acetate and washed with water until neutral pH. The organic layer was dried over sodium sulfate and evaporated. The dark oil was purified by chromatography on silica gel eluting with 10% ethyl acetate in hexane to yield 52 mg (61%) of the desired product; 20- α -(t-butyldimethylsiloxyethyl)-3-carbomethoxy-5- α -pregn-3-ene.

(v) 20- α -Hydroxymethyl)-3-carbomethoxy-5- α -pregn-3-ene

20- α -(t-Butyldimethylsiloxyethyl)-3-carbomethoxy-5- α -pregn-3-ene (500 mg, 1.05 mmol) was dissolved in THF (20 ml) and 2 ml of a 1 molar solution of tetrabutylammonium fluoride in THF was added. The reaction mixture was stirred at room temperature for 3.5 hours and then diluted with water. The aqueous mixture was washed thoroughly with dichloromethane. The organic layers were combined, dried over sodium sulfate and evaporated to dryness. Purification by flash chromatography eluting with 20% ethyl acetate in hexane afforded 300 mg (78%) of 20- α -hydroxymethyl-3-carbomethoxy-5- α -pregn-3-ene.

(vi) 20- α -(Hydroxymethyl)-5- α -pregn-3-ene-3-carboxylic acid

20- α -(Hydroxymethyl)-3-carbomethoxy-5- α -pregn-3-ene (300 mg, 0.802 mmol) was dissolved in THF (15 ml) and methanol (15 ml). Lithium hydroxide (8 ml of a 1 N aqueous solution) was added and the reaction mixture was stirred overnight. The reaction mixture was then diluted with water and evaporated to remove excess methanol and THF. The aqueous solution was acidified with 5% hydrochloric acid and washed several times with ethyl acetate. The organic layers were combined, washed with brine, dried over sodium sulfate, and evaporated to dryness. Recrystallization from ethyl acetate and hexane afforded 242 mg (84%) of the desired acid; 20- α -(hydroxymethyl)-5- α -pregn-3-ene-3-carboxylic acid, m.p. 197-203°C.

EXAMPLE 2**N,N-Diisopropyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid****(i) 17 β -(Hydroxymethyl)-androst-4-ene-3-ol**

Approximately 750 ml of dry THF was added to a 3-neck round bottom flask equipped with a condenser, argon bubbler and mechanical stirrer. The flask was cooled to 0°C and lithium aluminum hydride (LAH) (11.39 g, 0.3 mol) was slowly added. After all of the LAH was added, the flask was warmed to room temperature. A solution of methyl androst-4-ene-3-one-17 β -carboxylate (86 g, 0.2 mol) in 600 ml of THF was very slowly added to the LAH slurry. After the addition of the steroid, the reaction mixture was slowly warmed to reflux. After 2 hours the excess LAH was quenched with 11.4 ml water, 11.4 ml 15% sodium hydroxide (NaOH) and 28 ml water. The salts were removed by filtration and washed with approximately 1 liter of warm THF. Concentration of the combined organic solutions afforded 63 g (94%) of 17 β -(hydroxymethyl)-androst-4-ene-3-ol as mixture of α and β isomers.

(ii) 3-Oxo-17 β -(hydroxymethyl)-4-androstene

A solution of 17 β -(hydroxymethyl)-androst-4-ene-3-ol (27 g, 0.089 mol) in 1200 ml trichloromethane was treated with activated manganese dioxide (86 g). After 3 hours the mixture was filtered. Concentration afforded 26 g (86%) of 3-oxo-17 β -(hydroxymethyl)-4-androstene (m.p. 151°C).

(iii) 3-Oxo-17 β -(t-butyldimethylsilyloxymethyl)-4-androstene

To a solution of 3-oxo-17 β -(hydroxymethyl)-4-androstene (15 g, 0.05 mol) in 200 ml DMF was added 5.8 g (0.085 mol) imidazole followed by 9.7 g (0.085 mol) t-butyldimethylsilyl chloride. The reaction mixture was stirred at room temperature under argon, for 2.5 hours. The reaction mixture was then poured into 250 ml ice water and washed 3 times with ethyl acetate. The combined organic layers were washed twice with cold 5% hydrochloric acid and once each with saturated sodium bicarbonate solution and brine. The organic layer was dried over sodium sulfate and evaporated. Recrystallization from methanol afforded 16.9 g (82%) of 3-oxo-17 β -(t-butyldimethylsilyloxymethyl)-4-androstene as a white crystalline solid.

(iv) 17 β -(t-Butyldimethylsilyloxymethyl)-3-(trifluoromethylsulfonate)-5- α -androst-3-ene

Ammonia (300 ml) was double distilled into a 3-neck round bottom flask equipped with a dry ice condenser and argon bubbler. Li wire, 250 mg (3 eq), was dissolved in the ammonia and stirred for 15 minutes to ensure dryness. Freshly distilled aniline, 0.53 ml (0.8 eq), was then added. A solution of 3 g (7.2 mmol) of 3-oxo-17 β -(t-butyldimethylsilyloxymethyl)-4-androstene in 50 ml of dry THF was added dropwise to the Li/NH₃ solution. An additional 50 ml dry THF was added to aid in solubility. The reaction mixture was stirred at -78°C for 2 hours and then quenched with isoprene until the blue color disappeared. The volatiles were slowly evaporated (to avoid excess foaming) by slow warming, and eventually at 0.5 mmHg for 1.5 hours. The oily residue was redissolved in dry THF (100 ml) and cooled to 0°C. A solution of 7.7 g (3 eq) of N-phenyltrifluoromethylsulfonimide in 50 ml THF was added, the flask was tightly sealed, and stirred overnight at 4°C. The mixture was then concentrated to dryness, and chromatographed on silica eluting with hexane. Recrystallization from ethyl acetate yielded 2.5 g (83%) of 17 β -(t-butyldimethylsilyloxymethyl)-3-(trifluoromethylsulfonate)-5- α -androst-3-ene (m.p. 120-121°C).

(v) Methyl 17 β -(t-butyldimethylsilyloxymethyl)-5- α -androst-3-ene-3-carboxylate

To a solution of 3 g (5.46 mmol) of 17 β -(t-butyldimethylsilyloxymethyl)-3-(trifluoromethylsulfonate)-5- α -androst-3-ene in 10 ml DMF and 10 ml methanol was added 1.5 ml (2 eq) triethylamine and 123 mg (0.03 eq) of the catalyst bis (triphenylphosphine) palladium (II) acetate. Carbon monoxide (CO) was bubbled through the solution for 5 minutes and the reaction mixture was then stirred at room temperature overnight under 1 atmosphere of CO. The mixture was diluted with ethyl acetate and washed with water until neutral pH. The organic layer was dried over sodium sulfate and evaporated. Chromatography on silica gel eluting successively with 5%, 10%, and 20% ethyl acetate in hexane followed by recrystallization from methanol afforded methyl 17 β -(t-butyldimethylsilyloxymethyl)-5- α -androst-3-ene-3-carboxylate.

(vi) 3-Carbomethoxy-3-androstene-17 β -carboxylic acid

Methyl 17 β -(*t*-butyldimethylsilyloxymethyl)-5 α -androst-3-ene-3-carboxylate (500 mg), was dissolved in 150 ml acetone. Jones reagent was added until a red color persisted. Isopropanol was then added to quench
 5 excess Jones reagent. The acetone was decanted off and the residual chromium salts were then dissolved in water and washed 3 times with dichloromethane. The organic layers were combined and passed through a plug of florisil and concentrated to give 360 mg (99%) of 3-carbomethoxy-3-androstene-17 β -carboxylic acid.

(vii) 3-Carbomethoxy-3-androstene-17 β -N,N-diisopropylcarboxamide

3-Carbomethoxy-3-androstene-17 β -carboxylic acid, (360 mg, 0.78 mmol) was suspended in 10 ml of dry toluene and treated with 0.4 ml of oxalyl chloride for 2 hours under argon. The reaction mixture was then evaporated (1 mm Hg) and the residue was dissolved in 10 ml dry THF. A solution of 0.6 ml diisopropylamine in 2 ml
 15 dry THF was added and the reaction mixture stirred for 1 hour. The mixture was diluted with ice water and extracted with dichloromethane. The organic layer was then washed twice with cold 5% hydrochloric acid, sodium hydroxide and brine; dried over sodium sulfate and evaporated. Chromatography on silica gel eluting with 20% ethyl acetate in hexane followed by recrystallization from diethyl ether afforded 3-carbomethoxy-3-androstene-17 β -N,N-diisopropylcarboxamide.

20 (viii) N,N-Diisopropyl-5 α -androst-3-ene-17 β -carboxamide-3-carboxylic acid

3-Carbomethoxy-3-androstene-17 β -N,N-diisopropylcarboxamide (300 mg, 0.7 mmol) and 300 mg of K₂CO₃ were added to 20 ml of 10 : 1 methanol : water solution and refluxed under argon for 20 hours. The mixture was then concentrated to dryness and diluted with water. The aqueous layer was rinsed with ethyl acetate
 25 and acidified. The emulsion was washed several times with dichloromethane. The organic layer was dried over sodium sulfate and evaporated. The product was recrystallized by dissolving in ethyl ether, adding ethyl acetate and concentration to afford N,N-diisopropyl-5 α -androst-3-ene-17 β -carboxamide-3-carboxylic acid, m.p. 159-162°C.

30 EXAMPLE 3N,N-Diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid(i) Androst-4-ene-3-one-17 β -carboxylic acid

Methyl androst-4-ene-3-one-17 β -carboxylate (20 g, 60 mmol) was dissolved in 700 ml of a 20 : 1 solution of methanol : water and potassium hydroxide (7 g) was added and the solution was refluxed under argon for 24 hours. The reaction mixture was then acidified with 5% hydrochloric acid and 250 ml water was added. After
 35 aging for 1 hour, the mixture was filtered and dried to yield 18 g (94%) of androst-4-ene-3-one-17 β -carboxylic acid as a white crystalline solid.

(ii) Androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide

A solution of androst-4-ene-3-one-17 β -carboxylic acid (18 g, 0.06 mol) in 350 ml of toluene was azeotropically dried until approximately 100 ml distillate was collected. The solution was then cooled to 10°C. Pyridine (6.7 ml, 0.08 mol) was added, followed by slow addition of a solution of oxalyl chloride (7.2 ml, 0.08 mol) in 10 ml of toluene. The reaction mixture was stirred at room temperature (under argon) for 2 hours, and then cooled to 0°C. A solution of diisopropylamine (89 ml, 0.6 mol) in 40 ml toluene was added dropwise such that the temperature did not exceed 40°C. The reaction mixture was stirred for 1 hour and then quenched with 300 ml ice
 45 water. The layers were separated and the aqueous layer was extracted 4 times with ethyl acetate (800 ml). The organic layers were combined and washed with 5% hydrochloric acid and brine. The organic layer was then dried over sodium sulfate and concentrated to dryness. Recrystallization by dissolving in 10 ml toluene and adding 200 ml hexane afforded 16.5 g (69%) of androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide (m.p. 236-239°C).

55 (iii) 17 β -(N,N-Diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene

Androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide (5 g, 12.5 mmol) was dissolved into 50 ml of

methylene chloride. 2,6-Di-*t*-butyl-4-methylpyridine (3.08 g, 17.0 mmol) was then added to the steroid solution and stirred at room temperature for 15 minutes. Trifluoromethane sulfonic anhydride (3.5 ml, 19 mmol) was added to the solution and stirring continued for 30 minutes. The reaction mixture was then diluted with 50 ml methylene chloride and filtered. The organic layer was washed twice with 5% hydrochloric acid, saturated sodium bicarbonate, and brine. It was then dried over sodium sulfate and evaporated. The triflate was purified by chromatography on silica gel eluting with 20% ethyl acetate in hexane to yield 4 g (61%) of 17 β -(*N,N*-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene.

(iv) 3-Carbomethoxy-androst-3,5-diene-17 β -*N,N*-diisopropylcarboxamide

To a solution of 17 β -(*N,N*-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene (4 g, 7.5 mmol) in 60 ml of a 1 : 1 solution of methanol in DMF was added bis (triphenylphosphine) palladium (II) acetate (570 mg) and a large excess (20 ml) of triethylamine. Carbon monoxide was bubbled through the solution for 5 minutes and the reaction was stirred at 65°C overnight under 1 atmosphere of CO. The mixture was then diluted with ethyl acetate and washed with water until neutral pH. The organic layer was dried over sodium sulfate and evaporated to a brown oil. Purification by chromatography on silica gel eluting with 20% ethyl acetate in hexane, followed by recrystallization from ethyl ether and hexane afforded 2.1 g (64%) of 3-carbomethoxy-androst-3,5-diene-17 β -*N,N*-diisopropylcarboxamide, m.p. 159-162°C.

(v) *N,N*-Diisopropyl-androst-3,5 diene-17 β -carboxamide-3-carboxylic acid

3-Carbomethoxy-androst-3,5-diene-17 β -*N,N*-diisopropylcarboxamide (1.4 g, 3.17 mmol) and 1 g of K₂CO₃ were added to 88 ml of a 10 : 1 solution of methanol-water and refluxed under argon for 20 hours. The mixture was then concentrated to dryness and diluted with water. The aqueous layer was rinsed with ethyl acetate and acidified. The emulsion was washed several times with dichloromethane. The organic layer was dried over sodium sulfate and evaporated. The product was recrystallized by dissolving in ethyl ether, adding ethyl acetate and concentration to afford *N,N*-diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid (m.p. 230-234°C).

EXAMPLE 4

17 β -(*N,N*-Diisopropylcarboxamide)-4-fluoro-5- α -androst-3-ene-3-carboxylic Acid

(i) 3-Oxo-17 β -(hydroxymethyl)-5- α -androstane

Ammonia (500 ml) was distilled into a 3-neck roundbottom flask equipped with a dry ice condenser and argon bubbler. Li wire (3 g) was dissolved in the ammonia and stirred for 15 minutes to ensure dryness. A solution of 3-oxo-17 β -(hydroxymethyl)-4-androstene (prepared as described in Example 2 (ii), 37.5 g, 0.123 mol) in 625 ml THF and *t*-butyl alcohol (6.25 ml, 0.8 eq) was added dropwise to the Li/NH₃ solution. The reaction was stirred at -78°C for 2 hours and quenched with isoprene until the blue color disappeared. The resulting enolate was then quenched with ammonium chloride and the ammonia was allowed to evaporate. Acetone was added to the residue and gently refluxed. The acetone solution was then filtered and evaporated to dryness to yield 24.7 g (79%) of 3-oxo-17 β -(hydroxymethyl)-5- α -androstane.

(ii) 3-Oxo-5- α -androstane-17 β -carboxylic Acid

The title compound was prepared according to Example 2 (vi) by replacing 3-oxo-17 β -(hydroxymethyl)-5- α -androstane for methyl 17 β -(*t*-butyldimethylsilyloxymethyl)-5- α -androst-3-ene-3-carboxylate.

(iii) 3-Oxo-5- α -androstane-17 β -*N,N*-diisopropylcarboxamide

3-Oxo-5- α -androstane-17 β -carboxylic acid was suspended in toluene (100 ml) and an excess of oxalyl chloride (8 ml) was added. The reaction mixture was stirred for 1 hour at 25°C (under argon). The volatiles were then removed (0.5 mmHg for 2 hours). The residue was resuspended in THF (25 ml), cooled to 0°C, and diisopropyl amine (10 ml) was added. The reaction mixture was stirred at 0°C for 2 hours and then diluted with water. The aqueous mixture was extracted with ethyl acetate and evaporated. Purification by chromatography on silica gel eluting with 20% ethyl acetate in hexane afforded 3.15 g (78%) of 3-oxo-5- α -androstane-17 β -*N,N*-diisopropylcarboxamide.

(iv) 3-Oxo-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide

To a solution of 3-oxo-5- α -androstane-17 β -N,N-diisopropylcarboxamide (2.3 g, 5.74 mmol) in 100 ml ethyl acetate was added phenylselenenylchloride (1.1 g, 5.74 mmol) and the reaction mixture was stirred for 2 hours. The reaction mixture was then washed with 5% sodium bicarbonate solution and brine. The ethyl acetate solution was cooled to 0°C and 50 ml THF was added. Hydrogen peroxide (6 ml of a 30% solution) was slowly added and the reaction mixture stirred for 2 hours. The reaction mixture was then washed with 5% sodium bicarbonate solution, brine and evaporated to dryness. Purification by chromatography on silica gel eluting with 20% ethyl acetate in hexane afforded 1.3 g (58.5%) of 3-oxo-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide.

(v) 3-Oxo-5- α -androstane-1,2- α -epoxide-17 β -N,N-diisopropylcarboxamide

3-Oxo-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide (4.6 g, 11.5 mmol) was dissolved in 50 ml methanol and cooled to 15°C. To the solution was added hydrogen peroxide (0.8 ml of a 30% solution) followed by sodium hydroxide (0.16 ml of a 10% solution) in 2 ml methanol. The ice bath was removed and stirring was continued at room temperature for 1 hour. The reaction mixture was then poured into ice water and washed twice with dichloromethane. The organic layers were combined and washed with water and brine; dried over sodium sulfate and evaporated. Trituration in acetone afforded 4.0 g (83.7%) of the desired epoxide; 3-oxo-5- α -androstane-1,2- α -epoxide-17 β -N,N-diisopropylcarboxamide.

(vi) 3-Oxo-4-fluoro-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide

3-Oxo-5- α -androstane-1,2- α -epoxide-17 β -N,N-diisopropylcarboxamide (1.7 g, 4 mmol) was dissolved in 25 ml THF and cooled to -20°C. Pyridinium poly (hydrogen fluoride) (10 ml) was slowly added to the solution (under argon). The reaction mixture was warmed to 0°C, stirred 30 minutes then warmed to room temperature and stirred for 15 minutes. The reaction mixture was poured into ice water and washed with ethyl acetate. The organic layer was washed with water, 5% sodium bicarbonate solution and brine; dried over sodium sulfate and evaporated. Purification by chromatography on silica gel eluting with 20% ethyl acetate in hexane yielded 750 mg (44%) of the desired 3-oxo-4-fluoro-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide.

(vii) 17 β -(N,N-Diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-4-fluoro-5- α -androst-1,3-diene

A solution of lithium bis (trimethylsilyl) amide (4.2 mmol, 2.2 eq) in 2 ml THF was cooled to -78°C. A solution of 3-oxo-4-fluoro-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide (800 mg, 1.9 mmol) in 10 ml THF was added and the reaction mixture was stirred for 1 hour. A solution of N-phenyltrifluoromethanesulfonimide (857 mg, 2.4 mmol) in 2 ml THF was then added and the reaction mixture was stirred for 1.5 hours at -78°C. The reaction mixture was then evaporated to dryness and chromatographed on silica gel eluting with 20% ethyl acetate in hexane. Trituration in a hexane and ether solution afforded 460 mg (46%) of the desired product, 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethyl sulfonate)-4-fluoro-5- α -androst-1,3-diene.

(viii) 3-Carbomethoxy-4-fluoro-5- α -androst-1,3-diene-17 β -N,N-diisopropylcarboxamide

The title compound was prepared according to Example 1 (iv) by substituting 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-4-fluoro-5- α -androst-1,3-diene for 20- α -(t-butylidimethylsilyloxy)methyl)-3-(trifluoromethylsulfonate)-5- α -pregn-3-ene.

(ix) 3-Carbomethoxy-4-fluoro-5- α -androst-3-ene-17 β -N,N-diisopropylcarboxamide

3-Carbomethoxy-4-fluoro-5- α -androst-1,3-diene-17 β -N,N-diisopropylcarboxamide (120 mg, 0.26 mmol) in 15 ml of a 2 : 1 solution of ethyl acetate and hexane was hydrogenated at 25°C and 1 atmosphere over 20 mg 10% palladium on carbon. The solution was filtered to remove the catalyst and concentrated to a white solid (120 mg). Recrystallization from methanol and acetone afforded 55 mg (46%) of the desired 3-carbomethoxy-4-fluoro-5- α -androst-3-ene-17 β -N,N-diisopropylcarboxamide, m.p. 171-172°C.

(x) 17 β -(N,N-Diisopropylcarboxamide)-4-fluoro-5- α -androst-3-ene-3-carboxylic Acid

The title compound was prepared according to Example 2 (viii) by substituting 3-carbomethoxy-4-fluoro-5- α -androst-3-ene-17 β -diisopropylcarboxamide for 3-carbomethoxy-5- α -androst-3-ene-17 β -N,N-diisopropyl-

carboxamide.

EXAMPLE 5

5 20- α -(Hydroxymethyl)-4-fluoro-5- α -pregn-3-ene-3-carboxylic Acid

(i) 20- α -(Hydroxymethyl)-5- α -pregnan-3-one

The title compound was prepared according to Example 4 (i) by substituting 20- α -(hydroxymethyl)-pregn-4-ene-3-one for 3-oxo-17 β -(hydroxymethyl)-4-androstene.

(ii) 20- α -(Hydroxymethyl)-5- α -pregn-1-ene-3-one

The title compound was prepared according to Example 4 (iv) by substituting 20- α -(hydroxymethyl)-5- α -pregnane-3-one for 3-oxo-5- α -androstane-17 β -N,N-diisopropylcarboxamide.

(iii) 20- α -(Hydroxymethyl)-1,2- α -epoxide-5- α -pregnan-3-one

The title compound was prepared according to Example 4 (v) by substituting 20- α -(hydroxymethyl)-5- α -pregn-1-ene-3-one for 3-oxo-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide.

(iv) 20- α -(Hydroxymethyl)-4-fluoro-5- α -pregn-1-ene-3-one

The title compound was prepared according to Example 4 (vi) by substituting 20- α -(hydroxymethyl)-1,2- α -epoxide-5- α -pregnane-3-one for 3-oxo-1,2- α -epoxide-5- α -androstane-17 β -N,N-diisopropylcarboxamide.

(v) 20- α -(t-Butyldimethylsilyloxymethyl)-4-fluoro-5- α -pregn-1-ene-3-one

The title compound was prepared according to Example 1 (ii) by substituting 20- α -(hydroxymethyl)-4-fluoro-5- α -pregn-1-ene-3-one for 20- α -(hydroxymethyl)-pregn-4-ene-3-one.

(vi) 20- α -(t-Butyldimethylsilyloxymethyl)-4-fluoro-3-(trifluoromethylsulfonate)-5- α -pregn-1,3-diene

The title compound was prepared according to Example 4 (vii) by substituting 20- α -(t-butyldimethylsilyloxymethyl)-4-fluoro-5- α -pregn-1-ene-3-one for 3-oxo-4-fluoro-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide.

(vii) 3-Carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-4-fluoro-5- α -pregn-1,3-diene

The title compound was prepared according to Example 4 (viii) by substituting 20- α -(t-butyldimethylsilyloxymethyl)-4-fluoro-3-(trifluoromethylsulfonate)-5- α -pregn-1,3-diene for 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-4-fluoro-5- α -androst-1,3-diene.

(viii) 3-Carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-4-fluoro-5- α -pregn-3-ene

The title compound was prepared according to Example 4 (ix) by substituting 3-carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-4-fluoro-5- α -pregn-1,3-diene for 3-carbomethoxy-4-fluoro-5- α -androst-1,3-diene-17 β -N,N-diisopropylcarboxamide.

40 (ix) 3-Carbomethoxy-20- α -(hydroxymethyl)-4-fluoro-5- α -pregn-3-ene

To a solution of 3-carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-4-fluoro-5- α -pregn-3-ene (610 mg, 1.2 mmol) in THF 20 ml was added 2.4 mmol tetrabutylammonium fluoride and the reaction mixture was stirred at 25°C for 3.5 hours under argon. The reaction mixture was then poured into ether and washed with water and brine; dried over sodium sulfate and evaporated. Chromatography on silica gel eluting with 15% ethyl acetate in hexane yielded 200 mg (43%) of the desired 3-carbomethoxy-20- α -(hydroxymethyl)-4-fluoro-5- α -pregn-3-ene, m.p. 177°C.

(x) 20- α -(Hydroxymethyl)-4-fluoro-5- α -pregn-3-ene-3-carboxylic acid

The title compound (m.p. 233-236°C from methanol : acetone) was prepared according to Example 1 (vi) by substituting 3-carbomethoxy-20- α -(hydroxymethyl)-4-fluoro-5- α -pregn-3-ene for 20- α -(hydroxymethyl)-3-carbomethoxy-5- α -pregn-3-ene.

EXAMPLE 620- α -(Hydroxymethyl)-A-nor-5- α -pregn-1-ene-2-carboxylic acid(i) 20- α -(Hydroxymethyl)-A-nor-5- α -pregnan-2- α -carboxylic acid

20- α -(Hydroxymethyl)-5- α -pregnane-3-one (8 g, 24.1 mmol) was suspended in 180 ml of 95% acetic acid, treated with thallic acetate sesquihydrate (30.4 g, 74.5 mmol), and warmed to 85°C. After 3 hours the reaction mixture was cooled and poured into ice water. The precipitate was filtered, redissolved in ethyl acetate, washed with water and brine; dried over sodium sulfate and evaporated. The resulting oil was dissolved in methanol, treated with aqueous KOH (8 g in 50 ml water), warmed to 100°C for 40 minutes and then cooled to room temperature and allowed to stir 18 hours. The reaction mixture was then diluted with water and washed with ethyl acetate. The aqueous solution was acidified with concentrated hydrochloric acid and washed several times with ethyl acetate. The organic layers were combined, washed with water and brine; dried over sodium sulfate and evaporated. Recrystallization from methanol and acetone afforded 4.9 g (58%) of 20- α -(hydroxymethyl)-A-nor-5- α -pregnan-2- α -carboxylic acid.

(ii) 20- α -(Hydroxymethyl)-2- α -carbomethoxy-A-nor-5- α -pregnane

20- α -(Hydroxymethyl)-A-nor-5- α -pregnan-2- α -carboxylic acid (4.9 g, 13.5 mmol) was suspended in 200 ml diethylether and treated with approximately 67 mmol of diazomethane in an ethereal solution and the reaction mixture was stirred for 6 hours. The excess diazomethane and ether was removed *in vacuo* and recrystallization from methanol afforded 3.6 g (72%) of 20- α -(hydroxymethyl)-2- α -carbomethoxy-A-nor-5- α -pregnane.

(iii) 2- α -Carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-A-nor-5- α -pregnane

The title compound was prepared according to Example 1 (ii) by substituting 20- α -(hydroxymethyl)-2- α -carbomethoxy-A-nor-5- α -pregnane for 20- α -(hydroxymethyl)-pregn-4-ene-3-one.

(iv) 2- α -Carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-A-nor-5- α -pregn-2-ene

2- α -Carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-A-nor-5- α -pregnane (960 mg, 2 mmol) was dissolved in 30 ml THF and cooled to -78°C. Lithium isopropylcyclohexylamide (5 ml of a 0.72 M solution) was added and the solution was stirred for 30 minutes at -78°C, warmed to room temperature and stirred an additional 1 hour. The reaction mixture was again cooled to -78°C; a solution of phenylselenenylbromide (960 mg, 4 mmol) in 5 ml THF was added and stirred for 30 minutes. The reaction mixture was then warmed to room temperature and stirred 1 hour; poured into cold saturated NH₄Cl and washed with ethyl acetate. The organic layers were combined and washed with cold 5% hydrochloric acid, 5% sodium bicarbonate solution, water and brine. The ethyl acetate solution was then cooled to 10°C and hydrogen peroxide (1 ml of a 30% solution) was added. The reaction mixture was then stirred at room temperature for 2 hours, diluted with water and washed with saturated K₂CO₃, dilute sodium sulfite and brine, dried over sodium sulfate and evaporated. Purification by chromatography on silica gel eluting with 3% ethyl acetate in hexane followed by recrystallization from methanol afforded 680 mg (72%) of a 5 : 1 mixture of isomers : 2-carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-A-nor-5- α -pregn-1-ene and the desired isomer 2-carbomethoxy-20- α -(t-butyldimethylsilyloxymethyl)-A-nor-5- α -pregn-2-ene. The isomers were separated to yield 100 mg of the desired title compound.

(v) 20- α -(Hydroxymethyl)-2- α -carbomethoxy-A-nor-5- α -pregn-2-ene

The title compound was prepared according to Example 1 (v) by substituting 2-carbomethoxy 20- α -(t-butyldimethylsilyloxymethyl)-A-nor-5- α -pregn-2-ene for 20- α -(t-butyldimethylsilyloxymethyl)-3-carbomethoxy-5- α -pregn-3-ene.

(vi) 20- α -(Hydroxymethyl)-A-nor-5- α -pregn-1-ene-2-carboxylic acid

The title compound (m.p. 235°C from methanol) was prepared according to Example 1 (vi) by replacing 20- α -(hydroxymethyl)-2-carbomethoxy-A-nor-5- α -pregn-2-ene for 20- α -(hydroxymethyl)-3-carbomethoxy-5- α -pregn-3-ene.

EXAMPLE 717 β -N,N-Diisopropylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid(i) 17 β -(N,N-Diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-5- α -androst-1,3-diene

The title compound was prepared according to Example 4 (vii) by substituting 3-oxo-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide for 3-oxo-4-fluoro-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide.

(ii) 3-Carbomethoxy-5- α -androst-1,3-diene-17 β -N,N-diisopropylcarboxamide

The title compound (m.p. 174-176°C) was prepared according to Example 1 (iv) by substituting 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-5- α -androst-1,3-diene for 20- α -(t-butyldimethylsilyloxymethyl)-3-(trifluoromethylsulfonate)-5- α -pregn-3-ene.

(iii) 17 β -N,N-Diisopropylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid

The title compound (m.p. 163°C) was prepared according to Example 2 (viii) by substituting 3-carbomethoxy-5- α -androst-1,3-diene-17 β -N,N-diisopropylcarboxamide for 3-carbomethoxy-5- α -androst-3-ene-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 819-Nor-5- α -androst-3-ene-17 β -ol-3-carboxylic acid

The title compound is prepared according to Example 1 (ii through vi) by substituting 19-nor-testosterone for 20- α -(hydroxymethyl)-pregn-4-ene-3-one.

EXAMPLE 95- α -Pregn-3-ene-(20R)-3,20-dicarboxylic acid(i) 3-Carbomethoxy-5- α -pregn-3-ene-(20R)-20-carboxylic acid

To a solution of 20- α -(hydroxymethyl)-3-carbomethoxy-5- α -pregn-3-ene, prepared as in Example 1, (374 mg, 1.0 mmol) in 25 ml acetone is added Jones reagent dropwise until a red color persists. Isopropanol is then added to quench the excess oxidant. The solution is decanted from the gummy chromium salts, concentrated, and partitioned between dichloromethane and water. The salts are dissolved in water and extracted with dichloromethane. The combined organic layers are then washed with brine, dried over sodium sulfate, and concentrated to yield 3-carbomethoxy-5- α -pregn-3-ene-(20R)-20-carboxylic acid.

(ii) 5- α -Pregn-3-ene-(20R)-3,20-dicarboxylic acid

The title compound is prepared according to Example 1 (vi) by substituting 3-carbomethoxy-5- α -pregn-3-ene-(20R)-20-carboxylic acid for 20- α -(hydroxymethyl)-3-carbomethoxy-5- α -pregn-3-ene.

EXAMPLE 10N,N-Diisopropyl-5- α -pregn-3-ene-(20R)-20-carboxamide-3-carboxylic acid

The title compound was prepared according to Example 2 (vii-viii) by substituting 3-carbomethoxy-5- α -pregn-3-ene-(20R)-20-carboxylic acid, prepared as in Example 9, for 3-carbomethoxy-3-androstene-17 β -car-

boxylic acid.

EXAMPLE 11

5 5- α -3-Ene-17 β -carboxaldehyde-3-carboxylic acid

(i) 3-Carbomethoxy-5- α -androst-3-ene-17 β -carboxylchloride

10 A solution of 3-carbomethoxy-3-androstene-17 β -carboxylic acid (462 mg, 1.0 mmol) is suspended in 10 ml toluene and treated with 0.5 ml of oxalyl chloride for 2 hours. The volatile materials are then removed at 1 mmHg leaving a residue of 3-carbomethoxy-5- α -androst-3-ene-17 β -carboxylchloride.

(ii) 3-Carbomethoxy-5- α -androst-3-ene-17 β -carboxaldehyde

15 A solution of 3-carbomethoxy-5- α -androst-3-ene-17 β -carboxylchloride (480 mg, 1.0 mmol) in 10 ml tetrahydrofuran is treated with lithium tri-*t*-butoxyaluminum hydride (254 mg, 1.0 mmol) at 0°C for one hour to yield, after aqueous workup, 3-carbomethoxy-5- α -androst-3-ene-17 β -carboxaldehyde.

(iii) 5- α -3-Androst-3-ene-17 β -carboxaldehyde-3-carboxylic acid

20 The title compound is prepared according to Example 2 (viii) by substituting 3-carbomethoxy-5- α -androst-3-ene-17 β -carboxaldehyde for 3-carbomethoxy-3-androstene-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 12

25 5- α -Androst-3-ene-17 β -(1-oxobutyl)-3-carboxylic acid

(i) 3-Carbomethoxy-17 β -(1-oxobutyl)-5- α -androst-3-ene

30 A solution of 3-carbomethoxy-5- α -androst-3-ene-17 β -carboxylchloride (480 mg, 1 mmol), prepared as in Example 11, in 10 ml THF is treated with 1.0 mmol of di-*n*-butyl copperlithium at -78°C. The reaction is quenched with aqueous ammonium chloride. Extraction with dichloromethane followed by concentration of the organic extracts and chromatography of the residue yields 3-carbomethoxy-17 β -(1-oxobutyl)-5- α -androst-3-ene.

(ii) 5- α -Androst-3-ene-17 β -(1-oxobutyl)-3-carboxylic acid

35 The title compound is prepared according to Example 1 (vi) by substituting 3-carbomethoxy-17 β -(1-oxobutyl)-5- α -androst-3-ene for 20- α -(hydroxymethyl)-3-carbomethoxy-5- α -pregn-3-ene.

EXAMPLE 13

Androst-3,5-diene-17 β -ol-3-carboxylic acid

45 The title compound is prepared according to Example 3 (iii through v) by substituting commercially available testosterone acetate for androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 14

50 Androst-3,5-diene-17-one-3-carboxylic acid

The title compound is prepared according to Example 9 (i) by substituting androst-3,5-diene-17 β -ol-3-carboxylic acid (Example 13) for 20- α -(hydroxymethyl)-3-carbomethoxy-5- α -pregn-3-ene.

EXAMPLE 15**Ethyl pregn-3,5,17(20)-triene-3-carboxyl-21-oate**

A solution of sodium ethoxide (680 mg, 10 mmol) in 5 ml ethanol is added to a mixture of androst-3,5-diene-17-one-3-carboxylic acid (942 mg, 3 mmol) prepared as in Example 14, and methyl diethylphosphonoacetate (2.12 g, 10 mmol) and the resulting mixture heated at reflux for 4 hours. The mixture is cooled, concentrated, diluted with dilute acetic acid and washed with ether. The combined ethereal extracts are washed with water and brine, and concentrated to yield ethyl pregn-3,5,17(20)-triene-3-carboxy-21-oate.

EXAMPLE 16**Androst-3,5,16-triene-17-N,N-diisopropyl-carboxamide-3-carboxylic acid****(i) Androst-3,5,16-triene-17-(trifluoromethylsulfonate)-3-carboxylic acid**

To a solution of androst-3,5-diene-17-one-3-carboxylic acid (314 mg, 1 mmol), prepared as in Example 14, in 10 ml methylene chloride is added 2,6-di-*t*-butyl-4-methylpyridine (272 mg, 1.5 mmol) and trifluoromethanesulfonic anhydride (0.3 ml, 1.6 mmol) and the solution is stirred for 4 hours. The reaction mixture is then diluted with methylene chloride, washed with 10% hydrochloric acid, brine, and concentrated to yield crude androst-3,5,16-triene-17-(trifluoromethylsulfonate)-3-carboxylic acid.

(ii) Androst-3,5,16-triene-17-N,N-diisopropylcarboxamide-3-carboxylic acid

A mixture of androst-3,5,16-triene-17-(trifluoromethylsulfonate)-3-carboxylic acid (447 mg, 1 mmol), triethylamine (200 mg, 2 mmol), diisopropylamine (4 g, 40 mmol), and bis(triphenylphosphine) palladium(II) acetate (22 mg, 0.03 mmol) in 4 ml DMF is stirred under an atmosphere of carbon monoxide for 4 hours. The mixture is then diluted with 10% hydrochloric acid and thoroughly washed with dichloromethane. The dichloromethane solution is washed with brine, dried and concentrated, and the residue is recrystallized (diethylether) to yield androst-3,5,16-triene-17-N,N-diisopropylcarboxamide-3-carboxylic acid.

EXAMPLE 17**2',3'- α -Tetrahydrofuran-2'-spiro-17-(3,5-androstadiene-3-carboxylic acid**

The title compound is prepared according to Example 3 (iii through v) by substituting 2',3'- α -tetrahydrofuran-2'-spiro-17-(androst-4-ene-3-one) for androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 18**3-Carbomethoxy-17 β -acetamido-3,5-androstadiene**

The title compound is prepared according to Example 3 (iii-iv) by substituting 17 β -acetamido-4-androsten-3-one for androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 19**Androst-3,5-diene-17- α -ol-3,17 β -dicarboxylic acid****(i) 17 β -Cyano-17- α -acetoxyandrost-4-ene-3-one**

4-Androstan-3,17-dione (20 g) is dissolved by gentle warming in acetone cyanohydrin (30 ml). The crystals which form after several minutes are filtered, washed with pentane, and then dissolved in a mixture of pyridine (50 ml) and acetic anhydride (50 ml). After 48 hours the volatiles are removed under reduced pressure. The residue is then dissolved in ether and washed successively with 5% hydrochloric acid and aqueous sodium bicarbonate. The organic solution is dried and concentrated to afford a mixture of C-17 epimers of 17-cyano-17-acetoxyandrost-4-ene-3-one. Chromatography affords 17 β -cyano-17- α -acetoxyandrost-4-ene-3-one.

(ii) 3-Carbomethoxy-17 β -cyano-17- α -acetoxyandrost-3,5-diene

The title compound is prepared according to Example 3 (iii-iv) by substituting 17-cyano-17-acetoxyandrost-4-ene-3-one for androst-4-ene-3-one-17 β -N,N-disopropylcarboxamide.

(iii) Androst-3,5-diene-17- α -ol-3,17 β -dicarboxylic acid

A solution of 3-carbomethoxy-17 β -cyano-17- α -acetoxyandrost-3,5-diene in methanol is cooled to 15°C. Dry hydrochloric acid is bubbled into the solution and the mixture allowed to stand at room temperature for 2 hours. Solvent is then removed under reduced pressure. A mixture of 1 : 1 THF-water is added followed by excess sodium hydroxide and the mixture is stirred for 2 hours. The reaction mixture then is acidified and extracted with chloroform. Concentration of the organic solution affords androst-3,5-diene-17- α -ol-3,17 β -dicarboxylic acid which is recrystallized from methanol.

EXAMPLE 20

5- α -Androst-3,8(14)-diene-17 β -ol-3-carboxylic acid(i) Androst-5,7-diene-3 β ,17 β -diol

A mixture of androst-5-ene-3 β ,17 β -diol diacetate (3.75 g, 10 mmol), dibromantin (2.03 g, 7 mmol), and sodium bicarbonate (4.54 g, 54 mmol) in hexane (200 ml) is heated under reflux for 0.5 hours. The mixture is then cooled and filtered and the filtrate evaporated to dryness. The residue is dissolved in 50 ml toluene and treated with lithium bromide (2 g) in 5 ml of acetone. The mixture is stirred at 0°C for 2 hours and then treated with 2 ml triethylamine and 1.5 ml benzenethiol. After stirring at room temperature for 1.5 hours, 100 ml ethyl acetate is added and the organic solution is washed with 1 N hydrochloric acid and water. The organic phase is dried and concentrated. The residue is then redissolved in 75 ml ethyl acetate, cooled to 0°C and treated with 2.6 g of *m*-chloroparbenzoic acid for 2 hours. The mixture is washed with 10% sodium bicarbonate solution and then concentrated. The residue is dissolved in 100 ml toluene, treated with triethylamine (3.6 ml), heated at 70°C for 24 hours, cooled, and washed with water. The organic solution was concentrated and chromatographed to yield androst-5,7-diene-3 β ,17 β -diol diacetate. The diacetate is treated with K₂CO₃ in a 10:1 methanol : water solution overnight to yield, after extractive workup, androst-5,7-diene-3 β ,17 β -diol.

(ii) Androst-4,7-diene-3,17-dione

A solution of androst-5,7-diene-3 β ,17 β -diol (2.9 g, 10 mmol) in 150 ml toluene is azeotropically dried for one hour. Butanone (15 ml) is added followed by aluminum isopropoxide (1.7 g, 8 mmol) and the mixture is heated at reflux for 2.5 hours. The solution is then concentrated to a volume of 25 ml, diluted with trichloromethane, and washed with 5% hydrochloric acid, aqueous sodium bicarbonate, and brine. Concentration and chromatography affords androst-4,7-diene-3,17-dione.

(iii) 5- α -Androst-7-ene-3-one-17 β -ol

The title compound is prepared according to the procedure of Example 4 (i) by substituting androst-4,7-diene-3,17-dione for 3-oxo-17 β -(hydroxymethyl)-4-androstene.

(iv) 5- α -Androst-8(14)-ene-3-one-17 β -ol

A solution of 5- α -androst-7-ene-3-one-17 β -ol in ethyl acetate is hydrogenated at room temperature and 1 atmosphere over 10% palladium on carbon for 8 hours. Filtration to remove the catalyst and concentration affords 5- α -androst-8(14)-ene-3-one-17 β -ol.

(v) 5- α -Androst-1,8(14)-diene-3-one-17 β -ol

The title compound is prepared according to Example 5 (ii) by substituting 5- α -androst-8(14)-ene-3-one-17 β -ol for 20- α -(hydroxymethyl)-5- α -pregnen-3-one.

(vi) 5- α -Androst-3,8(14)-diene-17 β -ol-3-carboxylic acid

The title compound is prepared according to Example 5 (v through x) by substituting 5- α -androst-1,8(14)-diene-3-one-17 β -ol for 20- α -(hydroxymethyl)-pregn-4-ene-3-one.

EXAMPLE 21N,N-Diisopropyl-androst-3,5,7-triene-17 β -carboxamide-3-carboxylic acid(i) Androst-4,6-diene-3-one-17 β -N,N-diisopropylcarboxamide

Androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide (12 g, 30 mmol) and chloranil (8.95 g, 36.4 mmol) in 700 ml t-butanol is heated at reflux for 3.5 hours then cooled and filtered. The filtrate is concentrated and the residue taken up in 700 ml trichloromethane and washed successively with 4 x 150 ml water, 3 x 150 ml aqueous sodium bicarbonate, 3 x 150 ml 5% sodium hydroxide, 3 x 150 ml brine, dried over sodium sulfate and concentrated to yield androst-4,6-diene-3-one-17 β -N,N-diisopropylcarboxamide.

(ii) N,N-Diisopropyl androst-3,5,7-triene-17 β -carboxamide-3-carboxylic acid

The title compound is prepared according to Example 3 (iii-v) by substituting androst-4,6-diene-3-one-17 β -N,N-diisopropylcarboxamide for androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 22A-Homo-5- α -4-ene-17 β -N,N-diisopropylcarboxamide-4-carboxylic acid(i) A-Homo-5- α -androstane-4-one-17 β -N,N-diisopropylcarboxamide

To a 0°C solution of 3-oxo-5- α -androstane-17 β -N,N-diisopropylcarboxamide (15 g), prepared as in Example 4, and KOH (28 g) in ether (500 ml) and methanol (850 ml) is added 20 g of N-methylnitrosourea over 20 minutes. After 5 hours, 300 ml of 10% hydrochloric acid is added and the mixture is filtered and concentrated to remove the organic solvents. The resulting aqueous suspension is extracted with ether and the ethereal solution is dried and concentrated. Chromatography of the residue yields A-homo-5- α -androstane-4-one-17 β -N,N-diisopropylcarboxamide.

(ii) A-Homo-5- α -4-ene-17 β -N,N-diisopropylcarboxamide-4-carboxylic acid

Utilizing the protocol of Example 3 (iii-v), substitution of androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide with A-homo-5- α -androstane-4-one-17 β -N,N-diisopropylcarboxamide yields a mixture of 3-ene, and 4-ene A-homo-4-carboxylic acids. Chromatography and recrystallization yields pure A-homo-5- α -androst-4-ene-17 β -N,N-diisopropylcarboxamide-4-carboxylic acid.

EXAMPLE 23N,N-Diisopropyl-4-chloro-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid(i) 3-Oxo-androstane-4-5- α -epoxide-17 β -N,N-diisopropylcarboxamide

The title compound is prepared according to Example 4 (v) by substituting androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide for 3-oxo-5- α -androst-1-ene-17 β -N,N-diisopropylcarboxamide.

(ii) 3-Oxo-4-chloro-4-androstene-17 β -N,N-diisopropylcarboxamide

A stream of hydrogen chloride gas is passed through a chloroform solution of 3-oxo-androstane-4,5-epoxide-17 β -N,N-diisopropylcarboxamide for 2 minutes. The solution is then washed with water, dried (Na₂SO₄), and concentrated to yield 3-oxo-4-chloro-4-androstene-17 β -N,N-diisopropylcarboxamide.

(iii) N,N-Diisopropyl-4-chloro-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid

The title compound is prepared according to Example 3 (iii through v) by substituting 3-oxo-4-chloro-4-androstene-17 β -N,N-diisopropylcarboxamide for androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 24N,N-Diisopropyl-4-methyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid(i) 3-Oxo-17 β -(hydroxymethyl)-4-methyl-4-androstene

A mixture of potassium-t-butoxide (5 g) in 100 ml t-butanol is heated to reflux. A solution of 3-oxo-17 β -(hydroxymethyl)-4-androstene (10 g) in t-butanol is added followed by a solution of methyl iodide (2.7 g) in t-butanol. Heating is continued for 3 hours. The mixture is then cooled, acidified, and extracted with dichloromethane. The dichloromethane solution is washed with brine, dried, and concentrated to yield 3-oxo-17 β -(hydroxymethyl)-4-methyl-4-androstene.

(ii) N,N-Diisopropyl-4-methyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid

The title compound is prepared according to Example 2 (iii through viii) by substituting 3-oxo-17 β -(hydroxymethyl)-4-methyl-4-androstene for 3-oxo-17 β -(hydroxymethyl)-4-androstene.

EXAMPLE 25N,N-Diisopropyl-4-trifluoromethyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid(i) 3-Oxo-4-trifluoromethyl-4-androstene-17 β -N,N-diisopropylcarboxamide

A solution of 3-oxo-4-androstene-17 β -N,N-diisopropylcarboxamide (1 g) in 10 ml of pyridine is cooled to -78°C. Trifluoromethyl iodide gas is condensed in a dry ice-acetone bath and added to the steroid-pyridine cooled solution. The resulting solution is photolyzed using a medium pressure 450 watt mercury vapor lamp at room temperature for 18 hours. The reaction mixture is then diluted with ethyl acetate, washed with cold dilute hydrochloric acid, 5% sodium bisulfite, water, brine, dried over anhydrous sodium sulfate, and concentrated to dryness. Purification on a silica gel column eluting with 20% ethyl acetate in hexane yields 3-oxo-4-trifluoromethyl-4-androstene-17 β -N,N-diisopropylcarboxamide.

(ii) N,N-Diisopropyl-4-trifluoromethyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid

The title compound is prepared according to Example 3 (iii through v) by substituting 3-oxo-4-trifluoromethyl-4-androstene-17 β -N,N-diisopropylcarboxamide for androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 26N,N-Diisopropyl-6-trifluoromethyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid(i) 3-Oxo-6-trifluoromethyl-4-androstene-17 β -N,N-diisopropylcarboxamide

17 β -N,N-diisopropylcarboxamide-3-(trifluoromethylsulfonate)-androst-3,5-diene (1 g) is dissolved in 10 ml of pyridine and is photolyzed using a Hanovia medium pressure 450 watt mercury vapor lamp at room temperature for 18 hours. The reaction solution is diluted with ethyl acetate which in turn is washed with cold dilute hydrochloric acid, water, brine, dried over anhydrous magnesium sulfate, and evaporated to dryness. Silica gel column chromatography eluting with 20% ethyl acetate in hexane affords 3-oxo-6-trifluoromethyl-4-androstene-17 β -N,N-diisopropylcarboxamide.

(ii) N,N-Diisopropyl-6-trifluoromethyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid

The title compound is prepared according to Example 3 (iii through v) by substituting 3-oxo-6-trifluoromethyl-4-androstene-17 β -N,N-diisopropylcarboxamide for 3-oxo-4-trifluoromethyl-4-androstene-17 β -N,N-diisopropylcarboxamide.

fluoromethyl-4-androstene-17 β -N,N-diisopropylcarboxamide for androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide.

EXAMPLE 27

17 β -N,N-Diisopropylcarboxamide-6-fluoro-androst-3,5-diene-3-carboxylic acid

(i) 17 β -N,N-Diisopropylcarboxamide-5- α -androstene-3-spiro-2'-dioxolane

To a solution of 3-oxo-4-androstene-17 β -N,N-diisopropylcarboxamide (8 g) in 300 ml of benzene was added 30 ml of ethylene glycol and p-toluenesulfonic acid (240 mg). The resulting solution was refluxed under argon with water collection using a Dean Stark trap for 30 hours. The reaction mixture was then allowed to cool to room temperature and diluted with ethyl acetate. The organic layer was washed with 5% sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, and evaporated to dryness. The crude material was purified on a silica gel column using 20% ethyl acetate in hexane as the eluting solvent to afford 7 g of 17 β -N,N-diisopropylcarboxamide-5- α -androstene-3-spiro-2'-dioxolane (80%).

(ii) 17 β -N,N-Diisopropylcarboxamide-5- α ,6- α -epoxy-androstene-3-spiro-2'-dioxolane

To a solution of 17 β -N,N-diisopropylcarboxamide-5-androstene-3-spiro-2'-dioxolane (4.43 g, 10 mmol) in 100 ml of dry dichloromethane at 0°C was added a solution of m-chloroperbenzoic acid (2.8 g) in 40 ml of dichloromethane dropwise through a dropping funnel. After completion of addition of m-chloroperbenzoic acid, the reaction mixture was allowed to warm to room temperature and stirred for another 30 minutes. The reaction mixture was then washed with 10% aqueous sodium sulfite solution four times followed by 5% aqueous sodium bicarbonate solution, brine, dried over anhydrous magnesium sulfate, and concentrated to a syrup. Column chromatography, eluting with 30% ethyl acetate in hexane, yielded 2.76 g of 17 β -N,N-diisopropylcarboxamide-5- α ,6- α -epoxy-androstene-3-spiro-2'-dioxolane as a white solid (61%).

(iii) 3-Oxo-6-fluoro-4-androstene-17 β -N,N-diisopropylcarboxamide

17 β -N,N-diisopropylcarboxamide-5- α ,6- α -epoxy-androstene-3-spiro-2'-dioxolane (2.5 g) was dissolved in a mixture of 50 : 50 (v/v) benzene and ether. To this solution was added borontrifluoride-etherate (2.5 ml) under argon. The reaction solution was stirred at room temperature under argon for four hours and then quenched with 5% aqueous sodium carbonate. The organic layer was washed with water, brine, dried over anhydrous magnesium sulfate, and evaporated to dryness under reduced pressure. The residue was then treated with 15 ml of saturated hydrogen chloride in glacial acetic acid. The resulting solution was stirred at room temperature under argon for 1.5 hours and then diluted with ethyl acetate. The ethyl acetate solution was washed with 5% aqueous sodium bicarbonate, water, brine, dried over anhydrous magnesium sulfate, and evaporated to dryness. The crude material was purified on a silica gel column eluting with 25% ethyl acetate in hexane to yield 3-oxo-6 β -fluoro-4-androstene-17 β -N,N-diisopropylcarboxamide (675 mg, 30%) and 3-oxo-6- α -fluoro-4-androstene-17 β -N,N-diisopropylcarboxamide (900 mg, 40%).

(iv) 17 β -N,N-Diisopropylcarboxamide-3-(trifluoromethylsulfonate)-6-fluoro-androst-3,5-diene

To a solution of the epimers of 3-oxo-6-fluoro-4-androstene-17 β -N,N-diisopropylcarboxamide (1.4 g) in 50 ml of dry dichloromethane was added 2,6-di-*t*-butyl-4-methylpyridine (850 mg) followed by trifluoromethanesulfonic anhydride (9.75 ml) under argon. The resulting solution was stirred at room temperature under argon for 3 hours. The solvent was then removed under reduced pressure. The residue was redissolved in ethyl acetate which in turn was washed with cold dilute hydrochloric acid, water, brine, dried over anhydrous magnesium sulfate, and evaporated to an oil. Column chromatography (silica gel, 10% ethyl acetate in hexane) yielded 17 β -N,N-diisopropylcarboxamide-3-(trifluoromethylsulfonate)-6-fluoro-androst-3,5-diene and 17 β -N,N-diisopropylcarboxamide-3-(trifluoromethylsulfonate)-6-fluoro-androst-2,4-diene.

(v) Ethyl 17 β -N,N-diisopropylcarboxamide-6-fluoro-androst-3,5-diene-3-carboxylate

A mixture of 17 β -N,N-diisopropylcarboxamide-3-(trifluoromethylsulfonate)-6-fluoro-androst-3,5-diene (250 mg), triethylamine (0.12 ml), ethanol (1.5 ml), N,N-dimethylformamide (2 ml) and bis (triphenylphosphine) palladium (II) acetate (25 mg) was purged with carbon monoxide for 10 minutes. The reaction mixture was stirred

under one atmosphere of carbon monoxide at room temperature overnight and then diluted with ethyl acetate. The ethyl acetate solution was then washed with cold dilute hydrochloric acid, water, brine, dried over anhydrous magnesium sulfate, and concentrated to dryness. Silica gel column chromatography eluting with 10% ethyl acetate in hexane yielded 108 mg of ethyl 17 β -N,N-diisopropylcarboxamide-6-fluoro-androst-3,5-diene-3-carboxylate (55%).

(vi) 17 β -N,N-Diisopropylcarboxamide-6-fluoro-androst-3,5-diene-3-carboxylic Acid

The title compound was prepared according to Example 2 (viii) by substituting ethyl 17 β -N,N-diisopropylcarboxamide-6-fluoro-androst-3,5-diene-3-carboxylate for 3-carbomethoxy-3-androstene-17 β -N,N-diisopropylcarboxamide. The product had a melting point of 225-226°C (recrystallized from acetonitrile).

EXAMPLE 28

N-t-Butyl Androst-3,5-diene-17 β -carboxamide-3-Carboxylic Acid

(i) Androst-4-ene-3-one-17 β -N-t-Butyl Carboxamide

The title compound was prepared according to Example 3 (ii) by using tert-butylamine in place of diisopropylamine.

(ii) 17 β -(N-t-butylcarboxamide)-3-(trifluoromethyl sulfonate)-androst-3,5-diene

The title compound was prepared in 45% yield according to Example 3 (iii) by using androst-4-ene-3-one-17 β -N-t-butylcarboxamide in place of androst-4-ene-3-one-17 β -N,N-diisopropyl carboxamide.

(iii) 3-Carbomethoxyandrost-3,5-diene-17 β -N-t-butylcarboxamide

The title compound was prepared according to Example 3 (iv) by using 17 β -(N-t-butylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene in place of 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene.

(iv) N-t-Butyl Androst-3,5-diene-17 β -carboxamide-3-carboxylic Acid

The title compound was prepared according to Example 3 (v) by using 3-carbomethoxyandrost-3,5-diene-17 β -N-t-butylcarboxamide in place of 3-carbomethoxyandrost-3,5-diene-17 β -N,N-diisopropylcarboxamide. The title compound was recrystallized from acetonitrile, m.p. 247-250°.

EXAMPLE 28A

N-t-Butyl Androst-3,5-diene-17 β -carboxamide-3-carboxylic Acid

(i) N-t-Butyl Androst-3,5-diene-3-bromo-17 β -carboxamide

To an ice cooled solution of 3-oxo-androst-4-ene-17-carboxylic acid (10g, 30 mmol) in toluene (100 mL) was added a solution of oxalyl bromide (24.2 g, 11 mL, 112 mmol) in toluene (100 mL). The reaction mixture was warmed to room temperature until gas evolution ceased.

Excess oxalyl bromide was evaporated at room temperature and the residual androst-3,5-diene-3-bromo-17 β -acid bromide in toluene solution was ice cooled. T-butyl amine (40 mL) in toluene (70 mL) was slowly added and the mixture was stirred 19 hours.

The reaction mixture was diluted with water (200 mL) and toluene (100 mL). The organic soluble material was separated and washed with water (2 x 250 mL), dried over magnesium sulfate, and evaporated. The oil/solid residue was flash chromatographed using silica gel, flash grade, eluting with 5 : 1 hexane : ethyl acetate to give 5.5 g of white solid, mp 174-77°C (40.3%).

(ii) N-t-Butyl Androst-3,5-diene 17 β -carboxamide-3-carboxylic Acid

N-Butyl lithium (2.5 M in hexane, 90 mL, 225 mmol) was added over 20 minutes to a solution of androst-

3,5-diene-3-bromo-17 β -N-t-butylcarboxamide (25 g, 57.7 mmol) in dry tetrahydrofuran (650 mL) cooled to -64°C. After 2.5 hours the reaction mixture was quenched with dry CO₂ for hour, diluted with toluene (500 mL), 10% hydrochloric acid solution (100 mL), and water (500 mL). The organic soluble extract was separated, washed with water (2 x 300 mL), dried over magnesium sulfate and evaporated. The crude off-white solid was recrystallized from ethyl acetate to give 3.5 g of white solid, mp 242-49°C

EXAMPLE 28B

N-t-Butyl Androst-3,5-diene-3-bromo-17 β -carboxamide-3-carboxylic Acid

(i) Methyl Androst-3,5-diene-3-bromo-17 β -carboxylate

Methyl androst-4-ene-17 β -carboxylate (100 g, 316 (mmol) was dissolved in glacial acetic acid (500 mL), and phosphorous tribromide (119 g, 80 ml, 440 mmol) was added over 15 minutes. After stirring at room temperature for 2 hours, the yellow precipitate that formed was filtered, washed with methanol (400 mL), and dried in vacuo to give 97.9 g (81.4%) of white solid, mp 178-180°C.

(ii) Androst-3,5-diene-3-bromo-17 β -carboxylic Acid

A solution of potassium hydroxide (50 g, 890 mmol) in 9 : 1 methanol : water (500 mL) was added to a slurry of methyl androst-3,5-diene-3-bromo-17 β -carboxylate. After refluxing 41 hours, the resultant yellow solution was cooled and brought to pH4 using 10% hydrochloric acid solution. The white solid that formed was filtered and washed with water. After drying in vacuo at 40°C, 49 g (100%) of product, mp 248-250°C was obtained.

(iii) N-t-Butyl Androst-3,5-diene-3-bromo-17 β -carboxamide

Oxalyl chloride (17 mL, 190 mmol) was added to a cooled mixture of androst-3,5-diene-3-bromo-17 β -carboxylic acid (30 g, 79 mmol) in dry toluene (300 mL) over 14 minutes. The reaction mixture was stirred at room temperature until gas evolution ceased (about 1.5 hours).

Excess oxalyl chloride was removed by concentration in vacuo at room temperature. The reaction mixture was ice cooled and t-butylamine (102 mL, 954 mmol) was added over 10 minutes. The reaction mixture was stirred at room temperature for 1.5 hours.

The mixture was diluted with water (300 mL) and toluene (50 mL). The organic layer was separated, washed with water (2 x 300 mL), dried over magnesium sulfate and evaporated. The resultant pale yellow solid was slurried first methanol : water (7.3, 200 mL) then acetonitrile : water (39 : 11, 300 mL). After filtration and drying in vacuo, 33.2 (77.5%) of white solid product was obtained.

(iv) N-t-Butyl Androst-3,5-diene-17 β -carboxamide-3-carboxylic Acid

N-Butyl lithium (2.5 M in hexane, 90 mL, 225 mmol) was added over 20 minutes to a solution of androst-3,5-diene-3-bromo-17-N-t-butylcarboxamide (25 g 57.7 mmol) in dry tetrahydrofuran (650 mL) cooled to -64°C. After 2.5 hours the reaction mixture was quenched with dry CO₂ for one hour, diluted with toluene (500 mL), 10% hydrochloric acid solution (100 mL), and water (500 mL). The organic soluble extract was separated, washed with water (2 x 300 mL), dried over magnesium sulfate and evaporated. The crude off-white solid was recrystallized from ethyl acetate to give 3.5 g of white solid, mp 242-49°C.

EXAMPLE 28C

N,N-Diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic Acid

The title compound was prepared by substituting diisopropylamine for t-butylamine in the process of Example 28B.

EXAMPLE 28D

Androst-3,5-diene-3-methoxycarbonyl-17 β -t-butylcarboxamide

A mixture of N-t-butyl androst-3,5-diene-3-bromo-17 β -carboxamide (42 mg), prepared as in Example 28B,

palladium (II) acetate (20 mg), triphenylphosphine (40 mg), methanol (5 mL), dimethyl formamide (5 mL), and triethylamine (3 mL) was heated at 85-95°C under a carbon monoxide atmosphere until the starting material disappeared. The title compound was isolated by flash chromatography on silica gel with 6 : 1 hexane : ethyl acetate.

EXAMPLE 28E

Androst-3,5-diene-3-Methoxycarbonyl-17 β -N,N-diisopropylcarboxamide

The title compound is prepared according to Example 28D, substituting N,N-diisopropylamine for N-t-butylamine.

EXAMPLE 29

N,N-Diisopropyl 5 α -Androst-2-ene-17 β -carboxamide-3-carboxylic Acid

(i) 17 β -(N,N-Diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-5 α -androst-2-ene

The title compound was prepared according to Example 4 (vii) by using 3-oxo-5 α -androstane-17 β -N,N-diisopropylcarboxamide in place of 3-oxo-4-fluoro-5 α -androst-1-ene-17 β -N,N-diisopropylcarboxamide.

(ii) 3-Carbomethoxy-5 α -Androst-2-ene-17 β -N,N-diisopropylcarboxamide

The title compound was prepared according to Example 3 (iv) by using 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-5 α -androst-2-ene in place of 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate) androst-3,5-diene.

(iii) N,N-Diisopropyl 5 α -Androst-2-ene-17 β -carboxamide-3-carboxylic Acid

The title compound was prepared according to Example 3 (v) by using 3-carbomethoxy-5 α -androst-2-ene-17 β -N,N-diisopropylcarboxamide in place of 3-carbomethoxyandrost-3,5-diene-17 β -N,N-diisopropylcarboxamide. The title compound was recrystallized from acetonitrile ; m.p. 203-205°.

EXAMPLE 30

N,N-Diisopropyl Androst-2,4-diene-17 β -carboxamide-3-carboxylic Acid

(i) 17 β -(N,N-Diisopropylcarboxamide)-3-trifluoromethylsulfonate) androst-2,4-diene

The title compound was prepared according to Example 4 (vii) by using 3-oxoandrost-4-ene-17 β -N,N-diisopropylcarboxamide in place of 3-oxo-4-fluoro-5 α -androst-1-ene-17 β -N,N-diisopropylcarboxamide. The title compound was recrystallized from methanol ; m.p. 165-168°.

(ii) 3-Carbomethoxyandrost-2,4-diene-17 β -N,N-diisopropylcarboxamide

The title compound was prepared according to Example 3 (iv) by using 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate) androst-2,4-diene in place of 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene. The title compound had a melting point of 162° after trituration with methanol.

(iii) N,N-Diisopropyl Androst-2,4-diene-17 β -carboxamide-3-carboxylic Acid

The title compound was prepared according to Example 3 (v) by using 3-carbomethoxy-androst-2,4-diene-17 β -N,N-diisopropylcarboxamide in place of 3-carbomethoxy androst-3,5-diene-17 β -N,N-diisopropylcarboxamide. The title compound was recrystallized from methanol-acetone ; m.p. 227°.

EXAMPLE 31

N,N-Diisopropyl 5- α -Androstane-17 β -carboxamide-3 β -carboxylic Acid(i) 3 β -Carbomethoxy-5 α -androstane-17 β -N,N-diisopropylcarboxamide

3-Carbomethoxy-5 α -androst-2-ene-17 β -N,N-diisopropylcarboxamide (87 mg, 0.19 mmol) (Example 29, (ii)) in 15 ml of a 10 : 1 solution of ethyl acetate and acetic acid was hydrogenated at 25° and 1 atm over 20 mg 10% Pd on carbon. The solution was filtered to remove the catalyst and concentrated to yield 77 mg (88%) of the title compound.

(ii) N,N-Diisopropyl 5- α -Androstane-17 β -carboxamide-3 β -carboxylic Acid

The title compound was prepared according to Example 3 (v) by using 3 β -carbomethoxy-5 α -androstane-17 β -N,N-diisopropylcarboxamide in place of 3-carbomethoxyandrost-3,5-diene-17 β -N,N-diisopropylcarboxamide. The title compound was recrystallized from acetonitrile ; m.p. 142-144°.

EXAMPLE 32

N,N-Diisopropyl Estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic Acid(i) 3-Methoxy-estr-1,3,5(10),16-tetraene-17-N,N-diisopropylcarboxamide

The title compound was prepared according to the two steps of Example 3 (iii, iv) by using methyl estrone in place of androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide and diisopropylamine in place of methanol.

(ii) 3-Methoxy-estr-1,3,5(10)-triene-17 β -N,N-diisopropylcarboxamide

3-Methoxy-estr-1,3,5(10),16-tetraene-17-N,N-diisopropylcarboxamide (4.45 g, 11.3 mmol) in 100 ml of a 3 : 1 solution of ethyl acetate and ethanol was hydrogenated at 25° and 1 atm. over PtO₂ (350 mg) for 6 hours. The solution was filtered to remove the catalyst and concentrated to afford 4.36 g (98%) of the title compound.

(iii) 3-Oxo-estr-5(10)-ene-17 β -N,N-diisopropylcarboxamide

To a solution of 3-methoxyestr-1,3,5(10)-triene-17 β -N,N-diisopropylcarboxamide (1.4 g, 3.5 mmol) in liquid ammonia (25 ml), THF (10 ml), and t-butanol (10 ml) at -33°C was added 0.5 g of lithium wire. The solution was stirred for 5 hours and then methanol (10 ml) was slowly added. The ammonia was allowed to evaporate and the residue was then partitioned between water and chloroform. The organic phase was concentrated to a white solid which was suspended in a methanol-water mixture and then treated with 1.4 g oxalic acid for 1.5 hours. The reaction mixture was then diluted with water and extracted with ethyl acetate. The organic phase was concentrated and the residue chromatographed (silica, 1 : 9 ethyl acetate-hexane) to yield 0.4 g of the title compound.

(iv) N,N-Diisopropyl Estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic Acid

The title compound was prepared according to Example 29, (i-iii), by using 3-oxoestr-5(10)-ene-17 β -N,N-diisopropylcarboxamide for 3-oxo-5 α -androstane-17 β -N,N-diisopropylcarboxamide. The title compound was recrystallized from acetonitrile ; m.p. 250-253°.

EXAMPLE 33

N,N-Diisopropyl Estr-3,5-diene-17 β -carboxamide-3-carboxylic Acid(i) 3-Oxoestr-4-ene-17 β -N,N-diisopropylcarboxamide

3-Oxoestr-5(10)-ene-17 β -N,N-diisopropylcarboxamide (Example 29, (iii)) was dissolved in methanol and 10% aqueous HCl (2 : 1) and heated at 65° for 1 hour, cooled, and thoroughly extracted with chloroform. The organic extracts were concentrated to yield the title compound as a white solid.

(i) N,N-Diisopropyl Estr-3,5-diene-17 β -carboxamide-3-carboxylic Acid

The title compound was prepared according to Example 3 (iii-v) by using 3-oxo-estr-4-ene-17 β -N,N-diisopropylcarboxamine in place of androst-4-ene-3-one-17 β -N,N-diisopropylcarboxamide. The title compound had a melting point of 215°.

EXAMPLE 3417 β -(N,N-Diisopropylcarboxamide)-Androst-3,5,11-triene-17 β -carboxylic Acid(i) Androst-4-ene-3-one-11-ol-17 β -carboxylic Acid

Corticosterone is dissolved in methanol and treated with an aqueous solution of periodic acid at room temperature for 18 hours. The solution is then diluted with water to induce precipitation of androst-4-ene-3-one-11-ol-17 β -carboxylic acid which is collected by filtration.

(ii) Androst-4-ene-3,11-dione-17 β -carboxylic Acid

To a solution of androst-4-ene-3-one-11-ol-17 β -carboxylic acid in acetone is added Jones Reagent dropwise until a red color persists. Isopropanol is then added to quench the excess oxidant. The solution is decanted and the residual chromium salts are thoroughly washed with acetone. The combined organic solutions are then filtered through magnesium sulfate and concentrated to yield androst-4-ene-3,11-dione-17 β -carboxylic acid.

(iii) Androst-4-ene-3,11-dione-17 β -(N,N-diisopropyl-carboxamide).

The title compound is prepared according to Example 3 (ii) by substituting androst-4-ene-3,11-dione-17 β -carboxylic acid for androst-4-ene-3-one-17 β -carboxylic acid.

(iv) 17 β -(N,N-Diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-11-oxo-androst-3,5 diene.

The title compound is prepared according to Example 3 (iii) by substituting androst-4-ene-3,11-dione-17 β -(N,N-diisopropylcarboxamide) for androst-4-ene-3-one-17 β -(N,N-diisopropylcarboxamide).

(v) 3-Carbomethoxy-11-oxo-androst-3,5-diene-17 β -(N,N-diisopropylcarboxamide).

The title compound is prepared according to Example 3 (iv) by substituting 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-11-oxo-androst-3,5-diene for 17 β -(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene.

(vi) 3-Carbomethoxy-11-(trifluoromethylsulfonate)-androst-3,5,11-triene-17 β -(N,N-diisopropylcarboxamide).

The title compound is prepared according to Example 4 (vi) by substituting 3-carbomethoxy-11-oxo-androst-3,5-diene-17 β -(N,N-diisopropylcarboxamide) for 3-oxo-4-fluoro-5 α -androst-1-ene-17 β -(N,N-diisopropylcarboxamide).

(vii) 3-Carbomethoxy-androst-3,5,11-triene-17 β -(N,N-diisopropylcarboxamide).

The title compound is prepared according to the procedure of Cacchi (Tet. Lett. 25 (42) 4821-4824 (1984)) by substituting 3-carbomethoxy-11-(trifluoromethylsulfonate)-androst-3,5,11-triene-17 β -(N,N-diisopropylcarboxamide) for 17 β -acetoxycandrosta-3,5-diene-3-yl-triflate.

(viii) 17 β -(N,N-Diisopropylcarboxamide)-androst-3,5,11-triene-3-carboxylic Acid.

The title compound is prepared according Example 3 (v) by substituting 3-carbomethoxy-androst-3,5,11-triene-17 β -(N,N-diisopropylcarboxamide) for 3-carbomethoxy-androst-3,5-diene-17 β -(N,N-diisopropylcarboxamide).

EXAMPLE 35**17 β -(N-t-Butylcarboxamide)-androst-3,5,11-triene-3-carboxylic Acid**

- 5 The process of Example 34 wherein N-t-butyl amine is used in place of diisopropylamine yields 17 β -(N-t-Butylcarboxamide)-androst-3,5,11-triene-3-carboxylic Acid.

EXAMPLE 36**17 β -(N,N-diisopropylcarboxamide)-androst-3,5-diene-3-thiocarboxylic Acid**

- 10 A solution of 17 β -(N,N-diisopropylcarboxamide)-androst-3,5-diene-3-carboxylic acid (1 mmol) is suspended in 10 mL toluene and treated with 0.5 mL of oxalyl chloride for two hours. The resulting solution is then slowly added to a solution of THF and hydrogen sulfide through which hydrogen sulfide is bubbled. The mixture is then diluted with ethyl acetate, washed with water, dried and concentrated the residue is recrystallized from acetonitrile to yield the title compound.

EXAMPLE 37**17 β -(N-t-Butylcarboxamide)-androst-3,5-diene-3-thiocarboxylic Acid**

- 20 The process of Example 36 wherein 17 β -(N,N-diisopropylcarboxamide)-androst-3,5-diene-3-carboxylic acid is replaced by 17 β -(N-t-Butylcarboxamide)-androst-3,5-diene-3-carboxylic acid yields 17 β -(N-t-Butylcarboxamide)-androst-3,5-diene-3-thiocarboxylic Acid.

EXAMPLE 38-47

- The following compounds are prepared by substituting diisopropylamine for t-butylamine using the procedures of examples 2, 3, 4, 7, 27, 29, 30, 31, 32, and 33, respectively :
- 30 N-t-Butyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid ;
 17 β -(N-t-Butylcarboxamide)-6-fluoro-5- α -androst-3-ene-3-carboxylic acid ;
 17 β -(N-t-Butylcarboxamide)-6-fluoro-androst-3,5-diene-3-carboxylic acid ;
 3-Carbomethoxy-N-t-butyl-androst-3,5-diene-17 β -carboxamide,
 17 β -N-t-Butylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid ;
 35 N-t-Butyl-5- α -androst-2-ene-17 β -carboxamide-3-carboxylic acid ;
 N-t-Butyl-androst-2,4-diene-17 β -carboxamide-3-carboxylic acid ;
 N-t-Butyl-5- α -androstane-17 β -carboxamide-3-carboxylic acid ;
 N-t-Butyl-estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic acid ; and
 N-t-Butyl-estr-3,5-diene-17 β -carboxamide-3-carboxylic acid.

EXAMPLE 48

- 45 An oral dosage form for administering Formula (Ia) compounds is produced by screening, mixing, and filling into hard gelatin capsules the ingredients in the proportions shown in Table V, below.

Table V

<u>Ingredients</u>	<u>Amounts</u>
20- α -(Hydroxymethyl)-5- α -pregn-3-ene-3-carboxylic acid	50 mg
magnesium stearate	5 mg
lactose	75 mg

EXAMPLE 49

The sucrose, calcium sulfate dihydrate and Formula (Ia) compound shown in Table VI below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

Table VI

<u>Ingredients</u>	<u>Amounts</u>
N,N-Diisopropyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid	100 mg
calcium sulfate dihydrate	150 mg
sucrose	20 mg
starch	10 mg
talc	5 mg
stearic acid	3 mg

EXAMPLE 50


20- α -(Hydroxymethyl)-4-fluoro-5- α -pregn-3-ene-3-carboxylic acid, 75 mg, is dispersed in 25 ml of normal saline to prepare an injectable preparation.

While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A compound represented by the formula (I) :



in which :

the A ring has up to 2 double bonds ;

the B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C₈-C₁₄ double bond when the B ring has a C₇-C₈ double bond ;

M is O or S ;

**EXAMPLE 49**

The sucrose, calcium sulfate dihydrate and Formula (Ia) compound shown in Table VI below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

Table VI

	<u>Ingredients</u>	<u>Amounts</u>
15	N,N-Diisopropyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid	100 mg
	calcium sulfate dihydrate	150 mg
	sucrose	20 mg
20	starch	10 mg
	talc	5 mg
25	stearic acid	3 mg

EXAMPLE 50


20- α -(Hydroxymethyl)-4-fluoro-5- α -pregn-3-ene-3-carboxylic acid, 75 mg, is dispersed in 25 ml of normal saline to prepare an injectable preparation.

While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A compound represented by the formula (I) :



(I)

in which :

the A ring has up to 2 double bonds ;

the B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C₇-C₁₄ double bond when the B ring has a C₇-C₈ double bond ;

M is O or S ;

Z is $(CH_2)_n$ and n is 0-2 ;

X is H, Cl, F, Br, I, CF_3 , or C_{1-6} alkyl ;

Y is H, CF_3 , F, or Cl, CH_3 , provided that Y is H when there is no C_5-C_6 double bond ;


R^4 is H or C_{1-6} alkyl ;

5 R^2 is absent or present as H or CH_3 provided R^2 is absent when the carbon to which it is attached is double bonded ;

R^{10} is absent when there is a C_4-C_5 , C_5-C_6 , or C_5-C_{10} double bond, or present as an alpha hydrogen ; and R^3 is

(1) α -hydrogen, α -hydroxyl, or α -acetoxy and/or

(2)



where W is a bond or C_{1-12} alkylene, and R^4 is

(i) hydrogen,

(ii) hydroxyl,

(iii) C_{1-6} alkyl,

(iv) hydroxy C_{1-6} alkyl,

(v) C_{1-6} alkoxy,

(vi) NR^5R^6 , where R^5 and R^6 are each independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl ; or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen, or

(vii) OR^7 , where R^7 is hydrogen, alkali metal, C_{1-18} alkyl, benzyl, or

(b) β -Alk- OR^8 , where Alk is C_{1-12} alkylene and R^8 is

(i) phenyl C_{1-6} alkylcarbonyl,

(ii) C_{6-10} cycloalkylcarbonyl,

(iii) benzoyl,

(iv) C_{1-6} alkoxycarbonyl,

(v) amino-, or C_{1-6} alkyl substituted aminocarbonyl,

(vi) hydrogen, or

(vii) C_{1-6} alkyl,

(2) $=CH-W-CO-R^4$ or $=CH-W-OR^8$, where W is a bond or C_{1-12} alkylene and R^4 and R^8 have the same meaning as above and R^8 also is hydrogen or C_{1-20} alkylcarbonyl ;

(3)



where the dashed bond replaces the 17- α -hydrogen,

(4) α -hydrogen and β - $NHCO-R^9$ where R^9 is C_{1-12} alkyl or β - NR^5R^6 where R^5 and R^6 have the same meaning as above,

(5) α -hydrogen and β -cyano,

(6) α -hydrogen and β -tetrazolyl, or

(7) keto ;

or a pharmaceutically acceptable salt thereof ; except compounds in which :

The A ring has a C_2-C_4 double bond and the B ring has a C_5-C_6 double bond, R^1 is CH_3 , and R^3 is keto ;

The A ring has a C_3-C_4 double bond and the B ring has a C_5-C_6 double bond, and

the D ring has a $C_{16}-C_{17}$ double bond, R^1 is CH_3 , and

R^3 is $COOCH_3$; and

The B ring has a C_5-C_6 double bond, R^1 is CH_3 , and R^3 is $COCH_3$.


2. The compound of Claim 1 that is N-t-butyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid or N,N-diallopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid.

3. The compound of Claim 1 that is



- 20- α -(hydroxymethyl)-5- α -pregn-3-ene-3-carboxylic acid,
 N,N-diisopropyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid,
 17 β -(N,N-diisopropylcarboxamide)-4-fluoro-5- α -androst-3-ene-3-carboxylic acid,
 17 β -(N,N-diisopropylcarboxamide)-4-fluoro-androst-3,5-diene-3-carboxylic acid,
 5 20- α -(hydroxymethyl)-4-fluoro-5- α -pregn-3-ene-3-carboxylic acid,
 3-carbomethoxy-N,N-diisopropyl-androst-3,5-diene-17 β -carboxamide,
 17 β -N,N-diisopropylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid,
 N,N-diisopropyl 5- α -androst-2-ene-17 β -carboxamide-3-carboxylic acid,
 N,N-diisopropyl androst-2,4-diene-17 β -carboxamide-3-carboxylic acid,
 10 N,N-diisopropyl 5- α -androstane-17 β -carboxamide-3 β -carboxylic acid,
 N,N-diisopropyl estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic acid,
 N,N-diisopropyl estr-3,5-diene-17 β -carboxamide-3-carboxylic acid,
 17 β -(N-t-butylcarboxamide)-androst-3,5,11-triene-3-carboxylic acid,
 17 β -(N-t-butylcarboxamide)-androst-3,5-diene-3-thiocarboxylic acid,
 15 N-t-Butyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid,
 17 β -(N-t-Butylcarboxamide)-6-fluoro-5- α -androst-3-ene-3-carboxylic acid,
 17 β -(N-t-Butylcarboxamide)-6-fluoro-androst-3,5-diene-3-carboxylic acid,
 20- α -(hydroxymethyl)-A-nor-5- α -pregn-1-ene-2-carboxylic acid,
 3-Carbomethoxy-N-t-butyl-androst-3,5-diene-17 β -carboxamide,
 20 17 β -N-t-Butylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid,
 N-t-Butyl-5- α -androst-2-ene-17 β -carboxamide-3-carboxylic acid,
 N-t-Butyl-androst-2,4-diene-17 β -carboxamide-3-carboxylic acid,
 N-t-Butyl-5- α -androstane-17 β -carboxamide-3-carboxylic acid,
 N-t-Butyl-estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic acid, or
 25 N-t-Butyl-estr-3,5-diene-17 β -carboxamide-3-carboxylic acid.

4. A compound represented by the formula (III) :




In which the B ring has an optional double bond where indicated by the broken line ;

R¹ and R² are each H or C₁₋₈ alkyl ;

40 R¹³ is HC(CH₃)CH₂OR²⁰ in which R²⁰ is H or C₁₋₈ alkyl ; or
 CONR²¹R²² in which R²¹ and R²² independently are H or C₁₋₈ alkyl, and M is O or S.

5. A compound of formula (II)



in which :

55 The A ring has up to 2 double bonds ;

The B and C rings have optional double bonds where indicated by the broken lines ;

M is O or S ;

X is H, or halo, and




R^1 is H or C_{1-8} alkyl; R^2 is H or C_{1-8} alkyl;

R^{10} is absent when there is a C_5-C_6 , C_5-C_8 , or C_5-C_{10} double bond, or present as an alpha hydrogen, and R^{13} is

(a) $HC(CH_3)CH_2OR^{20}$ wherein R^{20} is H or C_{1-8} alkyl, or

(b) $CONR^{21}R^{22}$ wherein R^{21} and R^{22} independently are H or C_{1-8} alkyl.

6. A pharmaceutical composition comprising a suitable pharmaceutical carrier and a compound of the formula (Ia):



in which:

The A ring has up to 2 double bonds;

The B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C_8-C_{14} double bond when the B ring has a C_7-C_8 double bond;

M is O or S;

Z is $(CH_2)_n$ and n is 0-2;

X is H, Cl, F, Br, I, CF_3 , or C_{1-8} alkyl;

Y is H, CF_3 , F, or Cl, CH_3 , provided that Y is H when there is no C_5-C_6 double bond;

R^1 is H or C_{1-8} alkyl;

R^2 is absent or present as H or CH_3 , provided R^2 is absent when the carbon to which it is attached is double bonded;

R^{10} is absent when there is a C_5-C_6 , C_5-C_8 , or C_5-C_{10} double bond, or present as an alpha hydrogen; and R^{13} is

(1) α -hydrogen, α -hydroxyl, or α -acetoxy and/or

(a)



where W is a bond or C_{1-12} alkylene and R^4 is

(i) hydrogen,

(ii) hydroxyl,

(iii) C_{1-8} alkyl,

(iv) hydroxy C_{1-8} alkyl,

(v) C_{1-8} alkoxy,

(vi) NR^5R^6 , where R^5 and R^6 are each independently selected from hydrogen, C_{1-8} -alkyl, C_{3-8} cycloalkyl, phenyl; or R^5 and R^6 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen, or

(vii) OR^7 , where R^7 is hydrogen, alkali metal, C_{1-18} alkyl, benzyl, or

(b) β -alk- OR^8 , where alk is C_{1-12} alkylene and R^8 is

(i) phenyl C_{1-8} alkylcarbonyl,

(ii) C_{5-10} cycloalkylcarbonyl,

(iii) benzoyl,

(iv) C_{1-8} alkoxy carbonyl,

(v) amino-, or C_{1-8} alkyl substituted aminocarbonyl,

(vi) hydrogen, or



(vii) C_{1-8} alkyl,

(2) $=CH-W-CO-R^4$ or $=CH-W-OR^5$, where W is a bond or C_{1-12} alkylene, and R^4 and R^5 have the same meaning as above and R^5 also is hydrogen or C_{1-20} alkylcarbonyl ;

(3)



where the dashed bond replaces the 17- α -hydrogen,

(4) α -hydrogen and $\beta-NHCOR^9$ where R^9 is C_{1-12} alkyl or $\beta-NR^5R^6$ where R^5 and R^6 have the same meaning as above,

(5) α -hydrogen and β -cyano,

(6) α -hydrogen and β -tetrazolyl, or

(7) keto ;


or a pharmaceutically acceptable salt thereof.

7. A composition of Claim 6 wherein the compound is N-t-butyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid or N,N-diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid.

8. A composition of Claim 6 wherein the compound is

20- α -(hydroxymethyl)-5- α -pregn-3-ene-3-carboxylic acid,
N,N-diisopropyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid,
17 β -(N,N-diisopropylcarboxamide)-4-fluoro-5- α -androst-3-ene-3-carboxylic acid,
17 β -(N,N-diisopropylcarboxamide)-4-fluoro-androst-3,5-diene-3-carboxylic acid,
20- α -(hydroxymethyl)-4-fluoro-5- α -pregn-3-ene-3-carboxylic acid,
3-carbomethoxy-N,N-diisopropyl-androst-3,5-diene-17 β -carboxamide,
17 β -N,N-diisopropylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid,
N,N-diisopropyl-5- α -androst-2-ene-17 β -carboxamide-3-carboxylic acid,
N,N-diisopropyl-androst-2,4-diene-17 β -carboxamide-3-carboxylic acid,
N,N-diisopropyl-5- α -androstane-17 β -carboxamide-3 β -carboxylic acid,
N,N-diisopropyl-estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic acid,
N,N-diisopropyl-estr-3,5-diene-17 β -carboxamide-3-carboxylic acid,
17 β -(N-t-butylcarboxamide)-androst-3,5,11-triene-3-carboxylic acid,
17 β -(N-t-butylcarboxamide)-androst-3,5-diene-3-thiocarboxylic acid,
N-t-butyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid,
17 β -(N-t-butylcarboxamide)-8-fluoro-5- α -androst-3-ene-3-carboxylic acid,
17 β -(N-t-butylcarboxamide)-8-fluoro-androst-3,5-diene-3-carboxylic acid,
3-Carbomethoxy-N-t-butyl-androst-3,5-diene-17 β -carboxamide,
17 β -N-t-butylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid,
N-t-butyl-5- α -androst-2-ene-17 β -carboxamide-3-carboxylic acid,
N-t-butyl-androst-2,4-diene-17 β -carboxamide-3-carboxylic acid,
N-t-butyl-5- α -androstane-17 β -carboxamide-3-carboxylic acid,
N-t-butyl-estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic acid, or
N-t-butyl-estr-3,5-diene-17 β -carboxamide-3-carboxylic acid.

9. A process for preparing a compound of formula :




in which R^2 , X and Y are as described for formula (Ia) in claim 6 and R^{14} is the same as R^3 as described for



formula (Ia) in claim 6,

R¹ is H or C₁₋₈ alkyl; and


M is O or S, which comprises treating a compound of formula



in which X¹ is bromo, chloro, fluoro or iodo; and R², R¹⁴, X and Y are as described above, with an alkyl lithium reagent followed by a carboxylating agent, or with a palladium catalyst in the presence of a base, a C₁₋₄ alcohol, and carbon monoxide.

10. The process of claim 9 wherein the compound prepared is N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid or N,N-diisopropyl-androst-3,5-diene-carboxamide-3-carboxylic acid.

11. A process for preparing a compound of the formula (I) as described in claim 1 that comprises treating with an organic base, a phosphine, a palladium (II) compound, and a C₁₋₆ alkyl alcohol, and then adding carbon monoxide to a compound of the formula:



wherein X, Y, Z, R², and R¹⁰ are as described above and R¹⁴ is R³ as described for formula (I) or moieties which can be chemically converted to R³.


12. A compound of Claim 1 for use as a therapeutic agent.

13. A compound of Claim 1 for use as a steroid 5-α-reductase inhibitor.

14. A compound of Claim 1 for use in treatment to reduce prostate size.

Claims for following Contracting State: ES

1. A process for preparing a compound of the formula (I)



(I)

in which:



the A ring has up to 2 double bonds ;

the B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C₈-C₁₄ double bond when the B ring has a C₇-C₈ double bond ;

M is O or S ;

5 Z is (CH₂)_n and n is 0-2 ;

X is H, Cl, F, Br, I, CF₃, or C₁₋₃ alkyl ;


Y is H, CF₃, F, or Cl, CH₃, provided that Y is H when there is no C₅-C₆ double bond ;

R¹ is H or C₁₋₃ alkyl ;

10 R² is absent or present as H or CH₃, provided R² is absent when the carbon to which it is attached is double bonded ;

R¹⁰ is absent when there is a C₄-C₅, C₅-C₆, or C₅-C₁₀ double bond, or present as an alpha hydrogen ; and R³ is

- (1) α-hydrogen, α-hydroxyl, or α-acetoxy and/or
(a)



20 where W is a bond or C₁₋₁₂ alkylene and R⁴ is

- (i) hydrogen,
(ii) hydroxyl,
(iii) C₁₋₃ alkyl,
(iv) hydroxy C₁₋₃ alkyl,

25 (v) C₁₋₃ alkoxy,

(vi) NR⁵R⁶, where R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₃ alkyl, C₃₋₆ cycloalkyl, phenyl ; or R⁵ and R⁶ taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen, or

30 (vii) OR⁷, where R⁷ is hydrogen, alkali metal, C₁₋₁₈ alkyl, benzyl, or

(b) β-Alk-OR⁸, where Alk is C₁₋₁₂ alkylene, and R⁸ is

- (i) phenyl C₁₋₃ alkylcarbonyl,
(ii) C₃₋₁₀ cycloalkylcarbonyl,
(iii) benzoyl,

35 (iv) C₁₋₃ alkoxy carbonyl,

(v) amino-, or C₁₋₃ alkyl substituted aminocarbonyl,

(vi) hydrogen, or

(vii) C₁₋₃ alkyl,

40 (2) =CH-W-CO-R⁴ or =CH-W-OR⁸, where W is a bond or C₁₋₁₂ alkylene and R⁴ and R⁸ have the same meaning as above and R⁸ also is hydrogen or C₁₋₂₀ alkylcarbonyl ;

(3)



45 where the dashed bond replaces the 17-α-hydrogen,

50 (4) α-hydrogen and β-NHCOR⁹ where R⁹ is C₁₋₁₂ alkyl or β-NR⁵R⁶ where R⁵ and R⁶ have the same meaning as above,

(5) n-hydrogen and β-cyano,

(6) n-hydrogen and β-tetrazolyl, or

(7) keto ;

or a pharmaceutically acceptable salt thereof ; except compounds in which :

55 The A ring has C₃-C₄ double bond and the B ring has a C₅-C₆ double bond, R¹ is CH₃, and R² is keto ;


The A ring has C₃-C₄ double bond and the B ring has a C₅-C₆ double bond and

the D ring has a C₁₆-C₁₇ double bonds, R¹ is CH₃, and

R³ is COOCH₃ ; and



The B ring has a C₈-C₉ double bond, R¹ is CH₃, and R³ is COCH₃, that comprises treating with an organic base, a phosphine, a palladium (II) compound, and a C₁₋₈ alkyl alcohol, and then adding carbon monoxide to a compound of the formula (V) :




wherein X, Y, Z, R², and R¹⁰ are as described above and R¹⁴ is R³ or moieties which can be chemically converted to R³.

2. The process of Claim 1 wherein the compound prepared is N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid or N,N-diisopropyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid.

3. The process of Claim 1 wherein the compound prepared is

20-α-(hydroxymethyl)-5-α-pregn-3-ene-3-carboxylic acid,
 N,N-diisopropyl-5-α-androst-3-ene-17β-carboxamide-3-carboxylic acid,
 17β-(N,N-diisopropylcarboxamide)-4-fluoro-5-α-androst-3-ene-3-carboxylic acid,
 17β-(N,N-diisopropylcarboxamide)-4-fluoro-androst-3,5-diene-3-carboxylic acid,
 20-α-(hydroxymethyl)-4-fluoro-5-α-pregn-3-ene-3-carboxylic acid,
 3-carbomethoxy-N,N-diisopropyl-androst-3,5-diene-17β-carboxamide,
 17β-N,N-diisopropylcarboxamide-5-α-androst-1,3-diene-3-carboxylic acid,
 N,N-Diisopropyl 5-α-androst-2-ene-17β-carboxamide-3-carboxylic acid,
 N,N-diisopropyl androst-2,4-diene-17β-carboxamide-3-carboxylic acid,
 N,N-diisopropyl 5-α-androstane-17β-carboxamide-3β-carboxylic acid,
 N,N-diisopropyl estr-3,5(10)-diene-17β-carboxamide-3-carboxylic acid,
 N,N-diisopropyl estr-3,5-diene-17β-carboxamide-3-carboxylic acid,
 17β-(N-t-butylcarboxamide)-androst-3,5,11-triene-3-carboxylic acid,
 17β-(N-t-butylcarboxamide)-androst-3,5-diene-3-thiocarboxylic acid,
 N-t-Butyl-5-α-androst-3-ene-17β-carboxamide-3-carboxylic acid,
 17β-(N-t-Butylcarboxamide)-6-fluoro-5-α-androst-3-ene-3-carboxylic acid,
 17β-(N-t-Butylcarboxamide)-6-fluoro-androst-3,5-diene-3-carboxylic acid,
 3-Carbomethoxy-N-t-butyl-androst-3,5-diene-17β-carboxamide,
 17β-N-t-Butylcarboxamide-5-α-androst-1,3-diene-3-carboxylic acid,
 N-t-Butyl-5-α-androst-2-ene-17β-carboxamide-3-carboxylic acid,
 N-t-Butyl-androst-2,4-diene-17β-carboxamide-3-carboxylic acid,
 N-t-Butyl-5-α-androstane-17β-carboxamide-3-carboxylic acid,
 N-t-Butyl-estr-3,5(10)-diene-17β-carboxamide-3-carboxylic acid, or
 N-t-Butyl-estr-3,5-diene-17β-carboxamide-3-carboxylic acid.

4. A process for the preparation of a pharmaceutical composition which comprises bringing into association a compound of formula (Ia) :




(Ia)

In which :

- the A ring has up to 2 double bonds ;
- the B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C₈-C₁₄ double bond when the B ring has a C₇-C₈ double bond ;
- M is O or S ;
- Z is (CH₂)_n and n is 0-2 ;
- X is H, Cl, F, Br, I, CF₃, or C₁₋₆ alkyl ;
- Y is H, CF₃, F, or Cl, CH₃, provided that Y is H when there is no C₈-C₉ double bond ;
- R¹ is H or C₁₋₆ alkyl ;
- R² is absent or present as H or CH₃, provided R² is absent when the carbon to which it is attached is double bonded ;
- R¹⁰ is absent when there is a C₄-C₅, C₅-C₆, or C₆-C₁₀ double bond, or present as an alpha hydrogen ; and
- R³ is

- (1) α-hydrogen, α-hydroxyl, or α-acetoxy and/or
- (a)



where W is a bond or C₁₋₁₂ alkylene and R⁴ is

- (i) hydrogen,
- (ii) hydroxyl,
- (iii) C₁₋₆ alkyl,
- (iv) hydroxy C₁₋₆ alkyl,
- (v) C₁₋₆ alkoxy,
- (vi) NR⁵R⁶, where R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₆-alkyl, C₃₋₆ cycloalkyl, phenyl ; or R⁵ and R⁶ taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen, or
- (vii) OR⁷, where R⁷ is hydrogen, alkali metal, C₁₋₁₈ alkyl, benzyl, or
- (b) B-Alk-OR⁸, where Alk is C₁₋₁₂ alkylene, and R⁸ is
 - (i) phenyl C₁₋₆ alkylcarbonyl,
 - (ii) C₅₋₁₀ cycloalkylcarbonyl,
 - (iii) benzoyl,
 - (iv) C₁₋₆ alkoxy carbonyl,
 - (v) amino-, or C₁₋₆ alkyl substituted aminocarbonyl,
 - (vi) hydrogen, or
 - (vii) C₁₋₆ alkyl,
- (2) =CH-W-CO-R⁴ or =CH-W-OR⁸, where W is a bond or C₁₋₁₂ alkylene, and R⁴ and R⁸ have the same meaning as above and R also is hydrogen or C₁₋₂₀ alkylcarbonyl ;
- (3)



5

where the dashed bond replaces the 17- α -hydrogen,

(4) α -hydrogen and β -NHCOR⁹ where R⁹ is C₁₋₁₂ alkyl or β -NR⁵R⁶ where R⁵ and R⁶ have the same meaning as above,

(5) α -hydrogen and β -cyano.

10

(6) α -hydrogen and β -tetrazolyl, or


(7) keto ;

and a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

5. A process as claimed in claim 4 in which the compound of formula (Ia) is N-t-butyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid or N,N-diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid.

15

6. A process for preparing a compound of the formula




25

20

30

in which R², X and Y are as described for formula (Ia) in claim 4 and R¹⁴ is the same as R³ as described for formula (Ia) in claim 4 ; R¹ is hydrogen or C₁₋₈ alkyl, and M is O or S, which comprises treating a compound of formula



35

40

45

in which X¹ is bromo, chloro, fluoro or iodo ; and R², R¹⁴, X and Y are as described above, with an alkyl lithium reagent followed by a carboxylating agent, or with a palladium catalyst in the presence of a base, a C₁₋₄ alcohol and carbonyl monoxide.


7. The process of Claim 6 wherein the compound prepared is N-t-butyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid or N,N-diisopropyl-androst-3,5-diene-carboxamide-3-carboxylic acid.

50

Claims for the following Contracting State : GR

1. A process for preparing a compound of the formula (I) :

55



(I)

In which :

the A ring has up to 2 double bonds ;

the B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C₈-C₁₄ double bond when the B ring has a C₇-C₈ double bond ;

M is O or S ;

Z is (CH₂)_n and n is 0-2 ;

X is H, Cl, F, Br, I, CF₃, or C₁₋₃ alkyl ;

Y is H, CF₃, F, or Cl, CH₃, provided that Y is H when there is no C₅-C₆ double bond ;

R¹ is H or C₁₋₃ alkyl ;


R² is absent or present as H or CH₃, provided R² is absent when the carbon to which it is attached is double bonded ;

R¹⁰ is absent when there is a C₄-C₅, C₇-C₈, or C₉-C₁₀ double bond, or present as an alpha hydrogen ; and

R³ is

(1) α-hydrogen, α-hydroxyl, or α-acetoxy and/or

(a)



where W is a bond or C₁₋₁₂ alkylene and R⁴ is

(i) hydrogen,

(ii) hydroxyl,

(iii) C₁₋₃ alkyl,

(iv) hydroxy C₁₋₃ alkyl,

(v) C₁₋₃ alkoxy,

(vi) NR⁵R⁶, where R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₃-alkyl, C₃₋₆ cycloalkyl, phenyl ; or R⁵ and R⁶ taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen, or

(vii) OR⁷, where R⁷ is hydrogen, alkali metal, C₁₋₁₈ alkyl, benzyl, or

(b) β-Alk-OR⁸, where Alk is C₁₋₁₂ alkylene and R⁸ is

(i) phenyl C₁₋₃ alkylcarbonyl,

(ii) C₅₋₁₀ cycloalkylcarbonyl,

(iii) benzoyl,

(iv) C₁₋₁₈ alkoxy carbonyl,

(v) amino-, or C₁₋₃ alkyl substituted aminocarbonyl,

(vi) hydrogen, or

(vii) C₁₋₃ alkyl,

(2) =CH-W-CO-R⁹ or =CH-W-OR⁹, where W is a bond or C₁₋₁₂ alkylene and R⁴ and R⁸ have the same meaning as above and R⁹ also is hydrogen or C₁₋₂₀-alkylcarbonyl ;

(3)



where the dashed bond replaces the 17- α -hydrogen,

(4) α -hydrogen and β -NHCOR⁵ where R⁵ is C₁₋₁₂ alkyl or β -NHCOR⁵R⁶ where R⁵ and R⁶ have the same meaning as above,

(5) α -hydrogen and β -cyano,

(6) α -hydrogen and β -tetrazolyl, or

(7) keto ;

or a pharmaceutically acceptable salt thereof ; except compounds in which :

The A ring has C₂-C₄ double bond and the B ring has a C₅-C₆ double bond, R¹ is CH₃, and R³ is keto ;


The A ring has C₆-C₄ double bond and the B ring has a C₅-C₆ double bond and

the D ring has a C₁₅-C₁₇ double bonds, R¹ is CH₃, and

R³ is COOCH₃ ; and

The B ring has a C₇-C₈ double bond, R¹ is CH₃, and R³ is COCH₃.

that comprises treating with an organic base, a phosphine, a palladium (II) compound, and a C₁₋₆ alkyl alcohol, and then adding carbon monoxide to a compound of the formula (V) :



(V)

wherein X, Y, Z, R², and R¹⁰ are as described above and R¹⁴ is R³ or moieties which can be chemically converted to R³.

2. The process of Claim 1 wherein the compound prepared is N-t-butyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid or N,N-disopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid.

3. The process of Claim 1 wherein the compound prepared is

20- α -(hydroxymethyl)-5- α -pregn-3-ene-3-carboxylic acid,

N,N-disopropyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid,

17 β -(N,N-disopropylcarboxamide)-4-fluoro-5- α -androst-3-ene-3-carboxylic acid,

17 β -(N,N-disopropylcarboxamide)-4-fluoro-androst-3,5-diene-3-carboxylic acid,

20- α -(hydroxymethyl)-4-fluoro-5- α -pregn-3-ene-3-carboxylic acid,

3-carbomethoxy-N,N-disopropyl-androst-3,5-diene-17 β -carboxamide,

17 β -N,N-disopropylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid,

N,N-disopropyl 5- α -androst-2-ene-17 β -carboxamide-3-carboxylic acid,

N,N-disopropyl androst-2,4-diene-17 β -carboxamide-3-carboxylic acid,

N,N-disopropyl 5- α -androstane-17 β -carboxamide-3d-carboxylic acid,

N,N-disopropyl estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic acid,

N,N-disopropyl estr-3,5-diene-17 β -carboxamide-3-carboxylic acid,

17 β -(N-t-butylcarboxamide)-androst-3,5,11-triene-3-carboxylic acid,

17 β -(N-t-butylcarboxamide)-androst-3,5-diene-3-thiocarboxylic acid,

N-t-Butyl-5- α -androst-3-ene-17 β -carboxamide-3-carboxylic acid,

17 β -(N-t-Butylcarboxamide)-6-fluoro-5- α -androst-3-ene-3-carboxylic acid,

17 β -(N-t-Butylcarboxamide)-6-fluoro-androst-3,5-diene-3-carboxylic acid,

3-Carbomethoxy-N-t-butyl-androst-3,5-diene-17 β -carboxamide,

17 β -N-t-Butylcarboxamide-5- α -androst-1,3-diene-3-carboxylic acid,

N-t-Butyl-5- α -androst-2-ene-17 β -carboxamide-3-carboxylic acid,


N-t-Butyl-androst-2,4-diene-17 β -carboxamide-3-carboxylic acid,

N-t-Butyl-5- α -androstane-17 β -carboxamide-3-carboxylic acid,



N-t-Butyl-estr-3,5(10)-diene-17 β -carboxamide-3-carboxylic acid, or
N-t-Butyl-estr-3,5-diene-17 β -carboxamide-3-carboxylic acid.

4. A process for the preparation of a pharmaceutical composition which comprises bringing into association a compound of formula (Ia) :



in which :

the A ring has up to 2 double bonds ;

the B, C, and D rings have optional double bonds where indicated by the broken lines, provided that the C ring does not have a C₆-C₁₄ double bond when the B ring has a C₇-C₈ double bond ;

M is O or S ;

Z is (CH₂)_n and n is 0-2 ;

X is H, Cl, F, Br, I, CF₃, or C₁₋₆ alkyl ;

Y is H, CF₃, F, or Cl, CH₃, provided that Y is H when there is no C₈-C₉ double bond ;


R¹ is H or C₁₋₆ alkyl ;

R² is absent or present as H or CH₃, provided R² is absent when the carbon to which it is attached is double bonded ;

R¹⁰ is absent when there is a C₄-C₅, C₆-C₉, or C₈-C₁₀ double bond, or present as an alpha hydrogen ; and

R³ is

- (1) α -hydrogen, α -hydroxyl, or α -acetoxy and/or
(a)



where W is a bond or C₁₋₁₂ alkylene and R⁴ is

- (i) hydrogen,
- (ii) hydroxyl,
- (iii) C₁₋₆ alkyl,
- (iv) hydroxy C₁₋₆ alkyl,
- (v) C₁₋₆ alkoxy,
- (vi) NR⁵R⁶, where R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₆-alkyl, C₃₋₆ cycloalkyl, phenyl ; or R⁵ and R⁶ taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen, or
- (vii) OR⁷, where R⁷ is hydrogen, alkali metal, C₁₋₁₈ alkyl, benzyl, or
- (b) β -Alk-OR⁸, where Alk is C₁₋₁₂ alkylene, and R⁸ is
 - (i) phenyl C₁₋₆ alkylcarbonyl,
 - (ii) C₆₋₁₀ cycloalkylcarbonyl,
 - (iii) benzoyl,
 - (iv) C₁₋₆ alkoxycarbonyl,
 - (v) amino-, or C₁₋₆ alkyl substituted aminocarbonyl,
 - (vi) hydrogen, or
 - (vii) C₁₋₆ alkyl,

(2) =CH-W-CO-R^4 or =CH-W-OR^8 , where W is a bond or C₁₋₁₂ alkylene, and R⁴ and R⁸ have the same meaning as above and R⁸ also is hydrogen or C₁₋₂₀ alkylcarbonyl ;



(3)



where the dashed bond replaces the 17- α -hydrogen,

(4) α -hydrogen and β -NHCOR⁵ where R⁵ is C₁₋₁₂ alkyl or β -NR⁵R⁶ where R⁵ and R⁶ have the same meaning as above,

(5) α -hydrogen and β -cyano,


(6) α -hydrogen and β -tetrazolyl, or

(7) keto;


or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

5. A process as claimed in claim 4 in which the compound of formula (Ia) N-t-butyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid or N,N-diisopropyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid.

6. A process for preparing a compound of the formula



In which R², X and Y are as described for formula (Ia) in claim 4 and R¹⁴ is the same as R³ as described for formula (Ia) in claim 4; R¹ is hydrogen or C₁₋₈ alkyl, and M is O or S, which comprises treating a compound of formula




in which X¹ is bromo, chloro, fluoro or iodo; and R², R¹⁴, X and Y are as described above, with an alkyl lithium reagent followed by a carboxylating agent, or with a palladium catalyst in the presence of a base, a C₁₋₄ alcohol and carbon monoxide.

7. The process of Claim 6 wherein the compound prepared is N-t-butyl-androst-3,5-diene-17 β -carboxamide-3-carboxylic acid or N,N-diisopropyl-androst-3,5-diene-carboxamide-3-carboxylic acid.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten: AT, BE, CH, FR, GB, IT, LI, LU, NL, SE

1. Verbindung der Formel (I):



(I)

in der:

der Ring A bis zu 2 Doppelbindungen hat,

die Ringe B, C und D fakultative Doppelbindungen, angezeigt durch die unterbrochenen Linien, haben, mit der Maßgabe, daß der Ring C keine C₈-C₁₄-Doppelbindung aufweist, falls der Ring B eine C₇-C₈-Doppelbindung hat,

M ein Sauerstoff- oder Schwefelatom bedeutet,

Z einen Rest der Formel (CH₂)_n bedeutet, und n 0-2 ist,

X ein Wasserstoff-, Chlor-, Fluor-, Brom-, Iodat, einen Rest der Formel CF₃ oder einen C₁₋₈-Alkylrest bedeutet,

Y ein Wasserstoffatom, ein Rest der Formel CF₃, ein Fluor- oder Chloratom, ein Rest der Formel CH₃ ist, mit der Maßgabe, daß Y ein Wasserstoffatom ist, falls es keine C₅-C₆-Doppelbindung gibt,

R¹ ein Wasserstoffatom oder einen C₁₋₈-Alkylrest bedeutet,


R² fehlt oder als ein Wasserstoffatom oder ein Rest der Formel CH₃ vorliegt, mit der Maßgabe, daß R² fehlt, falls das Kohlenstoffatom, an das er gebunden ist, eine Doppelbindung trägt,

R¹⁰ fehlt, falls es eine C₆-C₇, C₈-C₉ oder eine C₉-C₁₀-Doppelbindung gibt, oder als α-Wasserstoffatom vorliegt, und

R³

(1) ein α-Wasserstoffatom, eine α-Hydroxyl- oder eine α-Acetoxygruppe und/oder

(a) ein Rest der Formel



wobei W eine Bindung oder einen C₁₋₁₂-Alkylrest bedeutet, und R⁴

(i) ein Wasserstoffatom,

(ii) eine Hydroxylgruppe,

(iii) ein C₁₋₈-Alkylrest,

(iv) ein Hydroxyl-C₁₋₈-alkylrest,

(v) ein C₁₋₈-Alkoxyrest,

(vi) ein Rest der Formel NR⁵R⁶, wobei R⁵ und R⁶ jeweils unabhängig voneinander aus einem Wasserstoffatom, einem C₁₋₈-Alkyl-, einem C₃₋₈-Cycloalkyl-, einem Phenylrest ausgewählt sind oder R⁵ und R⁶ zusammengefaßt mit dem Stickstoffatom, an das sie gebunden sind, einen 5-6-gliedrigen, gesättigten Ring, umfassend bis zu einem weiteren, aus einem Sauerstoff- und Stickstoffatom ausgewählten Heteroatom, bedeuten, oder

(vii) ein Rest der Formel OR⁷ ist, wobei R⁷ ein Wasserstoffatom, ein Alkalimetall, einen C₁₋₁₈-Alkyl-, einen Benzylrest bedeutet, oder

(b) ein Rest der Formel β-Alk-OR⁸, wobei Alk einen C₁₋₁₂-Alkylrest bedeutet, und R⁸

(i) eine Phenyl-C₁₋₈-alkylcarbonylgruppe,

(ii) eine C₆₋₁₀-Cycloalkylcarbonylgruppe,

(iii) ein Benzoylrest,

(iv) eine C₁₋₈-Alkoxycarbonylgruppe,

(v) eine Amino- oder eine C₁₋₈-Alkyl-substituierte Aminocarbonylgruppe,

(vi) ein Wasserstoffatom oder

(vii) ein C₁₋₈-Alkylrest ist,

(2) ein Rest der Formel =CH-W-CO-R⁴ oder der Formel =CH-W-OR⁸, wobei W eine Bindung oder einen C₁₋₁₂-Alkylrest bedeutet, und R⁴ und R⁸ die gleiche Bedeutung wie vorstehend haben, und R⁸ ebenfalls



ein Wasserstoffatom oder eine C₁₋₂₀-Alkylcarbonylgruppe bedeutet,
(3) ein Rest der Formel



wobei die gestrichelte Bindung das 17- α -Wasserstoffatom ersetzt,

(4) ein α -Wasserstoffatom und ein Rest der Formel β -NHCOR⁹, wobei R⁹ einen C₁₋₁₂-Alkylrest oder einen Rest der Formel β -NR⁵R⁶ bedeutet, wobei R⁵ und R⁶ die gleiche Bedeutung wie vorstehend haben,

(5) ein α -Wasserstoffatom und eine β -Cyanogruppe,

(6) ein α -Wasserstoffatom und eine β -Tetrazolylgruppe oder

(7) eine Ketogruppe ist,

oder ein pharmazeutisch verträgliches Salz davon, mit Ausnahme von Verbindungen, in denen :

der Ring A eine C₃-C₄-Doppelbindung und der Ring B eine C₅-C₆-Doppelbindung haben, R¹ einen Rest der Formel CH₃ bedeutet, und R³ eine Ketogruppe ist,

der Ring A eine C₃-C₄-Doppelbindung und der Ring B eine C₅-C₆-Doppelbindung und der Ring D eine C₁₈-C₁₇-Doppelbindung haben, R¹ einen Rest der Formel CH₃ bedeutet, und R³ ein Rest der Formel COOCH₃ ist, und

der Ring B eine C₅-C₆-Doppelbindung hat, R¹ einen Rest der Formel CH₃ bedeutet, und R³ ein Rest der Formel COCH₃ ist.

2. Verbindung nach Anspruch 1, nämlich N-t-Butylandrost-3, 5-dien-17 β -carboxamid-3-carbonsäure oder N,N-Diisopropylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure.

3. Verbindung nach Anspruch 1, nämlich 20- α -(Hydroxymethyl)-5- α -pregn-3-en-3-carbonsäure,

N,N-Diisopropyl-5- α -androst-3-en-17 β -carboxamid-3-carbonsäure,

17 β -(N,N-Diisopropylcarboxamid)-4-fluor-5- α -androst-3-en-3-carbonsäure,

17 β -(N,N-Diisopropylcarboxamid)-4-fluor-androst-3,5-dien-3-carbonsäure,

20- α -(Hydroxymethyl)-4-fluor-5- α -pregn-3-en-3-carbonsäure,

3-Carbomethoxy-N,N-diisopropylandrost-3,5-dien-17 β -carboxamid,

17 β -N,N-Diisopropylcarboxamid-5- α -androst-1,3-dien-3-carbonsäure,

N,N-Diisopropyl-5- α -androst-2-en-17 β -carboxamid-3 β -carbonsäure,

N,N-Diisopropylandrost-2,4-dien-17 β -carboxamid-3-carbonsäure,

N,N-Diisopropyl-5- α -androstan-17 β -carboxamid-3 β -carbonsäure,

N,N-Diisopropyl-3,5(10)-dien-17 β -carboxamid-3-carbonsäure,

N,N-Diisopropyl-3,5-dien-17 β -carboxamid-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)androst-3,5,11-trien-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)androst-3,5-dien-3-thiocarbonsäure,

N-t-Butyl-5- α -androst-3-en-17 β -carboxamid-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)-8-fluor-5- α -androst-3-en-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)-8-fluorandrost-3,5-dien-3-carbonsäure,

20- α -(Hydroxymethyl)-A-nor-5- α -pregn-1-en-2-carbonsäure.

3-Carbomethoxy-N-t-butylandrost-3,5-dien-17 β -carboxamid,

17 β -N-t-Butylcarboxamid-5- α -androst-1,3-dien-3-carbonsäure,

N-t-Butyl-5- α -androst-2-en-17 β -carboxamid-3-carbonsäure,


N-t-Butylandrost-2,4-dien-17 β -carboxamid-3-carbonsäure,

N-t-Butyl-5- α -androstan-17 β -carboxamid-3-carbonsäure,

N-t-Butyl-3,5(10)-dien-17 β -carboxamid-3-carbonsäure oder

N-t-Butyl-3,5-dien-17 β -carboxamid-3-carbonsäure.

4. Verbindung der Formel (III) :



(III)

in der:

der Ring B eine fakultative Doppelbindung, angezeigt durch die unterbrochene Linie, hat,


R^1 und R^2 jeweils ein Wasserstoffatom oder einen C_{1-8} -Alkylrest bedeuten,

R^{13} ein Rest der Formel $HC(CH_3)CH_2OR^{20}$, in der R^{20} ein Wasserstoffatom oder einen C_{1-8} -Alkylrest bedeutet,

oder ein Rest der Formel $CONR^{21}R^{22}$ ist, in der R^{21} und R^{22} unabhängig voneinander ein Wasserstoffatom oder einen C_{1-8} -Alkylrest bedeuten, und

M ein Sauerstoff- oder Schwefelatom ist.

5. Verbindung der Formel (II)



(II)

in der:

der Ring A bis zu 2 Doppelbindungen hat,

die Ringe B und C fakultative Doppelbindungen, angezeigt durch die unterbrochenen Linien, haben,

M ein Sauerstoff- oder Schwefelatom bedeutet,

X ein Wasserstoff- oder ein Halogenatom ist, und

R^1 ein Wasserstoffatom oder einen C_{1-8} -Alkylrest bedeutet,

R^2 ein Wasserstoffatom oder ein C_{1-8} -Alkylrest ist,


R^{10} fehlt, falls es eine C_4-C_5 , C_5-C_6 oder eine C_8-C_{10} Doppelbindung gibt, oder als α -Wasserstoffatom vorliegt, und

R^{13}

(a) einen Rest der Formel $HC(CH_3)CH_2OR^{20}$, wobei R^{20} ein Wasserstoffatom oder ein C_{1-8} -Alkylrest ist, oder

(b) einen Rest der Formel $CONR^{21}R^{22}$ bedeutet, wobei R^{21} und R^{22} unabhängig voneinander ein Wasserstoffatom oder ein C_{1-8} -Alkylrest sind.

6. Arzneimittel, umfassend einen geeigneten pharmazeutischen Träger und eine Verbindung der Formel (Ia);



(Ia)



in der:

der Ring A bis zu 2 Doppelbindungen hat,
die Ringe B, C und D fakultative Doppelbindungen, angezeigt durch die unterbrochenen Linien, haben, mit der Maßgabe, daß der Ring C keine C₈-C₁₄-Doppelbindung aufweist, falls der Ring B eine C₇-C₈-Doppelbindung hat,

M ein Sauerstoff- oder Schwefelatom bedeutet,

Z einen Rest der Formel (CH₂)_n bedeutet, und n 0-2 ist,

X ein Wasserstoff-, Chlor-, Fluor-, Brom-, Iodatomb, einen Rest der Formel CF₃ oder einen C₁₋₈-Alkylrest bedeutet,

Y ein Wasserstoffatom, ein Rest der Formel CF₃, ein Fluor- oder Chloratom, ein Rest der Formel CH₃ ist, mit der Maßgabe, daß Y ein Wasserstoffatom ist, falls es keine C₅-C₈-Doppelbindung gibt,


R¹ ein Wasserstoffatom oder einen C₁₋₈-Alkylrest bedeutet,

R² fehlt oder als ein Wasserstoffatom oder ein Rest der Formel CH₃ vorliegt, mit der Maßgabe, daß R² fehlt, falls das Kohlenstoffatom, an das er gebunden ist, eine Doppelbindung trägt,

R¹⁰ fehlt, falls es eine C₄-C₈, C₅-C₉ oder eine C₅-C₁₀-Doppelbindung gibt, oder als α-Wasserstoffatom vorliegt, und
R³

(1) ein α-Wasserstoffatom, eine α-Hydroxyl- oder eine α-Acetoxygruppe und/oder

(a) ein Rest der Formel



wobei W eine Bindung oder einen C₁₋₁₂-Alkylrest bedeutet, und R⁴

(i) ein Wasserstoffatom,

(ii) eine Hydroxylgruppe,

(iii) ein C₁₋₈-Alkylrest,

(iv) ein Hydroxyl-C₁₋₈-alkylrest,

(v) ein C₁₋₈-Alkoxyrest

(vi) ein Rest der Formel NR⁵R⁶, wobei R⁵ und R⁶ jeweils unabhängig voneinander aus einem Wasserstoffatom, einem C₁₋₈-Alkyl-, einem C₂₋₆-Cycloalkyl-, einem Phenylrest ausgewählt sind oder R⁵ und R⁶ zusammengekommen mit dem Stickstoffatom, an das sie gebunden sind, einen 5-6-gliedrigen, gesättigten Ring, umfassend bis zu einem weiteren, aus einem Sauerstoff- und Stickstoffatom ausgewählten Heteroatom, bedeuten, oder

(vii) ein Rest der Formel OR⁷ ist, wobei R⁷ ein Wasserstoffatom, ein Alkalimetall, einen C₁₋₁₈-Alkyl-, einen Benzylrest bedeutet, oder

(b) ein Rest der Formel β-Alk-OR⁸, wobei Alk einen C₁₋₁₂-Alkylrest bedeutet, und R⁸

(i) eine Phenyl-C₁₋₈-alkylcarbonylgruppe,

(ii) eine C₆₋₁₀-Cycloalkylcarbonylgruppe,

(iii) ein Benzoylrest,

(iv) eine C₁₋₈-Alkoxycarbonylgruppe,

(v) eine Amino- oder eine C₁₋₈-Alkyl-substituierte Aminocarbonylgruppe,

(vi) ein Wasserstoffatom oder

(vii) ein C₁₋₈-Alkylrest ist,

(2) ein Rest der Formel =CH-W-CO-R⁴ oder der Formel =CH-W-OR⁸, wobei W eine Bindung oder einen C₁₋₁₂-Alkenylrest bedeutet, und R⁴ und R⁸ die gleiche Bedeutung wie vorstehend haben, und R⁸ ebenfalls ein Wasserstoffatom oder eine C₁₋₂₀-Alkylcarbonylgruppe bedeutet,

(3) ein Rest der Formel



wobei die gestrichelte Bindung das 17-α-Wasserstoffatom ersetzt,

(4) ein α-Wasserstoffatom und ein Rest der Formel β-NHCOR⁹, wobei R⁹ einen C₁₋₁₂-Alkylrest oder einen Rest der Formel β-NR⁵R⁶ bedeutet, wobei R⁵ und R⁶ die gleiche Bedeutung wie vorstehend haben,




- (5) ein α -Wasserstoffatom und eine β -Cyanogruppe,
 (6) ein α -Wasserstoffatom und eine β -Tetrazolylgruppe oder
 (7) eine Ketogruppe ist, oder ein pharmazeutisch verträgliches Salz davon.

7. Mittel nach Anspruch 6, wobei die Verbindung N-t-Butylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure oder N,N-Diisopropylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure ist.

8. Mittel aus Anspruch 6, wobei die Verbindung 20- α -(Hydroxymethyl)-5- α -pregn-3-en-3-carbonsäure, N,N-Diisopropyl-5- α -androst-3-en-17 β -carboxamid-3-carbonsäure, 17 β -(N,N-Diisopropylcarboxamid)-4-fluor-5- α -androst-3-en-3-carbonsäure, 17 β -(N,N-Diisopropylcarboxamid)-4-fluor-androst-3,5-dien-3-carbonsäure, 20- α -(Hydroxymethyl)-4-fluor-5- α -pregn-3-en-3-carbonsäure, 3-Carbomethoxy-N,N-diisopropylandrost-3,5-dien-17 β -carboxamid, 17 β -N,N-Diisopropylcarboxamid-5- α -androst-1,3-dien-3-carbonsäure, N,N-Diisopropyl-5- α -androst-2-en-17 β -carboxamid-3-carbonsäure, N,N-Diisopropylandrost-2,4-dien-17 β -carboxamid-3-carbonsäure, N,N-Diisopropyl-5- α -androstan-17 β -carboxamid-3 β -carbonsäure, N,N-Diisopropylestr-3,5(10)-dien-17 β -carboxamid-3-carbonsäure, N,N-Diisopropylestr-3,5-dien-17 β -carboxamid-3-carbonsäure, 17 β -(N-t-Butylcarboxamid)androst-3,5,11-trien-3-carbonsäure, 17 β -(N-t-Butylcarboxamid)androst-3,5-dien-3-thiocarbonsäure, N-t-Butyl-5- α -androst-3-en-17 β -carboxamid-3-carbonsäure, 17 β -(N-t-Butylcarboxamid)-6-fluor-5- α -androst-3-en-3-carbonsäure, 17 β -(N-t-Butylcarboxamid)-6-fluorandrost-3,5-dien-3-carbonsäure, 3-Carbomethoxy-N-t-butylandrost-3,5-dien-17 β -carboxamid, 17 β -N-t-Butylcarboxamid-5- α -androst-1,3-dien-3-carbonsäure, N-t-Butyl-5- α -androst-2-en-17 β -carboxamid-3-carbonsäure, N-t-Butylandrost-2,4-dien-17 β -carboxamid-3-carbonsäure, N-t-Butyl-5- α -androstan-17 β -carboxamid-3-carbonsäure, N-t-Butylestr-3,5(10)-dien-17 β -carboxamid-3-carbonsäure oder N-t-Butylestr-3,5-dien-17 β -carboxamid-3-carbonsäure ist.


9. Verfahren zur Herstellung einer Verbindung der Formel :



in der :

R², X und Y wie für Formel (Ia) in Anspruch 6 beschrieben sind, und R¹⁴ gleich R³ ist, wie für Formel (Ia) in Anspruch 6 beschrieben,

R¹ ein Wasserstoffatom oder ein C₁₋₈-Alkylrest ist, und
 M ein Sauerstoff- oder Schwefelatom bedeutet,
 umfassend die Behandlung einer Verbindung der Formel




in der :

X¹ ein Brom-, Chlor-, Fluor- oder ein Iodatombedeutet, und R², R¹⁴, X und Y wie vorstehend beschrieben sind, mit einem Alkylolithiumreagens und dann mit einem Carboxylierungsmittel oder mit einem Palladiumkatalysator in Gegenwart einer Base, eines C₁₋₄-Alkanols und von Kohlenstoffmonoxid.

10. Verfahren nach Anspruch 9, wobei die hergestellte Verbindung N-t-Butylandroster-3,5-dien-17β-carboxamid-3-carbonsäure oder N,N-Diisopropylandroster-3,5-dien-carboxamid-3-carbonsäure ist.

11. Verfahren zur Herstellung einer Verbindung der Formel (I) gemäß Anspruch 1, umfassend die Behandlung mit einer organischen Base, einem Phosphin, einer Palladium(II)-Verbindung und einem C₁₋₆-Alkylalkohol und anschließend die Zugabe von Kohlenstoffmonoxid zu einer Verbindung der Formel :



wobei X, Y, Z, R² und R¹⁰ wie vorstehend beschrieben sind, und R¹⁴ R³ ist, wie für Formel (I) beschrieben, oder Einheiten bedeutet, die chemisch in R³ umgewandelt werden können.


12. Verbindung nach Anspruch 1 zur Verwendung als therapeutischer Wirkstoff.

13. Verbindung aus Anspruch 1 zur Verwendung als Inhibitor der Steroid-5-α-Reduktase.

14. Verbindung aus Anspruch 1 zur Verwendung bei der Behandlung zur Verringerung der Prostatagröße.

Patentansprüche für folgenden Vertragszitat : ES

1. Verfahren zur Herstellung einer Verbindung der Formel (I) :



(I)

in der :

der Ring A bis zu 2 Doppelbindungen hat,

die Ringe B, C und D fakultative Doppelbindungen, angezeigt durch die unterbrochenen Linien, haben, mit der Maßgabe, daß der Ring C keine C₈-C₁₄-Doppelbindung aufweist, falls der Ring B eine C₇-C₈-Doppelbindung hat,



M ein Sauerstoff- oder Schwefelatom bedeutet,

Z einen Rest der Formel $(CH_2)_n$ bedeutet, und n 0-2 ist,

X ein Wasserstoff-, Chlor-, Fluor-, Brom-, Iodat, einen Rest der Formel CF_3 oder einen C_{1-6} -Alkylrest bedeutet,


5 Y ein Wasserstoffatom, ein Rest der Formel CF_3 , ein Fluor- oder Chloratom, ein Rest der Formel CH_3 ist, mit der Maßgabe, daß Y ein Wasserstoffatom ist, falls es keine C_5-C_6 -Doppelbindung gibt,

R¹ ein Wasserstoffatom oder einen C_{1-6} -Alkylrest bedeutet,

R² fehlt oder als ein Wasserstoffatom oder ein Rest der Formel CH_3 vorliegt, mit der Maßgabe, daß R² fehlt, falls das Kohlenstoffatom, an das er gebunden ist, eine Doppelbindung trägt,

10 R¹⁰ fehlt, falls es eine C_4-C_7 , C_7-C_8 oder eine C_8-C_{10} -Doppelbindung gibt, oder als α -Wasserstoffatom vorliegt, und
R³

- (1) ein α -Wasserstoffatom, eine α -Hydroxyl- oder eine α -Acetoxygruppe und/oder
(a) ein Rest der Formel



20 wobei W eine Bindung oder einen C_{1-12} -Alkylrest bedeutet, und R⁴

(i) ein Wasserstoffatom,

(ii) eine Hydroxylgruppe,

(iii) ein C_{1-6} -Alkylrest,

(iv) ein Hydroxyl- C_{1-6} -alkylrest,

25 (v) ein C_{1-6} -Alkoxyrest,

(vi) ein Rest der Formel NR^5R^6 , wobei R⁵ und R⁶ jeweils unabhängig voneinander aus einem Wasserstoffatom, einem C_{1-6} -Alkyl-, einem C_{3-6} -Cycloalkyl-, einem Phenylrest ausgewählt sind oder R⁵ und R⁶ zusammengekommen mit dem Stickstoffatom, an das sie gebunden sind, einen 5-6-gliedrigen, gesättigten Ring, umfassend bis zu einem weiteren, aus einem Sauerstoff und Stickstoffatom

30 ausgewählten Heteroatom, bedeuten, oder
(vii) ein Rest der Formel OR^7 ist, wobei R⁷ ein Wasserstoffatom, ein Alkalimetall, einen C_{1-15} -Alkyl-, einen Benzylrest bedeutet, oder

(b) ein Rest der Formel $\beta\text{-Alk-OR}^8$, wobei Alk einen C_{1-12} -Alkylrest bedeutet, und R⁸

(i) eine Phenyl- C_{1-6} -alkylcarbonylgruppe,

35 (ii) eine C_{5-10} -Cycloalkylcarbonylgruppe,

(iii) ein Benzoylrest,

(iv) eine C_{1-6} -Alkoxycarbonylgruppe,

(v) eine Amino- oder eine C_{1-6} -Alkyl-substituierte Aminocarbonylgruppe,

(vi) ein Wasserstoffatom oder

40 (vii) ein C_{1-6} -Alkylrest ist,

(2) ein Rest der Formel $=CH-W-CO-R^4$ oder der Formel $=CH-W-OR^8$, wobei W eine Bindung oder einen C_{1-12} -Alkylrest bedeutet, und R⁴ und R⁸ die gleiche Bedeutung wie vorstehend haben, und R⁸ ebenfalls ein Wasserstoffatom oder eine C_{1-25} -Alkylcarbonylgruppe bedeutet,

(3) ein Rest der Formel



45 wobei die gestrichelte Bindung das 17- α -Wasserstoffatom ersetzt.

(4) ein α -Wasserstoffatom und ein Rest der Formel $\beta\text{-NHCOR}^9$, wobei R⁹ einen C_{1-12} -Alkylrest oder einen Rest der Formel $\beta\text{-NR}^5R^6$ bedeutet, wobei R⁵ und R⁶ die gleiche Bedeutung wie vorstehend haben,

(5) ein α -Wasserstoffatom und eine β -Cyanogruppe,

55 (6) ein α -Wasserstoffatom und eine β -Tetrazolylgruppe oder

(7) eine Ketogruppe ist,


oder eines pharmazeutisch verträglichen Salzes davon, mit Ausnahme von Verbindungen, in denen :
der Ring A eine C_3-C_4 -Doppelbindung und der Ring B eine C_5-C_6 -Doppelbindung haben, R¹ einen Rest



der Formel CH_3 bedeutet, und R^3 eine Ketogruppe ist, der Ring A eine $\text{C}_3\text{-C}_4$ -Doppelbindung und der Ring B eine $\text{C}_5\text{-C}_6$ -Doppelbindung und der Ring D eine $\text{C}_{16}\text{-C}_{17}$ -Doppelbindung haben, R^1 einen Rest der Formel CH_3 bedeutet, und R^2 ein Rest der Formel COOCH_3 ist, und

der Ring B eine $\text{C}_7\text{-C}_8$ -Doppelbindung hat, R^1 einen Rest der Formel CH_3 bedeutet, und R^2 ein Rest der Formel COCH_3 ist,

umfassend die Behandlung mit einer organischen Base, einem Phosphin, einer Palladium(II)-Verbindung und einem C_{1-6} -Alkylalkohol und anschließend die Zugabe von Kohlenstoffmonoxid zu einer Verbindung der Formel (V) :



wobei X, Y, Z, R^2 und R^{10} wie vorstehend beschrieben sind, und R^{14} R^3 ist oder Einheiten bedeutet, die chemisch in R^3 umgewandelt werden können.

2. Verfahren nach Anspruch 1, wobei die hergestellte Verbindung N-t-Butylandroster-3,5-dien-17 β -carboxamid-3-carbonsäure oder N,N-Dilisopropylandroster-3,5-dien-17 β -carboxamid-3-carbonsäure ist.

3. Verfahren nach Anspruch 1, wobei die hergestellte Verbindung

20- α -(Hydroxymethyl)-5- α -pregn-3-en-3-carbonsäure,

N,N-Dilisopropyl-5- α -androster-3-en-17 β -carboxamid-3-carbonsäure,

17 β -(N,N-Dilisopropylcarboxamid)-4-fluor-5- α -androster-3-en-3-carbonsäure,

17 β -(N,N-Dilisopropylcarboxamid)-4-fluor-androster-3,5-dien-3-carbonsäure,

20- α -(Hydroxymethyl)-4-fluor-5- α -pregn-3-en-3-carbonsäure,

3-Carbomethoxy-N,N-dilisopropylandroster-3,5-dien-17 β -carboxamid,

17 β -N,N-Dilisopropylcarboxamid-5- α -androster-1,3-dien-3-carbonsäure,

N,N-Dilisopropyl-5- α -androster-2-en-17 β -carboxamid-3-carbonsäure,

N,N-Dilisopropylandroster-2,4-dien-17 β -carboxamid-3-carbonsäure,

N,N-Dilisopropyl-5- α -androster-17 β -carboxamid-3 β -carbonsäure,

N,N-Dilisopropylester-3,5(10)-dien-17 β -carboxamid-3-carbonsäure,

N,N-Dilisopropylester-3,5-dien-17 β -carboxamid-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)androster-3,5,11-trien-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)androster-3,5-dien-3-thiocarbonsäure,

N-t-Butyl-5- α -androster-3-en-17 β -carboxamid-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)-6-fluor-5- α -androster-3-en-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)-6-fluorandroster-3,5-dien-3-carbonsäure,

3-Carbomethoxy-N-t-butylandroster-3,5-dien-17 β -carboxamid,

17 β -N-t-Butylcarboxamid-5- α -androster-1,3-dien-3-carbonsäure,

N-t-Butyl-5- α -androster-2-en-17 β -carboxamid-3-carbonsäure,


N-t-Butylandroster-2,4-dien-17 β -carboxamid-3-carbonsäure,

N-t-Butyl-5- α -androster-17 β -carboxamid-3-carbonsäure,

N-t-Butylester-3,5(10)-dien-17 β -carboxamid-3-carbonsäure oder

N-t-Butylester-3,5-dien-17 β -carboxamid-3-carbonsäure ist.


4. Verfahren zur Herstellung eines Arzneimittels, umfassend die Vereinigung einer Verbindung der Formel (Ia) :



(Ia)

in der
 der Ring A bis zu 2 Doppelbindungen hat,
 die Ringe B, C und D fakultative Doppelbindungen, angezeigt durch die unterbrochenen Linien, haben, mit der
 Maßgabe, daß der Ring C keine C₅-C₁₂-Doppelbindung aufweist, falls der Ring B eine C₇-C₈-Doppelbindung
 hat,
 M ein Sauerstoff- oder Schwefelatom bedeutet,
 Z einen Rest der Formel (CH₂)_n bedeutet, und n 0-2 ist,
 X ein Wasserstoff-, Chlor-, Fluor-, Brom-, Iodatome, einen Rest der Formel CF₃ oder einen C₁₋₈-Alkylrest bedeu-
 tet,
 Y ein Wasserstoffatom, ein Rest der Formel CF₃, ein Fluor- oder Chloratom, ein Rest der Formel CH₃ ist, mit
 der Maßgabe, daß Y ein Wasserstoffatom ist, falls es keine C₅-C₆-Doppelbindung gibt,
 R¹ ein Wasserstoffatom oder einen C₁₋₈-Alkylrest bedeutet,
 R² fehlt oder als ein Wasserstoffatom oder ein Rest der Formel CH₃ vorliegt, mit der Maßgabe, daß R² fehlt,
 falls das Kohlenstoffatom, an das er gebunden ist, eine Doppelbindung trägt,
 R¹⁰ fehlt, falls es eine C₄-C₅, C₅-C₆ oder eine C₈-C₁₀- Doppelbindung gibt, oder als α-Wasserstoffatom vorliegt,
 und
 R³

- (1) ein α-Wasserstoffatom, eine α-Hydroxyl- oder eine α-Acetoxygruppe und/oder
 (a) ein Rest der Formel



wobei W eine Bindung oder einen C₁₋₁₂- Alkylrest bedeutet, und R⁴

- (i) ein Wasserstoffatom,
 (ii) eine Hydroxylgruppe,
 (iii) ein C₁₋₈-Alkylrest,
 (iv) ein Hydroxyl-C₁₋₈-alkylrest,
 (v) ein C₁₋₈-Alkoxyrest,
 (vi) ein Rest der Formel NR⁵R⁶, wobei R⁵ und R⁶ jeweils unabhängig voneinander aus einem Was-
 serstoffatom, einem C₁₋₈-Alkyl-, einem C₃₋₆-Cycloalkyl-, einem Phenylrest ausgewählt sind oder R⁵
 und R⁶ zusammengekommen mit dem Stickstoffatom, an das sie gebunden sind, einen 5-6-gliedri-
 gen, gesättigten Ring, umfassend bis zu einem weiteren, aus einem Sauerstoffund Stickstoffatom
 ausgewählten Heteroatom, bedeuten, oder
 (vii) ein Rest der Formel OR⁷ ist, wobei R⁷ ein Wasserstoffatom, ein Alkalimetall, einen C₁₋₁₈-Alkyl-,
 einen Benzylrest bedeutet, oder
 (b) ein Rest der Formel β-Alk-OR⁸, wobei Alk einen C₁₋₁₂-Alkylrest bedeutet, und R⁸
 (i) eine Phenyl-C₁₋₈-alkylcarbonylgruppe,
 (ii) eine C₅₋₁₀-Cycloalkylcarbonylgruppe,
 (iii) ein Benzoylrest,
 (iv) eine C₁₋₈-Alkoxy-carbonylgruppe,
 (v) eine Amino- oder eine C₁₋₈-Alkyl-substituierte Aminocarbonylgruppe,
 (vi) ein Wasserstoffatom oder
 (vii) ein C₁₋₈-Alkylrest ist,

(2) ein Rest der Formel =CH-W-CO-R⁴ oder der Formel =CH-W-OR⁸, wobei W eine Bindung oder einen
 C₁₋₁₂-Alkylrest bedeutet, und R⁴ und R⁸ die gleiche Bedeutung wie vorstehend haben, und R⁸ ebenfalls



ein Wasserstoffatom oder eine C_{1-20} -Alkylcarbonylgruppe bedeutet,
(3) ein Rest der Formel



wobei die gestrichelte Bindung das 17- α -Wasserstoffatom ersetzt,

(4) ein α -Wasserstoffatom und ein Rest der Formel $\beta-NHCOR^9$, wobei R^9 einen C_{1-12} -Alkylrest oder einen Rest der Formel $\beta-NR^5R^6$ bedeutet, wobei R^5 und R^6 die gleiche Bedeutung wie vorstehend haben,

(5) ein α -Wasserstoffatom und eine β -Cyanogruppe,


(6) ein α -Wasserstoffatom und eine β -Tetrazolylgruppe oder

(7) eine Ketogruppe ist,

und eines pharmazeutisch verträglichen Salzes davon und eines pharmazeutisch verträglichen Trägers.

5. Verfahren gemäß Anspruch 4, in dem die Verbindung der Formel (Ia) N-t-Butylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure oder N,N-Diisopropylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure ist.

6. Verfahren zur Herstellung einer Verbindung der Formel :




in der :

R^2 , X und Y wie für Formel (Ia) in Anspruch 4 beschrieben sind, und R^{14} gleich R^3 ist, wie für Formel (Ia) in Anspruch 4 beschrieben.

R^1 ein Wasserstoffatom oder ein C_{1-5} -Alkylrest ist, und

M ein Sauerstoff- oder Schwefelatom bedeutet,
umfassend die Behandlung einer Verbindung der Formel




in der :

X^1 ein Brom-, Chlor-, Fluor- oder ein Iodatome bedeutet, und R^2 , R^{14} , X und Y wie vorstehend beschrieben sind, mit einem Alkylolithiumreagens und dann mit einem Carboxylierungsmittel oder mit einem Palladiumkatalysator in Gegenwart einer Base, eines C_{1-4} -Alkohols und von Kohlenstoffmonoxid.

7. Verfahren nach Anspruch 6, wobei die hergestellte Verbindung N-t-Butylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure oder N,N-Diisopropylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure ist.

Patentansprüche für folgenden Vertragsstaat : GR

1. Verfahren zur Herstellung einer Verbindung der Formel (I) :



in der:

der Ring A bis zu 2 Doppelbindungen hat,

die Ringe B, C und D fakultative Doppelbindungen, angezeigt durch die unterbrochenen Linien, haben, mit der Maßgabe, daß der Ring C keine C₈-C₁₄-Doppelbindung aufweist, falls der Ring B eine C₇-C₈-Doppelbindung hat,

M ein Sauerstoff- oder Schwefelatom bedeutet,

Z einen Rest der Formel (CH₂)_n bedeutet, und n 0-2 ist,

X ein Wasserstoff-, Chlor-, Fluor-, Brom-, Iodatomb, einen Rest der Formel CF₃ oder einen C₁₋₆-Alkylrest bedeutet,

Y ein Wasserstoffatom, ein Rest der Formel CF₃, ein Fluor- oder Chloratom, ein Rest der Formel CH₃ ist, mit der Maßgabe, daß Y ein Wasserstoffatom ist, falls es keine C₅-C₈-Doppelbindung gibt,


R¹ ein Wasserstoffatom oder einen C₁₋₆-Alkylrest bedeutet,

R² fehlt oder als ein Wasserstoffatom oder ein Rest der Formel CH₃ vorliegt, mit der Maßgabe, daß R² fehlt, falls das Kohlenstoffatom, an das er gebunden ist, eine Doppelbindung trägt,

R¹⁰ fehlt, falls es eine C₄-C₇, C₈-C₉ oder eine C₈-C₁₀-Doppelbindung gibt, oder als α-Wasserstoffatom vorliegt, und
R³

(1) ein α-Wasserstoffatom, eine α-Hydroxyl- oder eine α-Acetoxygruppe und/oder

(a) ein Rest der Formel



wobei W eine Bindung oder einen C₁₋₁₂-Alkylrest bedeutet, und R⁴

(i) ein Wasserstoffatom,

(ii) eine Hydroxylgruppe,

(iii) ein C₁₋₆-Alkylrest,

(iv) ein Hydroxyl-C₁₋₆-alkylrest,

(v) ein C₁₋₆-Alkoxyrest,

(vi) ein Rest der Formel NR⁵R⁶, wobei R⁵ und R⁶ jeweils unabhängig voneinander aus einem Wasserstoffatom, einem C₁₋₆-Alkyl-, einem C₃₋₆-Cycloalkyl-, einem Phenylrest ausgewählt sind oder R⁵ und R⁶ zusammengekommen mit dem Stickstoffatom, an das sie gebunden sind, einen 5-6-gliedrigen, gesättigten Ring, umfassend bis zu einem weiteren, aus einem Sauerstoff und Stickstoffatom ausgewählten Heteroatom, bedeuten, oder

(vii) ein Rest der Formel OR⁷ ist, wobei R⁷ ein Wasserstoffatom, ein Alkalimetall, einen C₁₋₁₈-Alkyl-, einen Benzylrest bedeutet, oder

(b) ein Rest der Formel β-Alk-OR⁸, wobei Alk einen C₁₋₁₂-Alkylrest bedeutet, und R⁸

(i) eine Phenyl-C₁₋₆-alkylcarbonylgruppe,

(ii) eine C₆₋₁₀-Cycloalkylcarbonylgruppe,

(iii) ein Benzoylrest,

(iv) eine C₁₋₆-Alkoxycarbonylgruppe,

(v) eine Amino- oder eine C₁₋₆-Alkyl-substituierte Aminocarbonylgruppe,

(vi) ein Wasserstoffatom oder

(vii) ein C₁₋₆-Alkylrest ist.

(2) ein Rest der Formel =CH-W-CO-R⁴ oder der Formel =CH-W-OR⁸, wobei W eine Bindung oder einen C₁₋₁₂-Alkylrest bedeutet, und R⁴ und R⁸ die gleiche Bedeutung wie vorstehend haben, und R⁸ ebenfalls



ein Wasserstoffatom oder eine C_{1-20} -Alkylcarbonylgruppe bedeutet,
(3) ein Rest der Formel



wobei die gestrichelte Bindung das 17- α -Wasserstoffatom ersetzt,

(4) ein α -Wasserstoffatom und ein Rest der Formel $\beta-NHCOR^9$, wobei R^9 einen C_{1-12} -Alkylrest oder einen Rest der Formel $\beta-NR^5R^6$ bedeutet, wobei R^5 und R^6 die gleiche Bedeutung wie vorstehend haben,

(5) ein α -Wasserstoffatom und eine β -Cyanogruppe,

(6) ein α -Wasserstoffatom und eine β -Tetrazolylgruppe oder


(7) eine Ketogruppe ist,

oder eines pharmazeutisch verträglichen Salzes davon, mit Ausnahme von Verbindungen, in denen :
der Ring B C_3-C_4 - und C_5-C_6 -Doppelbindungen hat, R^1 einen Rest der Formel CH_3 bedeutet, und R^3 eine Ketogruppe ist,

der Ring B eine C_3-C_4 , C_5-C_6 und $C_{15}-C_{17}$ -Doppelbindung hat, R^1 einen Rest der Formel CH_3 bedeutet, und R^3 ein Rest der Formel $COOCH_3$ ist, und

der Ring B eine C_5-C_6 -Doppelbindung hat, R^1 einen Rest der Formel CH_3 bedeutet, und R^3 ein Rest der Formel $COCH_3$ ist,

umfassend die Behandlung mit einer organischen Base, einem Phosphin, einer Palladium(II)-Verbindung und einem C_{1-6} -Alkylalkohol und anschließend die Zugabe von Kohlenstoffmonoxid zu einer Verbindung der Formel (V) :



wobei X, Y, Z, R^2 und R^{10} wie vorstehend beschrieben sind, und R^{14} R^3 ist oder Einheiten bedeutet, die chemisch in R^3 umgewandelt werden können.

2. Verfahren nach Anspruch 1, wobei die hergestellte Verbindung N-t-Butylandroster-3,5-dien-17 β -carboxamid-3-carbonsäure oder N,N-Diisopropylandroster-3,5-dien-17 β -carboxamid-3-carbonsäure ist.

3. Verfahren nach Anspruch 1, wobei die hergestellte Verbindung

20- α -(Hydroxymethyl)-5- α -pregn-3-en-3-carbonsäure,

N,N-Diisopropyl-5- α -androster-3-en-17 β -carboxamid-3-carbonsäure,

17 β -(N,N-Diisopropylcarboxamid)-4-fluor-5- α -androster-3-en-3-carbonsäure,

17 β -(N,N-Diisopropylcarboxamid)-4-fluor-androster-3,5-dien-3-carbonsäure,

20- α -(Hydroxymethyl)-4-fluor-5- α -pregn-3-en-3-carbonsäure,

3-Carbomethoxy-N,N-diisopropylandroster-3,5-dien-17 β -carboxamid,

17 β -N,N-Diisopropylcarboxamid-5- α -androster-1,3-dien-3-carbonsäure,

N,N-Diisopropyl-5- α -androster-2-en-17 β -carboxamid-3-carbonsäure,

N,N-Diisopropylandroster-2,4-dien-17 β -carboxamid-3-carbonsäure,

N,N-Diisopropyl-5- α -androster-17 β -carboxamid-3 β -carbonsäure,

N,N-Diisopropyl-3,5(10)-dien-17 β -carboxamid-3-carbonsäure,

N,N-Diisopropyl-3,5-dien-17 β -carboxamid-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)androster-3,5,11-trien-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)androster-3,5-dien-3-thiocarbonsäure,

N-t-Butyl-5- α -androster-3-en-17 β -carboxamid-3-carbonsäure,


17 β -(N-t-Butylcarboxamid)-6-fluor-5- α -androster-3-en-3-carbonsäure,

17 β -(N-t-Butylcarboxamid)-6-fluorandroster-3,5-dien-3-carbonsäure,



3-Carbomethoxy-N-t-butylandro-3,5-dien-17 β -carboxamid,
17 β -N-t-Butylcarboxamid-5- α -andro-1,3-dien-3-carbonsäure,
N-t-Butyl-5- α -andro-2-en-17 β -carboxamid-3-carbonsäure,
N-t-Butylandro-2,4-dien-17 β -carboxamid-3-carbonsäure,
N-t-Butyl-5- α -androstan-17 β -carboxamid-3-carbonsäure,
N-t-Butylestr-3,5(10)-dien-17 β -carboxamid-3-carbonsäure oder
N-t-Butylestr-3,5-dien-17 β -carboxamid-3-carbonsäure ist.

4. Verfahren zur Herstellung eines Arzneimittels, umfassend die Vereinigung einer Verbindung der Formel (Ia) :



In der :

der Ring A bis zu 2 Doppelbindungen hat,

die Ringe B, C und D fakultative Doppelbindungen, angezeigt durch die unterbrochenen Linien, haben, mit der Maßgabe, daß der Ring C keine C₈-C₁₄-Doppelbindung aufweist, falls der Ring B eine C₇-C₈-Doppelbindung hat,

M ein Sauerstoff- oder Schwefelatom bedeutet,

Z einen Rest der Formel (CH₂)_n bedeutet, und n 0-2 ist,

X ein Wasserstoff-, Chlor-, Fluor-, Brom-, Iodatome, einen Rest der Formel CF₃ oder einen C₁₋₈-Alkylrest bedeutet,

Y ein Wasserstoffatom, ein Rest der Formel CF₃, ein Fluor- oder Chloratom, ein Rest der Formel CH₃ ist, mit der Maßgabe, daß Y ein Wasserstoffatom ist, falls es keine C₅-C₆-Doppelbindung gibt,


R¹ ein Wasserstoffatom oder einen C₁₋₈-Alkylrest bedeutet,

R² fehlt oder als ein Wasserstoffatom oder ein Rest der Formel CH₃ vorliegt, mit der Maßgabe, daß R² fehlt, falls das Kohlenstoffatom, an das er gebunden ist, eine Doppelbindung trägt,

R¹⁰ fehlt, falls es eine C₄-C₅, C₇-C₈ oder eine C₅-C₁₀-Doppelbindung gibt, oder als α -Wasserstoffatom vorliegt, und
R³

(1) ein α -Wasserstoffatom, eine α -Hydroxyl- oder eine α -Acetoxygruppe und/oder

(a) ein Rest der Formel



wobei W eine Bindung oder einen C₁₋₁₂-Alkylrest bedeutet, und R⁴

(i) ein Wasserstoffatom,

(ii) eine Hydroxylgruppe,

(iii) ein C₁₋₈-Alkylrest,

(iv) ein Hydroxyl-C₁₋₈-alkylrest,

(v) ein C₁₋₈-Alkoxyrest,

(vi) ein Rest der Formel NR⁵R⁶, wobei R⁵ und R⁶ jeweils unabhängig voneinander aus einem Wasserstoffatom, einem C₁₋₈-Alkyl-, einem C₃₋₆-Cycloalkyl-, einem Phenylrest ausgewählt sind oder R⁵ und R⁶ zusammengekommen mit dem Stickstoffatom, an das sie gebunden sind, einen 5-6-gliedrigen, gesättigten Ring, umfassend bis zu einem weiteren, aus einem Sauerstoffund Stickstoffatom ausgewählten Heteroatom, bedeuten, oder

(vii) ein Rest der Formel OR⁷ ist, wobei R⁷ ein Wasserstoffatom, ein Alkalimetall, einen C₁₋₁₈-Alkyl-, einen Benzylrest bedeutet, oder



(b) ein Rest der Formel β -Alk-OR⁸, wobei Alk einen C₁₋₁₂-Alkylrest bedeutet, und R⁸

(i) eine Phenyl-C₁₋₆-alkylcarbonylgruppe,

(ii) eine C₈₋₁₀-Cycloalkylcarbonylgruppe,

(iii) ein Benzoylrest,

(iv) eine C₁₋₆-Alkoxy-carbonylgruppe,

(v) eine Amino- oder eine C₁₋₆-Alkyl-substituierte Aminocarbonylgruppe,

(vi) ein Wasserstoffatom oder

(vii) ein C₁₋₆-Alkylrest ist,

(2) ein Rest der Formel $=CH-W-CO-R^4$ oder der Formel $=CH-W-OR^8$, wobei W eine Bindung oder einen C₁₋₁₂-Alkylrest bedeutet, und R⁴ und R⁸ die gleiche Bedeutung wie vorstehend haben, und R⁸ ebenfalls ein Wasserstoffatom oder eine C₁₋₂₀-Alkylcarbonylgruppe bedeutet,

(3) ein Rest der Formel



wobei die gestrichelte Bindung das 17- α -Wasserstoffatom ersetzt,

(4) ein α -Wasserstoffatom und ein Rest der Formel β -NHCOR⁹, wobei R⁹ einen C₁₋₁₂-Alkylrest oder einen Rest der Formel β -NR⁵R⁶ bedeutet, wobei R⁵ und R⁶ die gleiche Bedeutung wie vorstehend haben,

(5) ein α -Wasserstoffatom und eine β -Cyanogruppe,


(6) ein α -Wasserstoffatom und eine β -Tetrazolylgruppe oder

(7) eine Ketogruppe ist,

und eines pharmazeutisch verträglichen Salzes davon und eines pharmazeutisch verträglichen Trägers.

5. Verfahren gemäß Anspruch 4, in dem die Verbindung der Formel (Ia) N-t-Butylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure oder N,N-Diisopropylandrost-3,5-dien-17 β -carboxamid-3-carbonsäure ist.

6. Verfahren zur Herstellung einer Verbindung der Formel :




in der :

R², X und Y wie für Formel (Ia) in Anspruch 4 beschrieben sind, und R¹⁴ gleich R³ ist, wie für Formel (Ia) in Anspruch 4 beschrieben,

R¹ ein Wasserstoffatom oder ein C₁₋₆-Alkylrest ist, und

M ein Sauerstoff- oder Schwefelatom bedeutet,

umfassend die Behandlung einer Verbindung der Formel





In der


X¹ ein Brom-, Chlor-, Fluor- oder ein Iodatome bedeutet, und R², R¹⁴, X und Y wie vorstehend beschrieben sind, mit einem Alkylolithiumreagens und dann mit einem Carboxylierungsmittel oder mit einem Palladiumkatalysator in Gegenwart einer Base, eines C₁₋₄-Alkohols und von Kohlenstoffmonoxid.

7. Verfahren nach Anspruch 6, wobei die hergestellte Verbindung N-t-Butylandrost-3,5-dien-17β-carboxamid-3-carbonsäure oder N,N-Diisopropylandrost-3,5-dien-carboxamid-3-carbonsäure ist.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Composé représenté par la formule (I) :



(I)

dans laquelle :

le cycle A a jusqu'à 2 doubles liaisons ;

les cycles B, C et D ont des doubles liaisons facultatives indiquées par les pointillés, sous réserve que le cycle C n'a pas une double liaison C₈-C₁₄ lorsque le cycle B a une double liaison C₇-C₈ ;

M est O ou S ;

Z est (CH₂)_n et n est 0-2 ;

X est H, Cl, F, Br, I, CF₃ ou un groupe alkyle en C₁₋₆ ;

Y est H, CF₃, F, Cl ou CH₃, sous réserve que Y est H lorsqu'il n'y a pas de double liaison C₅-C₆ ;

R¹ est H ou un groupe alkyle en C₁₋₆ ;


R² est absent ou présent sous forme de H ou de CH₃, sous réserve que R² est absent lorsque l'atome de carbone auquel il est fixé porte une double liaison ;

R¹⁰ est absent lorsqu'il y a une double liaison C₄-C₅, C₅-C₆ ou C₅-C₁₀, ou est présent sous forme d'un atome d'hydrogène en α ; et

R³ est

(1) α-hydrogène, α-hydroxyle ou α-acétoxy et/ou

(a)



où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ est

(i) un atome d'hydrogène,

(ii) un groupe hydroxyle,

(iii) un groupe alkyle en C₁₋₆,

(iv) un groupe hydroxyalkyle en C₁₋₆,

(v) un groupe alcoxy en C₁₋₆,

(vi) NR⁵R⁶, où R⁵ et R⁶ sont chacun indépendamment choisis parmi un atome d'hydrogène, un groupe alkyle en C₁₋₆, un groupe cycloalkyle en C₃₋₆ ou un groupe phényle ; ou R⁵ et R⁶, ensemble avec l'atome d'azote auquel ils sont fixés, représentent un cycle saturé à 5 ou 6 chaînons comprenant au plus un autre hétéroatome choisi parmi l'oxygène et l'azote, ou



(vii) OR⁷, où R⁷ est un atome d'hydrogène, un atome de métal alcalin, un groupe alkyle en C₁₋₁₈ ou un groupe benzyle, ou

(b) β-Alk-OR⁸, où Alk est un groupe alkylène en C₁₋₁₂ et R⁸ est

(i) un groupe phényl (alkyl en C₁₋₆) carbonyle,

(ii) un groupe (cycloalkyl en C₅₋₁₀) carbonyle,

(iii) un groupe benzoyle,

(iv) un groupe (alcoxy en C₁₋₈) carbonyle,

(v) un groupe aminocarbonyle ou (aminoalkyl (C₁₋₈) substitué) carbonyle,

(vi) un atome d'hydrogène, ou

(vii) un groupe alkyle en C₁₋₁₈.

(2) =CH-W-CO-R⁴ ou =CH-W-OR⁵, où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ et R⁵ ont la même signification que ci-dessus et R⁵ est également un atome d'hydrogène ou un groupe (alkyl en C₁₋₂₀) carbonyle ;

(3)



où la liaison en pointillé remplace le 17-α-hydrogène,

(4) α-hydrogène et β-NHCOR⁹ où R⁹ est un groupe alkyle en C₁₋₁₂ ou β-NR⁵R⁶ où R⁵ et R⁶ ont la même signification que ci-dessus,

(5) α-hydrogène et β-cyano,

(6) α-hydrogène et β-tétrazolyle ou

(7) un groupe céto ;

ou un sel pharmaceutiquement acceptable de celui-ci ; à l'exception des composés dans lesquels :

le cycle A a une double liaison C₃-C₄ et le cycle B a une double liaison C₅-C₆, R¹ est CH₃ et R³ est un groupe céto ;

le cycle A a une double liaison C₃-C₄ et le cycle B a une double liaison C₅-C₆ et le cycle D a une double liaison C₁₄-C₁₇, R¹ est CH₃ et R³ est COOCH₃ ; et

le cycle B a une double liaison C₅-C₆, R¹ est CH₃ et R³ est COCH₃.

2. Composé selon la revendication 1 qui est l'acide N-tert-butyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique ou l'acide N,N-dlisopropyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique.

3. Composé selon la revendication 1 qui est l'acide 20-α-(hydroxyméthyl)-5-α-prégn-3-ène-3-carboxylique,

l'acide N,N-dlisopropyl-5-α-androst-3-ène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N,N-dlisopropylcarboxamide)-4-fluoro-5-α-androst-3-ène-3-carboxylique,

l'acide 17β-(N,N-dlisopropylcarboxamide)-4-fluoro-androsta-3,5-diène-3-carboxylique,

l'acide 20-α-(hydroxyméthyl)-4-fluoro-5-α-prégn-3-ène-3-carboxylique,

le 3-carbométhoxy-N,N-dlisopropyl-androsta-3,5-diène-17β-carboxamide,

l'acide 17β-N,N-dlisopropylcarboxamide-5-α-androsta-1,3-diène-3-carboxylique,

l'acide N,N-dlisopropyl-5-α-androst-2-ène-17β-carboxamide-3-carboxylique,

l'acide N,N-dlisopropyl-androsta-2,4-diène-17β-carboxamide-3-carboxylique,

l'acide N,N-dlisopropyl-5-α-androstane-17β-carboxamide-3β-carboxylique,

l'acide N,N-dlisopropyl-estra-3,5(10)-diène-17β-carboxamide-3-carboxylique,

l'acide N,N-dlisopropyl-estra-3,5-diène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-androsta-3,5,11-triène-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-androsta-3,5-diène-3-thiocarboxylique,

l'acide N-tert-butyl-5-α-androst-3-ène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-6-fluoro-5-α-androst-3-ène-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-6-fluoro-androsta-3,5-diène-3-carboxylique,

l'acide 20-α-(hydroxyméthyl)-A-nor-5-α-prégn-1-ène-2-carboxylique,

le 3-carbométhoxy-N-tert-butyl-androsta-3,5-diène-17β-carboxamide

l'acide 17β-N-tert-butylcarboxamide-5-α-androsta-1,3-diène-3-carboxylique

l'acide N-tert-butyl-5-α-androst-2-ène-17β-carboxamide-3-carboxylique,

l'acide N-tert-butyl-androsta-2,4-diène-17β-carboxamide-3-carboxylique,


l'acide N-tert-butyl-5-α-androstane-17β-carboxamide-3-carboxylique,

l'acide N-tert-butyl-estra-3,5(10)-diène-17β-carboxamide-3-carboxylique, ou



l'acide N-tert-butyl-estra-3,5-diène-17β-carboxamide-3-carboxylique.

4. Composé représenté par la formule (III) :




dans laquelle le cycle B a une double liaison facultative indiquée par le pointillé ;

R¹ et R² sont chacun H ou un groupe alkyle en C₁₋₈ ;

R¹³ est HC(CH₃)CH₂OR²⁰, où R²⁰ est H ou un groupe alkyle en C₁₋₈ ; ou

CONR²¹R²², où R²¹ et R²² sont indépendamment H ou un groupe alkyle en C₁₋₈, et M est O ou S.

5. Composé de formule (II)



dans laquelle :

le cycle A a jusqu'à 2 doubles liaisons ;

les cycles B et C ont des doubles liaisons facultatives indiquées par les pointillés ;

M est O ou S ;

X est H ou un groupe halogéno, et

R¹ est H ou un groupe alkyle en C₁₋₈ ;

R² est H ou un groupe alkyle en C₁₋₈ ;


R¹⁰ est absent lorsqu'il y a une double liaison C₄-C₅, C₅-C₈ ou C₈-C₁₀, ou est présent sous forme d'un atome d'hydrogène α ; et

R¹³ est

(a) HC(CH₃)CH₂OR²⁰, où R²⁰ est H ou un groupe alkyle en C₁₋₈, ou

(b) CONR²¹R²², où R²¹ et R²² sont indépendamment H ou un groupe alkyle en C₁₋₈.

6. Composition pharmaceutique comprenant un véhicule pharmaceutique approprié et un composé de formule (Ia) :



dans laquelle :

le cycle A a jusqu'à 2 doubles liaisons ;



les cycles B, C et D ont des doubles liaisons facultatives indiquées par les pointillés, sous réserve que le cycle C n'a pas une double liaison C₈-C₁₄ lorsque le cycle B a une double liaison C₇-C₈ ;

M est O ou S ;

Z est (CH₂)_n et n est 0-2 ;

5 X est H, Cl, F, Br, I, CF₃ ou un groupe alkyle en C₁₋₆ ;

Y est H, CF₃, F, Cl ou CH₃, sous réserve que Y est H lorsqu'il n'y a pas de double liaison C₅-C₆ ;

R¹ est H ou un groupe alkyle en C₁₋₆ ;


R² est absent ou présent sous forme de H ou de CH₃, sous réserve que R² est absent lorsque l'atome de carbone auquel il est fixé porte une double liaison ;

10 R¹⁰ est absent lorsqu'il y a une double liaison C₄-C₅, C₅-C₆ ou C₆-C₁₀, ou est présent sous forme d'un atome d'hydrogène en α ; et

R³ est

(1) α-hydrogène, α-hydroxyle ou α-acétoxy et/ou

(a)



20 où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ est

(i) un atome d'hydrogène,

(ii) un groupe hydroxyle,

(iii) un groupe alkyle en C₁₋₆,

(iv) un groupe hydroxyalkyle en C₁₋₆,

25 (v) un groupe alcoxy en C₁₋₆,

(vi) NR⁵R⁶, où R⁵ et R⁶ sont chacun indépendamment choisis parmi un atome d'hydrogène, un groupe alkyle en C₁₋₆, un groupe cycloalkyle en C₃₋₆ ou un groupe phényle ; ou R⁵ et R⁶, ensemble avec l'atome d'azote auquel ils sont fixés, représentent un cycle saturé à 5 ou 6 chaînons comprenant au plus un autre hétéroatome choisi parmi l'oxygène et l'azote, ou

30 (vii) OR⁷, où R⁷ est un atome d'hydrogène, un atome de métal alcalin, un groupe alkyle en C₁₋₁₈ ou un groupe benzyle, ou

(b) β-Alk-OR⁸, où Alk est un groupe alkylène en C₁₋₁₂ et R⁸ est

(i) un groupe phényl (alkyl en C₁₋₆) carbonyle,

(ii) un groupe (cycloalkyl en C₃₋₁₀) carbonyle,

35 (iii) un groupe benzoyle,

(iv) un groupe (alcoxy en C₁₋₆) carbonyle,

(v) un groupe aminocarbonyl ou (aminoalkyl (C₁₋₆) substitué) carbonyle,

(vi) un atome d'hydrogène, ou

(vii) un groupe alkyle en C₁₋₆.

40 (2) =CH-W-CO-R⁴ ou =CH-W-OR⁸, où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ et R⁸ ont la même signification que ci-dessus et R⁸ est également un atome d'hydrogène ou un groupe (alkyl en C₁₋₂₀) carbonyle ;

(3)



45 où la liaison en pointillé remplace le 17-α-hydrogène,

(4) α-hydrogène et β-NHCOR⁹ où R⁹ est un groupe alkyle en C₁₋₁₂ ou β-NR⁵R⁶ où R⁵ et R⁶ ont la même signification que ci-dessus,

(5) α-hydrogène et β-cyano,

(6) α-hydrogène et β-tétrazolyloxy ou

50 (7) un groupe céto ;

ou un sel pharmaceutiquement acceptable de celui-ci.

7. Composition selon la revendication 6, dans laquelle le composé est l'acide N-tert-butyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique ou l'acide N,N-diisopropyl-androsta-3,5-diène-17β-carboxamide-3-



carboxylique.

8. Composition selon la revendication 6, dans laquelle le composé est

l'acide 20- α -(hydroxyméthyl)-5- α -prégn-3-ène-3-carboxylique,

l'acide N,N-dlisopropyl-5- α -androst-3-ène-17 β -carboxamide-3-carboxylique,

5 l'acide 17 β -(N,N-dlisopropylcarboxamide)-4-fluoro-5- α -androst-3-ène-3-carboxylique,

l'acide 17 β -(N,N-dlisopropylcarboxamide)-4-fluoro-androsta-3,5-diène-3-carboxylique,

l'acide 20- α -(hydroxyméthyl)-4-fluoro-5- α -prégn-3-ène-3-carboxylique,

le 3-carbométhoxy-N,N-dlisopropyl-androsta-3,5-diène-17 β -carboxamide,

l'acide 17 β -N,N-dlisopropylcarboxamide-5- α -androsta-1,3-diène-3-carboxylique,

10 l'acide N,N-dlisopropyl-5- α -androst-2-ène-17 β -carboxamide-3-carboxylique,

l'acide N,N-dlisopropyl-androsta-2,4-diène-17 β -carboxamide-3-carboxylique,

l'acide N,N-dlisopropyl-5- α -androstane-17 β -carboxamide-3 β -carboxylique,

l'acide N,N-dlisopropyl-estra-3,5(10)-diène-17 β -carboxamide-3-carboxylique,

15 l'acide N,N-dlisopropyl-estra-3,5-diène-17 β -carboxamide-3-carboxylique,

l'acide 17 β -(N-tert-butylcarboxamide)-androsta-3,5,11-triène-3-carboxylique,

l'acide 17 β -(N-tert-butylcarboxamide)-androsta-3,5-diène-3-thiocarboxylique,

l'acide N-tert-butyl-5- α -androst-3-ène-17 β -carboxamide-3-carboxylique,

l'acide 17 β -(N-tert-butylcarboxamide)-6-fluoro-5- α -androst-3-ène-3-carboxylique,

l'acide 17 β -(N-tert-butylcarboxamide)-6-fluoro-androsta-3,5-diène-3-carboxylique,

20 le 3-carbométhoxy-N-tert-butyl-androsta-3,5-diène-17 β -carboxamide,

l'acide 17 β -N-tert-butylcarboxamide-5- α -androsta-1,3-diène-3-carboxylique,

l'acide N-tert-butyl-5- α -androst-2-ène-17 β -carboxamide-3-carboxylique,


l'acide N-tert-butyl-androsta-2,4-diène-17 β -carboxamide-3-carboxylique,

l'acide N-tert-butyl-5- α -androstane-17 β -carboxamide-3-carboxylique,

25 l'acide N-tert-butyl-estra-3,5(10)-diène-17 β -carboxamide-3-carboxylique, ou

l'acide N-tert-butyl-estra-3,5-diène-17 β -carboxamide-3-carboxylique.

9. Procédé pour préparer un composé de formule :




40 dans laquelle R², X et Y sont tels que décrits pour la formule (Ia) dans la revendication 6 et R¹⁴ est comme R³ tel que décrit pour la formule (Ia) dans la revendication 6,

R¹ est H ou un groupe alkyle en C₁₋₄; et

M est Q ou S,

qui comprend le traitement d'un composé de formule




55 dans laquelle X¹ est un groupe bromo, chloro, fluoro ou iodo; et R², R¹⁴, X et Y sont tels que décrits ci-dessus, avec un agent alkylolithium, puis un agent de carboxylation, ou avec un catalyseur au palladium en présence



d'une base, d'un alcool en C_{1-6} et de monoxyde de carbone.

10. Procédé selon la revendication 9, dans lequel le composé préparé est l'acide N-tert-butyl-androsta-3,5-diène-17 β -carboxamide-3-carboxylique ou l'acide N,N-diisopropyl-androsta-3,5-diène-carboxamide-3-carboxylique.

11. Procédé pour préparer un composé de formule (I) comme décrit dans la revendication 1, qui comprend le traitement d'un composé de formule :



dans laquelle X, Y, Z, R^2 et R^{10} sont tels que décrits ci-dessus et R^{14} est R^3 comme décrit pour la formule (I) ou des fragments qui peuvent être transformés chimiquement en R^3 , avec une base organique, une phosphine, un composé du palladium (II) et un alcool alkylque en C_{1-6} , puis l'addition de monoxyde de carbone.


12. Composé selon la revendication 1 pour l'utilisation comme agent thérapeutique.

13. Composé selon la revendication 1 pour l'utilisation comme inhibiteur de la stéroïde-5 α -réductase.

14. Composé selon la revendication 1 pour l'utilisation dans un traitement pour réduire la taille de la prostate.

Revendications pour l'Etat contractant suivant : ES

1. Procédé pour préparer un composé de formule (I)



dans laquelle :

le cycle A a jusqu'à 2 doubles liaisons ;

les cycles B, C et D ont des doubles liaisons facultatives indiquées par les pointillés, sous réserve que le cycle C n'a pas une double liaison C_7-C_{14} lorsque le cycle B a une double liaison C_7-C_8 ;

M est O ou S ;

Z est $(CH_2)_n$ et n est 0-2 ;

X est H, Cl, F, Br, I, CF_3 ou un groupe alkyle en C_{1-6} ;

Y est H, CF_3 , F, Cl ou CH_3 , sous réserve que Y est H lorsqu'il n'y a pas de double liaison C_5-C_6 ;

R^1 est H ou un groupe alkyle en C_{1-6} ;

R^2 est absent ou présent sous forme de H ou de CH_3 , sous réserve que R^2 est absent lorsque l'atome de carbone auquel il est fixé porte une double liaison ;


R^{10} est absent lorsqu'il y a une double liaison C_4-C_5 , C_5-C_6 ou C_6-C_{10} , ou est présent sous forme d'un atome d'hydrogène en α ; et

R^3 est

(1) α -hydrogène, α -hydroxyle ou α -acétoxy et/ou



(a)



où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ est

(i) un atome d'hydrogène,

(ii) un groupe hydroxyle,

(iii) un groupe alkyle en C₁₋₈,

(iv) un groupe hydroxyalkyle en C₁₋₈,

(v) un groupe alcoxy en C₁₋₈,

(vi) NR⁵R⁶, où R⁵ et R⁶ sont chacun indépendamment choisis parmi un atome d'hydrogène, un groupe alkyle en C₁₋₈, un groupe cycloalkyle en C₃₋₆ ou un groupe phényle ; ou R⁵ et R⁶, ensemble avec l'atome d'azote auquel ils sont fixés, représentent un cycle saturé à 5 ou 6 chaînons comprenant au plus un autre hétéroatome choisi parmi l'oxygène et l'azote, ou

(vii) OR⁷, où R⁷ est un atome d'hydrogène, un atome de métal alcalin, un groupe alkyle en C₁₋₁₈ ou un groupe benzyle, ou

(b) β-Alk-OR⁸, où Alk est un groupe alkylène en C₁₋₁₂ et R⁸ est

(i) un groupe phényl (alkyl en C₁₋₆) carbonyle,

(ii) un groupe (cycloalkyl en C₅₋₁₀) carbonyle,

(iii) un groupe benzoyle,

(iv) un groupe (alcoxy en C₁₋₈) carbonyle,

(v) un groupe aminocarbonyl ou (aminoalkyl (C₁₋₈) substitué) carbonyle,

(vi) un atome d'hydrogène, ou

(vii) un groupe alkyle en C₁₋₈.

(2) =CH-W-CO-R⁴ ou =CH-W-OR⁸, où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ et R⁸ ont la même signification que ci-dessus et R⁸ est également un atome d'hydrogène ou un groupe (alkyl en C₁₋₂₀) carbonyle ;

(3)



où la liaison en pointillé remplace le 17-α-hydrogène,

(4) α-hydrogène et β-NHCOR⁹ où R⁹ est un groupe alkyle en C₁₋₁₂ ou β-NR⁵R⁶ où R⁵ et R⁶ ont la même signification que ci-dessus,

(5) α-hydrogène et β-cyano,

(6) α-hydrogène et β-tétrazolyloxy ou

(7) un groupe céto ;


ou un sel pharmaceutiquement acceptable de celui-ci ; à l'exception des composés dans lesquels :

le cycle A a une double liaison C₃-C₄ et le cycle B a une double liaison C₅-C₆, R¹ est CH₃ et R² est un groupe céto ;

le cycle A a une double liaison C₃-C₄ et le cycle B a une double liaison C₅-C₆ et le cycle D a une double liaison C₁₄-C₁₇, R¹ est CH₃ et R² est COOCH₃ ; et

le cycle B a une double liaison C₅-C₆, R¹ est CH₃ et R² est COCH₃,

qui comprend le traitement d'un composé de formule (V) :



(V)

dans laquelle X, Y, Z, R² et R¹⁰ sont tels que définis ci-dessus et R¹⁴ est R³ ou des fragments qui peuvent être transformés chimiquement en R³,

avec une base organique, une phosphine, un composé du palladium (II) et un alcool alkylique en C₁₋₆, puis l'addition de monoxyde de carbone.

2. Procédé selon la revendication 1, dans lequel le composé préparé est l'acide N-tert-butyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique ou l'acide N,N-diisopropyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique.

3. Procédé selon la revendication 1, dans lequel le composé préparé est

l'acide 20-α-(hydroxyméthyl)-5-α-prégn-3-ène-3-carboxylique,

l'acide N,N-diisopropyl-5-α-androst-3-ène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N,N-diisopropylcarboxamide)-4-fluoro-5-α-androst-3-ène-3-carboxylique,

l'acide 17β-(N,N-diisopropylcarboxamide)-4-fluoro-androsta-3,5-diène-3-carboxylique,

l'acide 20-α-(hydroxyméthyl)-4-fluoro-5-α-prégn-3-ène-3-carboxylique,

le 3-carbométhoxy-N,N-diisopropyl-androsta-3,5-diène-17β-carboxamide,

l'acide 17β-N,N-diisopropylcarboxamide-5-α-androsta-1,3-diène-3-carboxylique,

l'acide N,N-diisopropyl-5-α-androst-2-ène-17β-carboxamide-3-carboxylique,

l'acide N,N-diisopropyl-androsta-2,4-diène-17β-carboxamide-3-carboxylique,

l'acide N,N-diisopropyl-5-α-androstane-17β-carboxamide-3β-carboxylique,

l'acide N,N-diisopropyl-estra-3,5(10)-diène-17β-carboxamide-3-carboxylique,

l'acide N,N-diisopropyl-estra-3,5-diène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-androsta-3,5,11-triène-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-androsta-3,5-diène-3-thiocarboxylique,

l'acide N-tert-butyl-5-α-androst-3-ène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-6-fluoro-5-α-androst-3-ène-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-6-fluoro-androsta-3,5-diène-3-carboxylique,

le 3-carbométhoxy-N-tert-butyl-androsta-3,5-diène-17β-carboxamide,

l'acide 17β-N-tert-butylcarboxamide-5-α-androsta-1,3-diène-3-carboxylique,

l'acide N-tert-butyl-5-α-androst-2-ène-17β-carboxamide-3-carboxylique,


l'acide N-tert-butyl-androsta-2,4-diène-17β-carboxamide-3-carboxylique,

l'acide N-tert-butyl-5-α-androstane-17β-carboxamide-3-carboxylique,

l'acide N-tert-butyl-estra-3,5(10)-diène-17β-carboxamide-3-carboxylique, ou

l'acide N-tert-butyl-estra-3,5-diène-17β-carboxamide-3-carboxylique.

4. Procédé pour la préparation d'une composition pharmaceutique qui comprend la mise en association d'un composé de formule (Ia) :



(Ia)



dans laquelle :

le cycle A a jusqu'à 2 doubles liaisons ;

les cycles B, C et D ont des doubles liaisons facultatives indiquées par les pointillés, sous réserve que le cycle C n'a pas une double liaison C₉-C₁₄ lorsque le cycle B a une double liaison C₇-C₈ ;

5 M est O ou S ;

Z est (CH₂)_n et n est 0-2 ;

X est H, Cl, F, Br, I, CF₃ ou un groupe alkyle en C₁₋₃ ;

Y est H, CF₃, F, Cl ou CH₃, sous réserve que Y est H lorsqu'il n'y a pas de double liaison C₅-C₆ ;

R¹ est H ou un groupe alkyle en C₁₋₃ ;


10 R² est absent ou présent sous forme de H ou de CH₃, sous réserve que R² est absent lorsque l'atome de carbone auquel il est fixé porte une double liaison ;

R¹⁰ est absent lorsqu'il y a une double liaison C₄-C₅, C₅-C₆ ou C₅-C₁₀, ou est présent sous forme d'un atome d'hydrogène en α ; et

R³ est

15 (1) α-hydrogène, α-hydroxyle ou α-acétoxy et / ou

(a)



20

où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ est

(i) un atome d'hydrogène,

(ii) un groupe hydroxyle,

25

(iii) un groupe alkyle en C₁₋₃,

(iv) un groupe hydroxyalkyle en C₁₋₃,

(v) un groupe alcoxy en C₁₋₃,

(vi) NR⁵R⁶, où R⁵ et R⁶ sont chacun indépendamment choisis parmi un atome d'hydrogène, un groupe alkyle en C₁₋₃, un groupe cycloalkyle en C₃₋₆ ou un groupe phényle ; ou R⁵ et R⁶, ensemble avec l'atome d'azote auquel ils sont fixés, représentent un cycle saturé à 5 ou 6 chaînons comprenant au plus un autre hétéroatome choisi parmi l'oxygène et l'azote, ou

30

(vii) OR⁷, où R⁷ est un atome d'hydrogène, un atome de métal alcalin, un groupe alkyle en C₁₋₁₈ ou un groupe benzyle, ou

(b) β-Alk-OR⁸, où Alk est un groupe alkylène en C₁₋₁₂ et R⁸ est

35

(i) un groupe phényl (alkyl en C₁₋₆) carbonyle,

(ii) un groupe (cycloalkyl en C₆₋₁₀) carbonyle,

(iii) un groupe benzoyl,

(iv) un groupe (alcoxy en C₁₋₃) carbonyle,

(v) un groupe aminocarbonyle ou (aminoalkyl (C₁₋₃) substitué) carbonyle,

40

(vi) un atome d'hydrogène, ou

(vii) un groupe alkyle en C₁₋₃.

(2) =CH-W-CO-R⁴ ou =CH-W-OR⁸, où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ et R⁸ ont la même signification que ci-dessus et R⁸ est également un atome d'hydrogène ou un groupe (alkyl en C₁₋₂₀) carbonyle ;

45

(3)



50

où la liaison en pointillé remplace le 17-α-hydrogène,

(4) α-hydrogène et β-NHCOR⁹ où R⁹ est un groupe alkyle en C₁₋₁₂ ou β-NR⁵R⁶ où R⁵ et R⁶ ont la même signification que ci-dessus,

55

(5) α-hydrogène et β-cyano,

(6) α-hydrogène et β-tétrazolyloxy ou


(7) un groupe céto ;



ou un sel pharmaceutiquement acceptable de celui-ci. et un véhicule pharmaceutiquement acceptable.

5. Procédé selon la revendication 4, dans lequel le composé de formule (Ia) est l'acide N-tert-butyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique ou l'acide N,N-disopropyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique.

6. Procédé pour préparer un composé de formule :




dans laquelle R², X et Y sont tels que décrits pour la formule (Ia) dans la revendication 4 et R¹⁴ est comme R³ tel que décrit pour la formule (Ia) dans la revendication 4,

R¹ est H ou un groupe alkyle en C₁₋₈ ; et

M est O ou S.

qui comprend le traitement d'un composé de formule




dans laquelle X¹ est un groupe bromo, chloro, fluoro ou iodo ; et R², R¹⁴, X et Y sont tels que décrits ci-dessus, avec un agent alkylolithium, puis un agent de carboxylation, ou avec un catalyseur au palladium en présence d'une base, d'un alcool en C₁₋₄ et de monoxyde de carbone.

7. Procédé selon la revendication 6, dans lequel le composé préparé est l'acide N-tert-butyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique ou l'acide N,N-disopropyl-androsta-3,5-diène-carboxamide-3-carboxylique.

Revendications pour l'Etat contractant suivant : GR

1. Procédé pour préparer un composé de formule (I)



(I)

dans laquelle :



le cycle A a jusqu'à 2 doubles liaisons ;

les cycles B, C et D ont des doubles liaisons facultatives indiquées par les pointillés, sous réserve que le cycle C n'a pas une double liaison C₅-C₁₄ lorsque le cycle B a une double liaison C₇-C₈ ;

M est O ou S ;

5 Z est (CH₂)_n et n est 0-2 ;

X est H, Cl, F, Br, I, CF₃ ou un groupe alkyle en C₁₋₆ ;

Y est H, CF₃, F, Cl ou CH₃, sous réserve que Y est H lorsqu'il n'y a pas de double liaison C₅-C₈ ;

R¹ est H ou un groupe alkyle en C₁₋₅ ;


10 R² est absent ou présent sous forme de H ou de CH₃, sous réserve que R² est absent lorsque l'atome de carbone auquel il est fixé porte une double liaison ;

R¹⁰ est absent lorsqu'il y a une double liaison C₄-C₆, C₅-C₈ ou C₅-C₁₀, ou est présent sous forme d'un atome d'hydrogène en α ; et

R³ est

(1) α-hydrogène, α-hydroxyle ou α-acétoxy et/ou

15 (a)



20

où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ est

(i) un atome d'hydrogène,

(ii) un groupe hydroxyle,

(iii) un groupe alkyle en C₁₋₈,

25 (iv) un groupe hydroxyalkyle en C₁₋₈,

(v) un groupe alcoxy en C₁₋₈,

(vi) NR⁵R⁶, où R⁵ et R⁶ sont chacun indépendamment choisis parmi un atome d'hydrogène, un groupe alkyle en C₁₋₈, un groupe cycloalkyle en C₃₋₈ ou un groupe phényle ; ou R⁵ et R⁶, ensemble avec l'atome d'azote auquel ils sont fixés, représentent un cycle saturé à 5 ou 6 chaînons comprenant au plus un autre hétéroatome choisi parmi l'oxygène et l'azote, ou

30

(vii) OR⁷, où R⁷ est un atome d'hydrogène, un atome de métal alcalin, un groupe alkyle en C₁₋₁₈ ou un groupe benzyle, ou

(b) β-Alk-OR⁸, où Alk est un groupe alkylène en C₁₋₁₂ et R⁸ est

(i) un groupe phényl (alkyl en C₁₋₈) carbonyle,

35

(ii) un groupe (cycloalkyl en C₅₋₁₀) carbonyle,

(iii) un groupe benzoyle,

(iv) un groupe (alcoxy en C₁₋₈) carbonyle,

(v) un groupe aminocarbonyle ou (aminoalkyl (C₁₋₈) substitué) carbonyle,

(vi) un atome d'hydrogène, ou

40

(vii) un groupe alkyle en C₁₋₈,

(2) =CH-W-CO-R⁹ ou =CH-W-OR⁹, où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ et R⁸ ont la même signification que ci-dessus et R⁹ est également un atome d'hydrogène ou un groupe (alkyl en C₁₋₂₀) carbonyle ;

(3)

45



50

où la liaison en pointillé remplace le 17-α-hydrogène,

(4) α-hydrogène et β-NHCOR⁹ où R⁹ est un groupe alkyle en C₁₋₁₂ ou β-NR⁵R⁶ où R⁵ et R⁶ ont la même signification que ci-dessus,

(5) α-hydrogène et β-cyano,

55


(6) α-hydrogène et β-tétrazolyloyle ou

(7) un groupe céto ;

ou un sel pharmaceutiquement acceptable de celui-ci ; à l'exception des composés dans lesquels : le cycle B a des doubles liaisons C₃-C₄ et C₅-C₆, R¹ est CH₃ et R³ est un groupe céto ;



le cycle B a des doubles liaisons C₃-C₄, C₅-C₆ et C₁₆-C₁₇, R¹ est CH₃ et R³ est COOCH₃; et
le cycle B a une double liaison C₅-C₆, R¹ est CH₃ et R³ est COCH₃,
qui comprend le traitement d'un composé de formule (V) :



dans laquelle X, Y, Z, R² et R¹⁰ sont tels que définis ci-dessus et R¹⁴ est R³ ou des fragments qui peuvent être transformés chimiquement en R³, avec une base organique, une phosphine, un composé du palladium (II) et un alcool alkylique en C₁₋₆, puis l'addition de monoxyde de carbone.

2. Procédé selon la revendication 1, dans lequel le composé préparé est l'acide N-tert-butyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique ou l'acide N,N-dlisopropyl-androsta-3,5-diène-17β-carboxamide-3-carboxylique.

3. Procédé selon la revendication 1, dans lequel le composé préparé est l'acide 20-α-(hydroxyméthyl)-5-α-prégn-3-ène-3-carboxylique,

l'acide N,N-dlisopropyl-5-α-androst-3-ène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N,N-dlisopropylcarboxamide)-4-fluoro-5-α-androst-3-ène-3-carboxylique,

l'acide 17β-(N,N-dlisopropylcarboxamide)-4-fluoro-androsta-3,5-diène-3-carboxylique,

l'acide 20-α-(hydroxyméthyl)-4-fluoro-5-α-prégn-3-ène-3-carboxylique,

le 3-carbométhoxy-N,N-dlisopropyl-androsta-3,5-diène-17β-carboxamide,

l'acide 17β-N,N-dlisopropylcarboxamide-5-α-androsta-1,3-diène-3-carboxylique,

l'acide N,N-dlisopropyl-5-α-androst-2-ène-17β-carboxamide-3-carboxylique,

l'acide N,N-dlisopropyl-5-α-androstane-17β-carboxamide-3β-carboxylique,

l'acide N,N-dlisopropyl-estra-3,5(10)-diène-17β-carboxamide-3-carboxylique,

l'acide N,N-dlisopropyl-estra-3,5-diène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-androsta-3,5,11-triène-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-androsta-3,5-diène-3-thiocarboxylique,

l'acide N-tert-butyl-5-α-androst-3-ène-17β-carboxamide-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-6-fluoro-5-α-androst-3-ène-3-carboxylique,

l'acide 17β-(N-tert-butylcarboxamide)-6-fluoro-androsta-3,5-diène-3-carboxylique,

le 3-carbométhoxy-N-tert-butyl-androsta-3,5-diène-17β-carboxamide,

l'acide 17β-N-tert-butylcarboxamide-5-α-androsta-1,3-diène-3-carboxylique,

l'acide N-tert-butyl-5-α-androst-2-ène-17β-carboxamide-3-carboxylique,


l'acide N-tert-butyl-androsta-2,4-diène-17β-carboxamide-3-carboxylique,

l'acide N-tert-butyl-5-α-androstane-17β-carboxamide-3-carboxylique,

l'acide N-tert-butyl-estra-3,5(10)-diène-17β-carboxamide-3-carboxylique, ou

l'acide N-tert-butyl-estra-3,5-diène-17β-carboxamide-3-carboxylique.

4. Procédé pour la préparation d'une composition pharmaceutique qui comprend la mise en association d'un composé de formule (Ia) :



(Ia)

dans laquelle :

le cycle A a jusqu'à 2 doubles liaisons ;

les cycles B, C et D ont des doubles liaisons facultatives indiquées par les pointillés, sous réserve que le cycle C n'a pas une double liaison C₇-C₁₄ lorsque le cycle B a une double liaison C₇-C₈ ;

M est O ou S ;

Z est (CH₂)_n et n est 0-2 ;

X est H, Cl, F, Br, I, CF₃ ou un groupe alkyle en C₁₋₆ ;

Y est H, CF₃, F, Cl ou CH₃, sous réserve que Y est H lorsqu'il n'y a pas de double liaison C₅-C₆ ;

R¹ est H ou un groupe alkyle en C₁₋₆ ;


R² est absent ou présent sous forme de H ou de CH₃, sous réserve que R² est absent lorsque l'atome de carbone auquel il est fixé porte une double liaison ;

R¹⁰ est absent lorsqu'il y a une double liaison C₄-C₅, C₅-C₆ ou C₅-C₁₀, ou est présent sous forme d'un atome d'hydrogène en α ; et

R³ est

(1) α-hydrogène, α-hydroxyle ou α-acétoxy et/ou

(a)



où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ est

(i) un atome d'hydrogène,

(ii) un groupe hydroxyle,

(iii) un groupe alkyle en C₁₋₆,

(iv) un groupe hydroxyalkyle en C₁₋₆,

(v) un groupe alcoxy en C₁₋₆,

(vi) NR⁵R⁶, où R⁵ et R⁶ sont chacun indépendamment choisis parmi un atome d'hydrogène, un groupe alkyle en C₁₋₆, un groupe cycloalkyle en C₃₋₆ ou un groupe phényle ; ou R⁵ et R⁶, ensemble avec l'atome d'azote auquel ils sont fixés, représentent un cycle saturé à 5 ou 6 chaînons comprenant au plus un autre hétéroatome choisi parmi l'oxygène et l'azote, ou

(vii) OR⁷, où R⁷ est un atome d'hydrogène, un atome de métal alcalin, un groupe alkyle en C₁₋₁₆ ou un groupe benzyle, ou

(b) β-Alk-OR⁸, où Alk est un groupe alkylène en C₁₋₁₂ et R⁸ est

(i) un groupe phényle (alkyl en C₁₋₆) carbonyle,

(ii) un groupe (cycloalkyl en C₃₋₁₀) carbonyle,

(iii) un groupe benzyle,

(iv) un groupe (alcoxy en C₁₋₆) carbonyle,

(v) un groupe aminocarbonyle ou (aminoalkyl (C₁₋₆) substitué) carbonyle,

(vi) un atome d'hydrogène, ou

(vii) un groupe alkyle en C₁₋₆.

(2) =CH-W-CO-R⁴ ou =CH-W-OR⁸, où W est une liaison ou un groupe alkylène en C₁₋₁₂ et R⁴ et R⁸ ont la même signification que ci-dessus et R⁸ est également un atome d'hydrogène ou un groupe (alkyl en C₁₋₂₀) carbonyle ;

(3)



5

où la liaison en pointillé remplace le 17- α -hydrogène,

(4) α -hydrogène et β -NHCOR⁸ où R⁸ est un groupe alkyle en C₁₋₁₂ ou β -NR⁵R⁶ où R⁵ et R⁶ ont la même signification que ci-dessus,

10

(5) α -hydrogène et β -cyano,

(6) α -hydrogène et β -tétrazolyloxy ou

(7) un groupe céto ;

et un sel pharmaceutiquement acceptable de celui-ci.


et un véhicule pharmaceutiquement acceptable.

15

5. Procédé selon la revendication 4, dans lequel le composé de formule (Ia) est l'acide N-tert-butyl-androsta-3,5-diène-17 β -carboxamide-3-carboxylique ou l'acide N,N-diisopropyl-androsta-3,5-diène-17 β -carboxamide-3-carboxylique.

6. Procédé pour préparer un composé de formule :

20



25

30

dans laquelle R², X et Y sont tels que décrits pour la formule (Ia) dans la revendication 4 et R¹⁴ est comme R³ tel que décrit pour la formule (Ia) dans la revendication 4,


R¹ est H ou un groupe alkyle en C₁₋₈ ; et

M est O ou S,

35

qui comprend le traitement d'un composé de formule

40



45

dans laquelle X¹ est un groupe bromo, chloro, fluoro ou iodo ; et R², R¹⁴, X et Y sont tels que décrits ci-dessus, avec un agent alkylolithium, puis un agent de carboxylation, ou avec un catalyseur au palladium en présence d'une base, d'un alcool en C₁₋₄ et de monoxyde de carbone.

50

7. Procédé selon la revendication 6, dans lequel le composé préparé est l'acide N-tert-butyl-androsta-3,5-diène-17 β -carboxamide-3-carboxylique ou l'acide N,N-diisopropyl-androsta-3,5-diène-carboxamide-3-carboxylique.

55